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utoimmune	  diseases	   result	   from	   the	   inability	   of	   the	   immune	   system	   to	  
discriminate	   between	   normal	   healthy	   tissue	   and	   foreign	   molecules	  
leading	   to	   the	   body	   attacking	   its	   own	   organs,	   tissues	   and	   cells.	  
Collectively,	  these	  diseases	  afflict	  millions	  of	  people	  worldwide,	  the	  incidence	  of	  
autoimmune	   disease	   in	   the	   developed	   world	   is	   estimated	   to	   be	   around	   10%	  
(1,2).	   The	   social	   and	   financial	   burdens	   imposed	   by	   these	   chronic,	   debilitating	  
diseases	  include	  poor	  quality	  of	  life	  and	  high	  health	  care	  costs.	  The	  first	  part	  of	  
this	   chapter	   will	   summarize	   our	   current	   knowledge	   on	   the	   underlying	  
mechanisms	   shared	   by	   many	   autoimmune	   diseases.	   The	   second	   part	   of	   this	  
chapter	   will	   focus	   on	   one	   of	   the	   components	   of	   the	   diagnostic	   process	   of	  
autoimmune	   diseases:	   the	   detection	   of	   autoantibodies	   and	   a	   new	   multiplex	  
platform	  for	  detecting	  antibodies:	  imaging	  surface	  plasmon	  resonance	  (iSPR).	  
1. The	  immune	  system	  
The	  human	  body	  provides	  an	   ideal	  environment	   for	  many	  microbes,	   like	  viruses	  
and	   bacteria,	   and	   it	   is	   the	   task	   of	   the	   immune	   system	   to	   detect	   these	   foreign	  
pathogens,	  and	  neutralize	   them.	  The	   immune	  system	   is	  composed	  of	   two	  major	  
subdivisions,	   the	   innate	   or	   non-­‐specific	   immune	   system	   and	   the	   adaptive	   or	  
specific	   immune	   system.	   The	   innate	   immune	   system	   is	   our	   first	   line	   of	   defense	  
against	   invading	  organisms;	   all	   the	  parts	   are	   immediately	   ready	   to	  be	  mobilized	  
upon	  infection.	  The	  adaptive	   immune	  system	  acts	  as	  a	  second	  line	  of	  defense,	   it	  
requires	   some	   time	   to	   react	   to	   a	   specific	   foreign	   pathogen,	   but	   it	   can	   display	  
immunological	   memory.	   Once	   the	   adaptive	   immune	   system	   has	   encountered	   a	  
foreign	   pathogen,	   it	   can	   “remember”	   the	   pathogen	   and	   react	   more	   rapidly	   on	  
subsequent	   exposures	   to	   this	   pathogen.	   Each	   of	   the	   major	   subdivisions	   of	   the	  
immune	  system	  has	  both	  cellular	  and	  humoral	   components	  by	  which	   they	  carry	  
out	   their	   protective	   function.	   Although	   these	   two	   subdivisions	   of	   the	   immune	  
system	   have	   distinct	   functions,	   there	   is	   interplay	   between	   these	   systems.	  
Together	   the	   immune	   system	   is	   a	   tightly	   regulated	   network	   of	  molecules,	   cells,	  
tissues	   and	   organs	   to	   protect	   our	   body	   against	   diseases.	   At	   the	   heart	   of	   the	  
system	  is	  the	  ability	  to	  recognize	  and	  respond	  to	  substances	  called	  antigens.	  	  
1.1. Antigen	  recognition	  
Some	   of	   the	   antigens	   are	   recognized	   by	   cells	   of	   the	   innate	   immune	   system.	  
Phagocytic	   cells,	   like	   macrophages	   and	   dendritic	   cells	   (DCs)	   express	   pathogen	  
recognition	  receptors	  on	  their	  surface,	  with	  which	  they	  recognize	  and	  respond	  to	  
the	  pathogen	  associated	  molecular	  patterns	  on	   the	  surface	  of	   the	  pathogen	   (3).	  
The	   phagocytic	   cells	   will	   engulf	   the	   antigen,	   process	   it	   into	   small	   peptide	  
fragments	   and	   present	   these	   peptide	   fragments	   associated	   with	   major	  
histocompatibility	   complex	   (MHC)	   class	   I	   or	   II	   molecules	   on	   their	   surface.	   The	  
specific	   recognition	   of	   pathogens	   is	   mediated	   by	   lymphocytes.	   The	   two	   most	  




(T-­‐cells).	  T-­‐cells	  express	  T-­‐cell	  receptors	  (TCR)	  on	  their	  surface.	  The	  TCR	  recognizes	  
processed	  antigens	  as	  peptide	  fragments	  when	  they	  are	  bound	  to	  MHC	  class	  I	  or	  II	  
molecules.	  B-­‐cells	  express	  a	  B-­‐cell	   receptor	   (BCR),	  which	  mediate	   internalization	  
for	  subsequent	  processing	  of	  Ag	  and	  presentation	  of	  peptides	  to	  helper	  T	  cells.	  A	  
critical	   feature	  of	  both	  T-­‐cells	  and	  B-­‐cells	   is	   that	  upon	  antigenic	  stimulation	  they	  
proliferate	   clonally,	   generating	   identical	   cells	   with	   a	   unique	   selectivity	   for	   the	  
primary	  antigenic	  stimulus	  (4-­‐6).	  The	  binding	  of	  a	  specific	  target	  to	  a	  BCR	  or	  TCR	  in	  
itself	   is	   not	   enough	   to	   activate	   the	   B-­‐cell	   and	   the	   T-­‐cell.	   They	   both	   require	  
additional	  costimulatory	  activation	  signals	  (6-­‐8).	  	  
1.2. Role	  of	  lymphocytes	  in	  immune	  reaction	  
The	   active	   T-­‐	   and	   B-­‐cells	   have	   different	   mechanisms	   and	   functions	   to	   remove	  
pathogens.	   T-­‐cells	   can	   either	   become	  CD4+	   regulatory	   T-­‐cells	   or	   CD8+	   cytotoxic	  
T-­‐cells.	  CD8+	  cytotoxic	  T-­‐cells	  are	  capable	  of	  removing	  pathogens	  themselves,	  by	  
binding	   MHC	   class	   I	   molecules,	   which	   are	   involved	   in	   presenting	   endogenous	  
antigens,	   like	  viral	  and	  self-­‐proteins.	  When	  a	  CD8+	  cytotoxic	  T	  cell	  binds	  to	  MHC	  
class	  I	  associated	  antigen	  it	  can	  kill	  the	  target	  by	  engaging	  the	  Fas	  pathway	  or	  the	  
perforin/granzyme	  pathway.	   Either	  way,	   apoptosis	  will	   be	   induced	   in	   the	   target	  
cell	   (9).	   CD4+	   regulatory	   T-­‐cells	   are	   able	   to	   bind	   antigens	   associated	  with	  MHC	  
class	   II	  molecules	  which	  are	  only	  present	  on	  antigen	  presenting	   cells	   (APCs)	   like	  
macrophages,	   DCs	   and	   B-­‐cells.	   After	   binding	   of	   its	   receptor,	   the	   CD4+	   T-­‐cell	   is	  
involved	  in	  stimulating	  the	  humoral	  response	  of	  the	  B-­‐cell	  and	  in	  facilitating	  cell-­‐
mediated	   immunity	  by	  activating	  macrophages	  and	  T-­‐cell	  mediated	   cytotoxicity.	  
B-­‐cells	  start	  acting	  as	  APCs	  once	  they	  leave	  the	  bone	  marrow.	  They	  will	  internalize	  
and	  process	  antigen	  and	  present	  the	  antigen	  fragments	  associated	  with	  MHC	  class	  
II	  to	  the	  T-­‐cells	  (Fig.	  1)	  (10,11).	  This	  amongst	  others	  causes	  activation	  of	  the	  B-­‐cell.	  
Once	   activated,	   the	   B-­‐cell	   can	   develop	   either	   into	   soluble	   antibody	   producing	  
plasma	  cells	  or	  memory	  cells.	  The	  mechanisms	  by	  which	  the	  B-­‐cell	  becomes	  either	  
of	   the	   two	   are	   poorly	   understood	   (12).	   Memory	   cells	   are	   important	   for	   a	  
secondary	   immune	   response.	   They	   will	   stay	   in	   the	   body	   and,	   after	   a	   second	  
encounter	   with	   the	   antigen,	   memory	   cells	   can	   produce	   high	   affinity	   antibodies	  
very	  fast,	  assuring	  a	  rapid	  removal	  of	  the	  antigen.	  Plasma	  cells	  can	  only	  produce	  a	  
single	  kind	  of	  antibody,	  in	  other	  words	  every	  B-­‐cell	  is	  specific	  to	  a	  single	  antigen,	  
but	  each	  cell	  can	  produce	  several	  thousand	  matching	  antibodies	  per	  second	  (13).	  
During	   an	   infection	   several	   B-­‐cells	  may	   recognize	  different	  parts	   of	   the	   antigen,	  
resulting	  in	  several	  different	  plasma	  cells	  and	  a	  polyclonal	  antibody	  response.	  
1.3. Antibodies	  
Antibodies	  are	  proteins	  of	  around	  150	  kDa.	  They	  contain	  2	  heavy	  chains	  of	  50	  kDa	  
and	  2	  light	  chains	  of	  25	  kDa,	  held	  together	  by	  disulfide	  bonds	  (14).	  The	  resulting	  
tetramer	  has	  a	  typical	  Y-­‐like	  shape.	  The	  N-­‐termini	  of	  the	  heavy	  and	  light	  chain	  are	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Figure	  1.	  Schematic	  representation	  of	  T	  cell	  stimulation	  of	  humoral	  response	  of	  the	  B-­‐cell.	  The	  B-­‐
cell	  receptor	  will	  recognize	  its	  specific	  target	  and	  internalize	  and	  process	  this	  target.	  The	  processed	  
antigenic	   peptides	   will	   be	   presented	   to	   a	   CD4+	   T-­‐cell,	   associated	   with	   MHC	   class	   II.	   The	   B-­‐cells	  
receive	   activation	   signals	   from	   the	   T-­‐cells	   and	   will	   either	   differentiate	   into	   memory	   cells	   or	   into	  
antibody-­‐secreting	  plasma	  cells.	  
	  
	  
folded	  together	  into	  a	  variable	  domain	  which	  contains	  3	  hypervariable	  loops,	  the	  
complementarity	   determining	   regions.	   The	   two	   antigen	   binding	   domains	   are	  
highly	  variable	  amongst	  antibodies,	  resulting	  in	  billions	  of	  different	  antibodies,	  all	  
recognizing	  different	   antigens.	   Parts	   of	   the	   two	  heavy	   chains	   form	   the	   constant	  
domain	   of	   the	   antibody,	   which	   specify	   the	   class/subclass.	   This	   Fc	   domain	   is	  
involved	   in	   phagocytosis	   and	   antibody	  mediated	   cellular	   cytotoxicity	   (14).	   Each	  
antibody	   can	   be	   produced	   with	   a	   hydrophobic	   transmembrane	   sequence,	   to	  
anchor	   the	   molecule	   in	   the	   B-­‐cell	   membrane,	   to	   form	   the	   B-­‐cell	   receptor.	   The	  
antibody	  can	  also	  be	   secreted	   from	  the	  B-­‐cell,	  which	   then	  has	   transformed	   to	  a	  
plasma	  cell;	  secreted	  antibodies	  lack	  the	  transmembrane	  sequence.	  The	  antibody	  
recognizes	  epitopes	  on	  different	  kinds	  of	  biological	  molecules,	  e.g.	  DNA,	  RNA	  and	  
protein.	   These	   epitopes	   could	   be	   linear	   epitopes	   or	   conformational	   epitopes,	  
which	  are	  dependent	  on	  the	  conformation	  of	  the	  molecule.	  Parts	  of	  the	  epitope	  
might	   be	   located	   on	   different	   regions	   of	   the	   antigenic	   polypeptide(s),	   and	   are	  
brought	  together	  by	  the	  folding	  of	  the	  protein	  (15).	  The	  enormous	  diversity	  of	  the	  
antibody	   repertoire	   is	   generated	   by	   two	   mechanisms:	   i)	   recombination	   of	  
immunoglobulin	   gene	   variable	   (V),	   diversity	   (D),	   and	   joining	   (J)	   gene	   segments	  
during	  the	  early	  stages	  of	  B-­‐cell	  development	  in	  the	  bone	  marrow,	  and	  ii)	  somatic	  
hypermutation	  of	  functional	  immunoglobulin	  genes	  from	  antigen-­‐activated	  B	  cells	  




There	  exists	  a	  fine	  line	  between	  recognizing	  and	  attacking	  foreign	  pathogens	  and	  
self-­‐antigens.	   Tolerance	   to	   self-­‐antigens	   is	   achieved	   by	   specific	   deletions	   of	  
nascent	  lymphocytes.	   In	  the	  thymus	  the	  immature	  T-­‐cells	  will	  encounter	  stromal	  
cells	   that	   can	   express	   a	   self-­‐antigen	   associated	   with	   the	   appropriate	   MHC	  
molecule	   (16).	   If	   the	   affinity	   to	   that	   self-­‐antigen	   is	   high	   enough	   the	   T-­‐cell	   will	  
receive	  a	  lethal	  signal	  and	  will	  go	  into	  apoptosis,	  a	  process	  called	  clonal	  deletion.	  
In	   addition	   to	   clonal	   deletion	   a	   process	   called	   clonal	   inactivation	   has	   been	  
proposed	   as	   a	   mechanism	   of	   thymic	   tolerance.	   In	   some	   circumstances	  
autoreactive	  T-­‐cells	  are	   inactivated	  rather	  than	  deleted	  (17).	  Some	  of	   the	  T-­‐cells	  
that	  receive	  a	  relatively	  strong	  signal	  in	  the	  thymus,	  which	  is	  insufficient	  for	  clonal	  
deletion,	   can	   develop	   immunosuppressive	   functions	   and	   negatively	   regulate	  
responses	   by	   other	   T-­‐cells	   (18).	   In	   the	   bone	   marrow	   autoreactive	   B-­‐cells	   are	  
controlled	   by	   3	   mechanisms	   i)	   a	   similar	   clonal	   deletion	   process	   in	   which	  
autoreactive	   B-­‐cells	   are	   removed	   by	   induction	   of	   apoptosis	   (19)	   ii)	   receptor	  
editing	   by	   secondary	   recombination	   of	   the	   BCR	   allows	   the	   B-­‐cells	   to	   decrease	  
selfreactivity	  and	  survive	  (20-­‐22)	  iii)	  anergy,	  a	  status	  in	  which	  the	  B-­‐cell	  becomes	  
unresponsive	  for	  antigens	  and	  allows	  the	  cell	  to	  leave	  the	  bone	  marrow	  (23).	  The	  
process	   of	   deletion	   of	   autoreactive	   T-­‐	   and	   B-­‐cells	   is	   not	   perfect.	   Healthy	  
individuals	  can	  have	  autoreactive	  T-­‐	  and	  B-­‐cells	   in	  their	  serum.	  Cells	   that	  escape	  
from	   central	   tolerance	   induction	   are	   controlled	   by	   peripheral	   tolerance	  
mechanisms	  (24,25).	  These	  include	  i)	  a	  deletion	  process	  similar	  to	  the	  one	  in	  the	  
central	  tolerance	  system,	  ii)	  the	  generation	  of	  hyporesponsiveness	  (anergy)	  by	  the	  
lack	   of	   costimulation	   (26),	   and	   iii)	   the	   suppression	   of	   autoreactive	   cells	   by	  
regulatory	  T	  cells	  (27).	  	  
2. Autoimmune	  diseases	  
The	   key	   to	   a	   healthy	   immune	   system	   is	   its	   remarkable	   ability	   to	   distinguish	  
between	   the	   body’s	   own	   macromolecules,	   recognized	   as	   “self,”	   and	   foreign	  
macromolecules,	  or	  “non-­‐self”.	  When	  the	  immune	  system	  fails	  to	  recognize	  self-­‐
proteins	   as	   self	   and	   starts	   an	   immune	   reaction	   against	   one	   or	   more	   self-­‐
components,	  autoimmunity	  develops.	  In	  the	  developed	  world	  around	  10%	  of	  the	  
population	   is	   suffering	   from	   autoimmune	   diseases.	   Seventy-­‐eight	   percent	   of	  
people	  with	  autoimmune	  diseases	  are	  women,	  indicating	  a	  role	  for	  sex	  hormones	  
in	  the	  predisposition	  to	  autoimmune	  diseases.	  To	  date	  80-­‐100	  different	  forms	  of	  
autoimmune	  diseases	  have	  been	  described.	  They	  can	  roughly	  be	  devided	   in	  two	  
categories:	  1)	  organ	  specific	  autoimmune	  diseases,	  and	  2)	  systemic	  autoimmune	  
diseases.	   An	   example	   of	   an	   organ	   specific	   autoimmune	   disease	   is	   thyroiditis	   or	  
Hashimoto’s	  disease.	  In	  this	  disease	  the	  disease-­‐specific	  autoantibodies	  only	  show	  
reactivity	  with	  cellular	  components	  in	  the	  thymus,	  resulting	  in	  localized	  lesions.	  In	  
systemic	  autoimmune	  diseases	   the	  autoantibodies	   react	  with	  molecules	  present	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in	   many,	   if	   not	   all	   organs	   and	   tissues.	   An	   example	   of	   a	   systemic	   autoimmune	  
disease	   is	   systemic	   lupus	   erythematosus	   (SLE),	   in	   which	   the	   autoantibodies	   are	  
directed	  towards	  nuclear	  proteins	  found	  in	  all	  cells.	  
2.1. Etiology	  of	  Autoimmune	  diseases	  
Multiple	   factors	   are	   thought	   to	   contribute	   to	   the	   development	   of	   immune	  
responses	   to	   self,	   including	   differences	   in	   genotypes,	   in	   hormonal	   content	   and	  
environmental	  factors.	  
Genotypes	  
The	  role	  of	  genetic	  factors	  in	  the	  development	  of	  autoimmune	  diseases	  is	  evident	  
from	   epidemiological	   studies,	   twin	   studies	   and	   studies	   with	   animal	   models	  
(28-­‐33).	   The	   genetic	   basis	   of	   autoimmune	   diseases	   is	   very	   complex;	   multiple	  
genes	  are	  associated	  with	  disease	  development,	  but	  independently	  they	  all	  have	  
modest	   effects	   (34).	   The	   genes	   involved	   in	   predisposition	   to	   autoimmunity	   can	  
roughly	   be	   divided	   in	   two	   groups:	   1)	   disease	   specific	   genes	   and	   2)	   the	   immune	  
regulatory	   genes,	   which	   can	   be	   subdivided	   in	   MHC	   and	   non-­‐MHC	   immune	  
regulatory.	  Disease	  specific	  genes	  are	  likely	  to	  be	  expressed	  in	  the	  tissues	  affected	  
by	   the	   organ	   specific	   autoimmune	   diseases.	   Examples	   of	   these	   genes	   are:	   the	  
insulin	   variable	   number	   of	   tandem	   repeats	   polymorphism	   in	   T1D	   (35-­‐37),	   the	  
NOD2	  gene	  in	  Crohn’s	  disease	  (38,39)	  and	  the	  thyroglobulin	  gene	  in	  autoimmune	  
thyroid	  disease	  (40-­‐42).	  The	  immune	  regulatory	  genes	  which	  are	  studied	  most	  in	  
combination	  with	  autoimmunity	  are	  the	  genes	  coding	  for	  MHC	  molecules	  (34,43).	  
The	  HLA-­‐DR4	  gene	  is	  associated	  with	  SLE,	  multiple	  sclerosis	  (MS),	  type	  1	  diabetes	  
(T1D),	  rheumatoid	  arthritis	  (RA)	  and	  inflammatory	  bowel	  disease	  (IBD)	  (43).	  Other	  
examples	   of	   immune	   regulatory	   genes	   are:	   various	   tumor	   necrosis	   factor	   (TNF)	  
encoding	  genes,	  which	  are	  associated	  with	  RA	  (44,45)	  and	  SLE	  (46,47);	  the	  IL2RA	  
involved	   in	   T	   cells	   homeostasis	   which	   is	   associated	   with	   MS,	   T1D	   and	   Grave’s	  
disease	   (48-­‐50)	   and	   the	   protein	   tyrosine	   phosphatase	   (PTPN22)	   gene	   which	   is	  
associated	   with	   RA	   (51),	   SLE	   (52),	   T1D	   (53)	   and	   Grave’s	   disease	   (54).	   Since	   the	  
emergence	  of	  genome-­‐wide	  association	   studies	   (GWAS)	   (55),	   there	  has	  been	  an	  
increase	  in	  the	  discovery	  of	  risk	  loci	  for	  many	  autoimmune	  diseases.	  After	  the	  first	  
wave	   of	   GWAS	   data,	   several	   general	   considerations	   can	   be	   done	   (56).	   First,	  
genetic	   predisposition	   to	   each	   autoimmune	  disease	   is	   based	  on	  multiple	   genes.	  
Second,	  multiple	   autoimmune	   diseases	   share	   some	   genetic	   variants,	   suggesting	  
that	  many	  of	  these	  diseases	  have	  common	  pathways	  of	  pathogenesis.	  Finally,	  the	  
causative	  genetic	  variants	  at	  the	  base	  of	  the	  associations	  have	  not	  been	  identified	  
in	  most	  of	  the	  autoimmune	  diseases.	  
Hormonal	  content	  
In	   almost	   all	   autoimmune	  diseases	  women	  are	   around	  3	   times	  more	   frequently	  
affected	  than	  men	  (57),	  suggesting	  that	  sex	  hormones	  influence	  the	  susceptibility	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to	   autoimmune	   diseases	   (58).	   In	   2002,	   Grimaldi	   et	   al.	   demonstrated	   that	   the	  
estrogen	  receptor	  is	  expressed	  on	  B-­‐cells	  and	  that	  high	  levels	  of	  estrogen	  protect	  
the	  immature	  B-­‐cell	  from	  deletion	  by	  apoptosis	  (59).	  
Environmental	  factors	  
Several	  environmental	   factors	  have	  been	  studied	  for	  their	  role	   in	  the	  etiology	  of	  
autoimmune	  diseases.	  Amongst	  these	  are	  certain	  food	  components	  (60,61),	  drugs	  
(62-­‐64),	  chemicals	   (65),	  metals	   (66)	  and	  cigarette	  smoke	  (67,68).	  Also	  ultraviolet	  
radiation	  from	  sun	  exposure	  can	  be	  associated	  with	  autoimmunity;	  the	  exposure	  
to	   UV-­‐light	   can	   exacerbate	   the	   disease	   in	   patients	   with	   systemic	   lupus	  
erythematosus	  (69,70).	  Infectious	  agents	  are	  the	  most	  often	  cited	  environmental	  
factors	   implicated	   as	   triggers	   of	   autoimmune	   diseases.	   A	   classic	   example	   is	   the	  
central	   role	  of	   the	  Group	  A	  beta-­‐hemolytic	  streptococcus	   in	  the	  development	  of	  
rheumatic	   heart	   disease	   (71,72).	   Among	   the	   autoimmunity	   triggering	   infectious	  
agents	  the	  most	  prominent	  seem	  to	  be	  viruses.	  This	   is	  supported	  by	  the	  disease	  
seasonal	  onset,	   the	   incidence	  after	   infections,	  and	  the	   isolation	  of	  viral	  genomic	  
DNA/RNA	  from	  affected	  tissues	  of	  patients	  once	  the	  disease	  gets	  started.(73-­‐75).	  
Several	  mechanisms	   have	   been	   proposed	   for	   the	   involvement	   of	   viruses	   in	   the	  
development	  of	  an	  anti-­‐self	   immune	  response,	   including	  molecular	  mimicry,	   the	  
expression	  of	  modified	  cryptic	  or	  new	  antigenic	  epitopes,	  and	  a	  mechanism	  based	  
upon	   the	   involvement	   of	   superantigens.	   In	   addition	   to	   these	   antigen-­‐specific	  
mechanisms,	   nonspecific	   mechanisms	   may	   play	   a	   role	   as	   well	   and	   these	   are	  
known	   as	   “bystander	   activation”.	   Bystander	   activation	   occurs	   during	   viral	  
infection,	   but	   no	   specific	   microbial	   determinant	   is	   implicated.	   The	   immune	  
response	   is	   nonspecifically	   stimulated	   by	   the	   infection	   resulting	   in	   activation	   of	  
autoimmunity	   in	   genetically	   susceptible	   individuals.	   According	   to	   the	  molecular	  
mimicry	  model	  immune	  responses	  directed	  to	  foreign	  proteins,	  i.e.	  viral	  proteins,	  
may	   be	   cross-­‐reactive	   with	   self-­‐proteins,	   which,	   at	   least	   in	   part,	   structurally	  
resemble	   the	   foreign	   proteins.	   For	   example	   GAD65,	   an	   autoantigen	   in	   type	   1	  
diabetes,	   has	   a	   high	   homology	  with	   the	   protein	   2C	   of	   Coxsackievirus	   B4	   (76).	   A	  
second	   model	   proposes	   that	   the	   stable	   association	   of	   viral	   proteins	   or	   nucleic	  
acids	  with	   host	   antigens	  might	   break	   tolerance.	   The	   initial	   immune	   response	   to	  
the	   viral	   protein	   spreads	   to	   the	   host	   proteins	   by	   intermolecular	   epitope	  
spreading.	   The	   La/SS-­‐B	   protein	   for	   example	   binds	   to	   hepatitis	   C	   virus,	   HIV	   and	  
Epstein-­‐Barr	  virus	  RNA	  (77-­‐79).	  Epstein-­‐Barr	  virus	  infection	  has	  been	  shown	  to	  be	  
strongly	  correlated	  with	  SLE	  (80),	  a	  disease	   in	  which	  La/SS-­‐B	   is	  one	  of	   the	  major	  
autoantigens.	   Finally,	   the	  genomes	  of	   several	   viruses	  encode	   for	  proteins	  which	  
modify	  host	  proteins	  directly,	  which	  may	  lead	  to	  the	  generation	  of	  neo-­‐epitopes.	  
An	  example	  is	  again	  the	  La/SS-­‐B	  autoantigen,	  which	  is	  an	  important	  substrate	  for	  
the	  poliovirus	  3C	  protease	  (81).	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3. Autoimmunity	  and	  cell	  death	  
Although	  we	  know	  that	  hormonal,	  genetic	  and	  environmental	  factors	  play	  a	  role	  
in	   the	   pathogenesis	   of	   autoimmune	   diseases,	   the	   primary	   trigger	   of	   these	  
diseases	   is	   generally	  not	  known.	  A	  model	   that	  has	   received	   increasing	  attention	  
during	   the	   last	   decade	   proposes	   that	   abnormalities	   in	   cell	   death,	   such	   as	  
increased	   rates	   of	   cell	   death	   or	   defective	   clearance	   of	   dying	   cells,	   facilitate	   the	  
generation	  of	  autoimmunity	  (Fig.	  2).	  In	  a	  normal	  situation	  many	  cells	  will	  die	  and	  
will	  be	  cleared	  by	  phagocytosis.	  During	  apoptosis,	  apoptotic	  blebs	  are	  formed	   in	  
which	   the	   potentially	   harmful	   cellular	   content	   is	   shielded	   from	   the	   immune	  
system.	  When	  cell	  death	  persists,	  for	  example	  by	  massive	  infections,	  as	  a	  result	  of	  
the	  exposure	  to	  toxins,	  or	  if	  due	  to	  a	  genetic	  defect	  phagocytosis	  is	  compromised,	  
the	   dying	   cell	   can	   undergo	   secondary	   necrosis	   (82).	   During	   this	   process	   the	  
released	  intracellular	  components	  may	  trigger	  an	  inflammatory	  reaction	  and	  they	  
may	  be	  exposed	  to	  the	  immune	  system.	  The	  mechanisms	  by	  which	  impaired	  cell	  
death	   can	   initiate	   autoimmunity	   are	   not	   exactly	   known	   yet.	   Several	   lines	   of	  
evidence	  support	  a	   role	  of	  abnormalities	   in	  cell	  death:	   i)	  Many	  autoantigens	  are	  
clustering	   and	   concentrating	   in	   the	   apoptotic	   blebs.	   ii)	   Many	   intracellular	  
autoantigens	   are	   prone	   to	   undergo	  modifications	   during	   cell	   death,	   which	  may	  




Figure	   2:	   Model	   for	   the	   role	   of	   posttranslational	   modifications	   in	   breaking	   immunological	  
tolerance.	  Environmental	  factors	  (e.g.	  viruses)	  or	  tissue	  injury	  may	  induce	  cellular	  stress,	  which	  will	  
be	  associated	  with	  posttranslational	  modifications	  of	  self	  proteins.	  High	  levels	  of	  cellular	  stress	  may	  
lead	  to	  cell	  death	  (apoptosis	  or	  necrosis)	  and	  can	  result	  in	  additional	  modifications	  of	  self	  proteins.	  
When	   cell	   remnants	   are	   not	   properly	   cleared,	   the	   resultant	   neo-­‐epitopes	  might	   be	   presented	   by	  
antigen	  presenting	  cells	  (APC)	  to	  the	  immune	  system	  and	  T	  helper	  cells	  (Th)	  will	  be	  activated.	  This	  
can	  lead	  to	  the	  activation	  of	  B	  cells	  (B),	  followed	  by	  the	  production	  of	  autoantibodies	  (Ab).	  Epitope	  











connective	   tissue	   disease	   patients	   are	   directed	   to	   the	   apoptotically	   modified	  	  
U1-­‐70K	   protein,	   while	   later	   in	   the	   disease	   these	   patients	   present	   antibodies	  
towards	   the	   native	   protein	   (89-­‐91).	   iv)	   Immunization	   of	   mice	   with	   syngeneic	  
apoptotic	  cells	  induced	  high	  titers	  of	  autoantibodies	  (92).	  
3.1. Posttranslational	  modifications	  and	  autoimmunity	  
During	   cell	   death,	   new	   epitopes	   might	   have	   been	   created	   by	   posttranslational	  
modifications.	  These	  epitopes	  might	  not	  be	  recognized	  as	  “self”	  and	  therefore	  the	  
immune	  system	  may	  not	  be	  tolerant	  for	  these	  epitopes.	  These	  modifications	  can	  
be	  the	  cleavage	  of	  the	  protein	  or	  the	  chemical	  or	  enzymatic	  conversion	  of	  the	  side	  
chains	   of	   an	   amino	   acid,	   such	   as	   for	   example	   the	   coupling	   or	   removal	   of	   a	  
phosphate	  group	  or	  the	  conversion	  of	  peptidylarginine	  into	  peptidylcitrulline.	  An	  
autoimmune	  disease	  in	  which	  the	  involvement	  of	  posttranslational	  modifications	  
is	   well	   established	   is	   rheumatoid	   arthritis	   (RA).	   RA	   patients	   produce	   antibodies	  
specifically	   directed	   to	   citrullinated	   proteins,	   although	   the	   actual	   citrullinated	  
autoantigen	  has	  not	  been	  defined	  yet	  (93).	  An	  autoantigen	  that	  is	  modified	  during	  
cell	   death	   is	   La	   or	   SS/B.	   This	   protein	   is	   an	   autoantigen	   in	   SLE	   and	   Sjögren’s	  
syndrome,	   which	   is	   dephosphorylated	   during	   apoptosis	   (94).	   Experimental	  
support	  for	  the	  involvement	  of	  neo-­‐epitopes	  in	  the	  development	  of	  autoimmunity	  
was	   provided	   by	   the	   results	   of	   studies	   addressing	   the	   autoreactivity	   of	   the	  
(modified)	   U1-­‐70K	   protein,	   an	   autoantigen	   in	   SLE	   and	   SLE-­‐overlap	   syndromes.	  
During	  apoptosis	  U1-­‐70K	  is	  cleaved	  into	  a	  40	  kDa	  product.	  In	  sera	  of	  SLE-­‐overlap	  
patients,	   antibodies	   were	   found	   that	   specifically	   bind	   to	   the	   apoptotically	  
modified	   U1-­‐70K,	   as	   a	   result	   of	   the	   formation	   of	   a	   neo-­‐epitope	   that	   is	   not	  
present/accessible	  on	  the	  native	  protein	  (89,90).	  This	  neo-­‐epitope	  was	  recognized	  
more	  efficiently	  than	  the	  epitopes	  on	  the	  native	  protein	  by	  early	  serum	  samples,	  
whereas	   later	   serum	   samples	   show	   comparable	   reactivities	   with	   both	   the	  
modified	  and	  non-­‐modified	  protein	  (91).	  This	  is	  consistent	  with	  a	  primary	  immune	  
response	  directed	  to	  the	  apoptotically	  modified	  U1-­‐70K	  and	  with	  the	  appearance	  
of	   autoreactivity	   to	   the	   non-­‐modified	   protein	   through	   epitope-­‐spreading	   (95).	  
Epitope	   spreading	   involves	   the	   acquired	   recognition	  of	   new	  epitopes	  within	   the	  
same	   self	   molecule	   (intramolecular	   epitope	   spreading)	   as	   well	   as	   epitopes	  
residing	   in	   proteins	   that	   are	   associated	   in	   the	   same	   macromolecular	   complex	  
(intermolecular	   epitope	   spreading),	   such	   as	   the	   nucleosome,	   spliceosome	   and	  
ribosome	  (96).	  
3.2. Apoptosis	  vs.	  necrosis	  
Cell	   death	   is	   an	   essential	   process	   in	   normal	   development	   and	   homeostasis,	   but	  
also	   plays	   a	   crucial	   role	   in	   various	   pathologies.	   Although	   several	   death	  
mechanisms	   have	   been	   described,	   apoptosis	   and	   necrosis	   are	   the	   best	   studied.	  
Apoptosis,	   or	   programmed	   cell	   death,	   is	   a	   process	   occurring	   in	   cells	   that	   are	  
damaged	  or	  no	   longer	  useful.	  Morphologically	   apoptosis	   is	   characterized	  by	   cell	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shrinkage,	   nuclear	   fragmentation,	   chromatin	   condensation	   and	   chromosomal	  
DNA	  fragmentation,	  but	  the	  most	  striking	  characteristics	  are	  membrane	  blebbing	  
and	  the	  formation	  of	  apoptotic	  bodies.	  Necrosis	  is	  a	  form	  of	  traumatic	  cell	  death	  
that	   results	   from	   acute	   cellular	   injury.	   During	   necrosis	   the	   cell	   starts	   to	   swell,	  
chromatin	  is	  digested	  and	  the	  plasma	  membrane	  is	  disrupted.	  The	  loss	  of	  plasma	  
membrane	   integrity	   will	   result	   in	   spilling	   of	   the	   cell’s	   intracellular	   content.	  
Although	   apoptotic	   cells	   don’t	   spill	   their	   intracellular	   content,	   the	   caspase	  
mediated	   cleavage	   of	   structural	   proteins	   facilitates	   the	   translocation	   of	   (often	  
nuclear)	   autoantigens	   to	   the	   surface	   of	   apoptotic	   cells,	   where	   they	   can	   be	  
exposed	   to	   the	   immune	   system	   (87)	   This	   is	   supported	   by	   the	   fact	   that	  
autoantibodies	   produced	   by	   SLE	   patients	   are	   able	   to	   bind	   to	   nuclear	   antigens,	  
which	   translocated	   to	   the	   cell	   surface	   upon	   apoptosis	   induction	   with	   UV	  
irradiation	   (97,98).	   Even	   though	   modified	   antigens	   in	   apoptotic	   cells	   can	   be	  
presented	  to	  the	  immune	  systems,	  apoptotic	  cell	  debris	  fails	  to	  raise	  the	  spectrum	  
of	  autoantibodies	  that	  characterize	  autoimmune	  diseases	  when	  injected	  into	  mice	  
(99,100).	   In	   vitro	   studies	   show	   that	   apoptotic	   cell	   debris	   is	   a	   poor	   activator	   of	  
murine	  macrophages	  (101)	  and	  dendritic	  cells	  (102).	  This	  is	  supported	  by	  studies	  
which	  show	  that	  apoptotic	  bodies	  function	  to	  suppress	  inflammation	  (103)	  and	  a	  
pro-­‐inflammatory	   environment	   inhibits	   apoptosis	   (104).	   By	   contrast,	   cells	  which	  
die	  by	  necrosis	  spill	  their	  intracellular	  contents	  including	  molecules	  that	  stimulate	  
inflammation	  and	  dendritic	   cell	   activation,	  which	   can	   initiate	   a	  primary	   immune	  
response.	   It	   is	   believed	   that	   a	   potent	   mediator	   of	   inflammation,	   high	   mobility	  
group	  box	  I	  (HMGB1),	  is	  passively	  released	  by	  necrotic	  cells.	  HMGB1	  plays	  a	  major	  
role	   in	   sepsis	   and	   synovial	   inflammation	   in	   arthritis	   (105).	   Other	   proteins	  
specifically	   released	   by	   necrotic	   cells,	   like	   Hsp70,	   Hsp90,	   gp96	   and	   calreticulin,	  
activate	   antigen	   presenting	   cells,	   including	   dendritic	   cells	   (106).	   Immature	  
dendritic	  cells	  efficiently	  phagocytose	  necrotic	  tumor	  cells	  and	  induce	  maturation	  
and	   presentation	   of	   tumor	   antigens	   (106,107).	   When	   necrotic	   cell	   debris	   is	  
injected	  into	  mice	  a	  full	  blown	  immune	  reaction	  will	  occur	  (108).	  Antigens	  such	  as	  
PARP,	  topoisomerase	  I,	  UBF	  and	  U1-­‐70K	  are	  fragmented	  during	  necrosis.	  Some	  of	  
the	   proteins	   cleaved	   during	   necrosis	   are	   also	   cleaved	   during	   apoptosis,	   but	   the	  
fragments	  produced	  by	  necrosis	  are	  distinct	  from	  the	  caspase-­‐derived	  fragments	  
observed	  during	  apoptosis.	  	  
3.3. Oxidative	  modification	  of	  antigens	  during	  cell	  death	  
One	  of	  the	  mechanisms	  the	  innate	  immune	  system	  uses	  to	  kill	  foreign	  pathogens	  
is	  the	  rapid	  release	  of	  reactive	  oxygen	  species	  (ROS),	  a	  process	  which	  is	  called	  the	  
oxygen	   or	   respiratory	   burst.	   ROS	   are	   oxygen-­‐based	  molecules	   which	   are	   highly	  
reactive.	   They	   include	   superoxide	   (O2•-­‐),	   hydroxyl	   radicals	   (OH•)	   and	   hydrogen	  
peroxide	  (H2O2).	  ROS	  are	  also	  formed	  in	  the	  mitochondria,	  as	  a	  natural	  byproduct	  
of	   normal	   oxygen	   metabolism.	   However	   during	   stress,	   like	   inflammation,	   ROS	  
levels	  can	  increase	  dramatically	  and	  damage	  DNA	  (109),	  proteins	  (110)	  and	  lipids	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(111).	  Oxidative	  modification	  of	  proteins	  has	  been	  shown	  to	  elicit	  antibodies	  in	  a	  
variety	   of	   diseases,	   including	   scleroderma	   (112)	   and	   systemic	   lupus	  
erythematosus	   (SLE)	   (113).	   There	   is	   evidence	   that	   excessive	   oxidative	   stress	   is	  
involved	   in	   the	   pathology	   of	   scleroderma	   either	   through	   a	   reduction	   of	  
antioxidants	   (114,115)	   or	   by	   abnormal	   generation	   of	   ROS	   (116),	   or	   both.	  When	  
immunodeficient	   BALB/c	   SCID	  mice	  were	   injected	  with	   pro-­‐oxidative	   agents	   the	  
mice	   experienced	   scleroderma-­‐like	   symptoms	   and	   produced	   antibodies	   to	  
topoisomerase	   I	   (117).	   Known	   autoantigens	   can	   also	   be	   modified	   by	   oxidative	  
stress.	   In	   vitro	   the	   scleroderma-­‐specific	   autoantigen	   topoisomerase	   I	   is	  
fragmented	  as	  a	  result	  of	  oxidative	  modification	   (118).	  Ro60,	  a	  60	  kDa	  antigenic	  
target	   for	   antibodies	   in	   SLE	  patients	   can	  be	  modified	  by	   the	   aldehydic	   products	  
formed	  by	  lipid	  oxidation	  (113).	  The	  aldehydic	  products,	  mainly	  the	  4-­‐hydroxy-­‐2-­‐
alkenals	  can	  form	  adducts	  with	  free	  amino	  groups	  of	  lysine	  and	  with	  other	  amino	  
acids.	  These	  aldehyde-­‐modified	  proteins	  are	  highly	  immunogenic	  (113).	  
4. Autoantibody	  prevalance	  in	  autoimmune	  disease	  
A	   distinctive	   characteristic	   of	   autoimmune	   diseases	   is	   the	   production	   of	   highly	  
specific	   autoantibodies	   by	   the	   patients.	   Although	   at	   least	   some	   autoantibodies	  
are	  known	  to	  be	  involved	  in	  cell	  and	  tissue	  damage,	  their	  mechanistic	  role	  in	  the	  
pathogenesis	   of	   the	   disease	   is	   generally	   not	   known	   (119).	   Nevertheless,	   the	  
specificity	  of	  autoantibody	  responses	  highlights	  their	  potential	  as	  important	  tools	  
for	  improved	  diagnosis,	  disease	  classification	  and	  prognosis.	  Table	  1	  lists	  the	  most	  
commonly	   found	   antigens	   recognized	   by	   the	   autoantibodies	   in	   sera	   of	   patients	  
with	   different	   autoimmune	   diseases,	   which	   may	   appear	   in	   the	   patient’s	   serum	  
months,	  or	  even	  years	  before	  the	  onset	  of	  clinical	  symptoms.	  
4.1. Multiplex	  analysis	  of	  antibodies	  
Screening	   for	  multiple	  autoantibody	   specificities	   rather	   than	  one,	   leading	   to	   the	  
generation	   of	   autoantibody	   profiles	   may	   enhance	   the	   clinical	   usefulness	   of	  
autoantibody	   testing.	   For	   instance,	   in	   T1D,	   autoantibodies	   to	   (pro)insulin,	  
	  
	  
Disease	   Prominent	  Autoantigens	  
Systemic	  lupus	  erythematosus	   DNA,	  histones,	  U1	  snRNP,	  Ro	  and	  La	  RNPs	  
Sjögren’s	  syndrome	   Ro	  and	  La	  RNPs	  
Mixed	  connective	  tissue	  disease	   U1	  snRNP	  
Systemic	  sclerosis	   Topoisomerase	  I,	  centromere	  proteins	  
Rheumatoid	  arthritis	   Citrullinated	  proteins/peptides,	  Rheumatoid	  
Factor	  
Type	  1	  diabetes	   Insulin,	  IA-­‐2,	  glutamic	  acid	  decarboxylase	  
	  
Table	  1.	  Autoimmune	  diseases	  characterized	  by	  the	  presence	  of	  diagnostic	  serum	  autoantibodies.	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glutamate	   decarboxylase	   and	   islet	   cell	   antigen	   IA-­‐2	   are	   the	   most	   frequently	  
occurring	   autoantibodies	   (120).	   The	   co-­‐occurrence	   of	   autoantibodies	   against	  
these	   three	   antigens,	   rather	   than	   their	   specificity,	   best	   predicts	   the	   risk	   of	  
developing	  the	  disease.	  When	  all	  three	  autoantibody	  specificities	  are	  present,	  the	  
risk	  of	  developing	  T1D	   is	  100%	   (120).	  Besides	   testing	   several	  molecular	  markers	  
simultaneously,	  reference	  markers	  can	  be	  tested	  under	  the	  exact	  same	  conditions	  
in	  multiplex	  assays,	  increasing	  assay	  specificity.	  In	  addition,	  autoantibody	  profiles	  
might	   provide	   a	   means	   to	   identify	   subsets	   of	   patients	   with	   different	   clinical	  
phenotypes	  or	  outcomes.	  Traditional	  methods	  for	  the	  detection	  of	  autoantibodies	  
in	   patient	   sera	   are	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA),	   immuno-­‐
diffusion,	   western	   blotting,	   immunofluorescence	   and	   immunoprecipitation.	   The	  
limitations	  of	  these	  assays	  are	  their	  single	  autoantibody	  specificity	  measurement	  
format	  and/or	  their	  inability	  to	  reveal	  reactivity	  against	  defined	  antigens.	  Most	  of	  
these	  assays	  are	  time	  consuming,	  laborious	  and	  not	  suitable	  for	  the	  development	  
of	  multiplex	  systems.	  In	  the	  last	  decade,	  new	  technologies	  have	  been	  developed	  
that	  allow	   the	  detection	  of	  multiple	  autoantibody	   reactivities	   simultaneously.	   In	  
1999	  a	  line-­‐blot	  immuno	  assay	  (LIA)	  for	  nuclear	  antigens	  was	  developed.	  Thirteen	  
antigens	  were	  simultaneously	  tested	  for	  binding	  with	  serum	  antibodies.	  Another	  
approach	   is	   to	   apply	   ‘virtual	   arrays’	   in	   a	   homogeneous	   assay	   system	   with	  
addressable	   beads,	   as	   was	   done	   by	   Fulton	   and	   colleagues	   in	   1997	   (121).	   An	  
approach	  similar	  to	  that	  of	  the	  fluorescently	  labeled	  beads,	  are	  the	  immunoassays	  
with	   ‘bar-­‐coded’	   particles	   (122).	   In	   2002	   Robinson	   and	   collaborators	   analyzed	  
protein	   and	   peptide	   arrays	   on	   poly-­‐L-­‐lysine-­‐coated	   glass	   microscope	   slides	   for	  
autoantibody	   binding	   with	   fluorescence-­‐based	   detection	   (123).	   More	   recently	  
Hansson	   and	   coworkers	   used	   a	   similar	   approach,	   but	   with	   chemically	   modified	  
glass	   slides,	   which	   allowed	   the	   immobilization	   of	   a	   three-­‐dimensional	   layer	   of	  
peptides	   resulting	   in	   an	   array	   with	   high	   binding	   capacity	   (124).	   In	   all	   of	   these	  
systems	  at	  least	  one	  of	  the	  interactants	  has	  to	  be	  labeled,	  which	  may	  disrupt	  the	  
binding	   sites	   involved	   in	   the	   interaction	   leading	   to	   false-­‐negatives	   (125).	   In	  
addition,	  the	   label	   itself	  might	   interact	  with	  the	  immobilized	  proteins,	   leading	  to	  
false-­‐positives	   (125).	   A	   way	   to	   circumvent	   these	   problems	   is	   to	   use	   a	   labeled	  
secondary	   binding	   molecule,	   which	   may	   result	   in	   decreased	   assay	   sensitivity.	  
Novel	   techniques	  are	  being	  developed	   that	  are	  based	  on	   label-­‐free	  detection	  of	  
biomolecular	   interactions.	   These	   may	   result	   in	   less	   material	   waste,	   higher	  
throughput,	   and	   an	   increased	   sensitivity	   and	   specificity.	   One	   of	   these	   novel	  
techniques	  is	  surface	  plasmon	  resonance	  (SPR)	  imaging.	  
4.2. Surface	  plasmon	  resonance	  
SPR	   is	   a	  method	   for	   the	   detection	   of	  molecular	   interaction	   on	   a	   surface	   that	   is	  
based	  on	  changes	   in	   the	   local	   refractive	   index	  as	  a	   result	  of	  mass	   increase	  on	  a	  
metal	   surface	   (typically	   gold).	   SPR	   imaging	   offers	   several	   advantages	   over	  
conventional	   methods,	   like	   ELISA,	   to	   visualize	   autoantibody-­‐autoantigen	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interactions.	  First	   since	  SPR	  measures	   refractive	   index	  changes,	   the	  detection	  of	  
analytes	  is	  direct	  and	  label-­‐free.	  Second,	  the	  measurements	  can	  be	  performed	  in	  
real-­‐time,	   allowing	   the	   user	   to	   collect	   data	   about	   the	   affinity	   and	   kinetics	   of	  
biomolecules	   and	   their	   interactions.	   Last,	   SPR	   is	   a	   very	   versatile	   technique,	  
capable	  of	  detecting	  analytes	  over	  a	  wide	  range	  of	  molecular	  weights	  and	  binding	  
affinities.	  Because	  of	   its	  unique	  features,	  SPR	  has	  become	  a	  powerful	  method	  to	  
study	   biomolecular	   interactions,	   such	   as	   protein-­‐protein	   interactions	   (126),	  
protein-­‐peptide	  interactions	  (126),	  protein-­‐DNA	  interactions	  (127,128),	  and	  DNA-­‐
DNA	   interactions	   (hybridization)	   (129).	   SPR	   can	   also	   be	   integrated	   with	   mass	  
spectrometry	   to	   allow	   for	   the	   identification	   of	   the	   bound	   analyte	   (130).	   Many	  
commercial	   SPR	   instruments	  are	  available	   for	   these	  applications,	   the	  most	  well-­‐
known	   of	   which	   is	   the	   Biacore	   system	   (131-­‐136).	   SPR	   imaging	   (iSPR),	   or	   SPR	  
microscopy	   (137-­‐141)	   combines	   the	   advantages	   of	   traditional	   SPR	   (kinetics	   and	  
affinity	   data)	   with	   high-­‐throughput	   capabilities,	   thereby	   allowing	   the	   simul-­‐
taneous	   monitoring	   of	   multiple	   biomolecular	   interactions.	   Microarrays	   of	  
thousands	  of	  spots	  containing	  peptides,	  proteins	  or	  DNA	  can	  be	  measured	  at	  the	  
same	  time,	  the	  only	  limit	  is	  the	  computational	  power	  of	  the	  computers.	  In	  iSPR,	  a	  
polarized	  monochromatic	   light	  beam	  is	  passed	  through	  a	  prism	  and	  its	  attached,	  
gold-­‐coated	  glass	  slide.	  The	  light	  is	  reflected	  off	  the	  thin	  gold	  coating,	  which	  is	  in	  
contact	  with	  the	  liquid	  solution	  of	  interest	  (Fig.	  3A).	  The	  reflected	  light	  is	  detected	  
by	  a	  CCD	  camera;	  each	  pixel	  on	  the	  CCD	  array	  corresponds	  to	  a	  specific	   location	  
on	  the	  gold	  surface.	  The	  photons	  of	  the	  incoming	  light	  can	  interact	  with	  the	  free	  
electrons	   of	   the	   gold	   surface,	   creating	   plasmons.	   The	   conversion	   of	   photons	   to	  
plasmons	  leads	  to	  a	  decreased	  reflected	  light	  intensity,	  resulting	  in	  a	  darker	  spot	  
(Fig.	  4).	  Grey	  values	  are	  averaged	  from	  the	  pixels	  in	  predefined	  Regions	  of	  Interest	  
(ROIs)	   and	   this	   way	   the	   reflected	   light	   intensity	   of	   a	   spot	   is	   determined.The	  
intensity	  of	  the	  reflected	  light	  of	  a	  ROI	  is	  plotted	  against	  the	  angle	  of	  the	  incident	  
light	  to	  obtain	  reflectivity-­‐versus-­‐angle	  plots	  (Fig.	  3B).	  The	  incident	  angle	  at	  which	  
the	   resonance	   occurs	   is	   highly	   dependent	   upon	   the	   refractive	   index	   in	   the	  
immediate	   vicinity	   of	   the	   metal	   surface.	   Absorbance	   of	   a	   (bio)molecule	   to	   the	  
sensor	  surface	  will	  lead	  to	  a	  change	  in	  the	  local	  refractive	  index,	  which	  results	  in	  a	  
shift	   of	   the	   incident	   angle	   at	  which	   resonance	  occurs,	   the	   “SPR	  dip”.	   Binding	  of	  
analyte	   to	   the	   surface	   of	   the	   so-­‐called	   sensor	   disc	   can	   thus	   be	   detected	   by	  
monitoring	  changes	  in	  reflected	  light	  intensity	  at	  the	  ROI.	  The	  actual	  angle	  shift	  of	  
the	  SPR	  dip	   followed	  as	  a	   function	   in	   time	   is	  plotted	   in	  a	  sensorgram	  (Fig.	  4).	   In	  
case	  of	   autoantibody-­‐autoantigen	   interactions,	   the	   sensor	  discs	   can	  be	  used	   for	  
up	  to	  50	  interaction/regeneration	  cycles.	  	  
4.3. SPR	  analysis	  cycle	  
After	  immobilization	  of	  a	  ligand,	  the	  analysis	  cycle	  starts	  with	  the	  introduction	  of	  
a	   buffer	   solution	   in	   the	   flow-­‐cell,	   in	   order	   to	   generate	   a	   (stable)	   baseline.	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Figure	  3:	  Surface	  Plasmon	  Resonance	  imaging	  
A:	  Schematic	  representation	  of	  the	  optical	  Kretschmann	  configuration.	  The	  sensor	  disc	  is	  placed	  on	  
the	  hemispheric	  prism.	  Experiments	  are	  typically	  performed	  in	  either	  a	  flow	  cell	  or	  a	  cuvette,	  which	  
can	   be	   applied	   on	   top	   of	   the	   sensor.	   The	   incident	   light	   is	   focused	   by	   a	   lens	   before	   reaching	   the	  
prism.	  The	   light	   reflects	   from	  the	  sensor	  and	  passes	   through	  another	   lens	  before	   the	  CCD	  camera	  
transfers	  the	  images	  to	  the	  software.	  B:	  The	  reflected	  light	  intensity	  can	  be	  plotted	  against	  the	  angle	  








Figure	   4:	   Reflectivity	   image	   from	   a	   24-­‐spot	  microarray	   at	   two	   incoming	   light	   angles.	   A:	  At	   this	  
angle	  of	  incoming	  light	  the	  spots	  with	  the	  higher	  amounts	  of	  molecular	  mass	  attached	  to	  the	  surface	  
are	  in	  resonance.	  B:	  At	  this	  angle	  of	  incoming	  light	  the	  spots	  with	  the	  negative	  controls,	  which	  did	  
not	  react	  with	  the	  RA	  patient	  antibodies,	  are	  in	  resonance.	  The	  other	  spots	  are	  not	  in	  resonance	  and	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Subsequently	   a	   sample	   containing	   the	   ligand’s	   binding	   partner	   (the	   analyte)	   is	  
introduced	  into	  the	  flow	  cell	  and	  the	  analyte	  can	  bind	  to	  the	  ligand,	  leading	  to	  the	  
selective	   accumulation	   of	   the	   analyte	   on	   the	   sensor	   surface.	   The	   increase	   in	  
adhered	  mass	  causes	  an	  increase	  of	  the	  refractive	  index	  near	  the	  sensor	  surface,	  
which	  can	  be	  measured	  in	  real-­‐time.	  After	  the	  association	  process	  non-­‐specifically	  
bound	  molecules	  are	  washed	  off	  by	  introducing	  a	  washing	  buffer	  solution,	  which	  
initiates	  the	  dissociation	  phase.	  The	  detachment	  of	  bound	  compounds	  results	  in	  a	  
decrease	   of	   refractive	   index.	   The	   exact	   amount	   of	   associated	  molecules	   can	   be	  
calculated	   from	  the	  difference	   in	   refractive	   indices	  before	  and	  after	  association.	  
Subsequently,	   a	   regeneration	   solution,	   which	   for	   instance	   induces	   a	   strong	   pH-­‐
shift	  (including	  a	  strong	  bulk	  refractive	  index	  shift)	  can	  be	  injected	  and	  the	  ligand-­‐
analyte	  complex	  dissociates	  (preferably)	  completely.	  This	  closes	  the	  analysis	  cycle	  
and	  the	  completed	  sensorgram	  is	  now	  available	  for	  analysis	  (Fig.	  5).	  The	  following	  




Figure	  5:	  A	  typical	  sensorgram	  showing	  the	  phases	  of	  two	  analysis	  cycli.	  	  
Baseline	   phase:	   initially,	   running	   buffer	   is	   in	   contact	   with	   the	   sensor	   surface	   to	   establish	   the	  
baseline.	  	  
Association	   phase:	   sample	   containing	   the	   target	   component	   (serum	   containing	   autoantibodies	   or	  
“analyte”)	  is	  injected;	  a	  bulk	  shift	  is	  observed	  as	  a	  consequence	  of	  differences	  between	  differences	  
in	  refractive	  indices	  between	  running	  buffer	  and	  the	  sample.	  The	  capturing	  elements	  on	  the	  sensor	  
surface	  bind	  the	  target	  component	  resulting	  in	  complex	  formation.	  	  
Dissociation	  phase:	  upon	  injection	  of	  running	  buffer,	  target	  components	  (as	  well	  as	  non-­‐specifically	  
bound	  molecules)	  dissociate	  from	  the	  surface.	  The	  double	  arrow	  indicates	  the	  amount	  of	  specifically	  
adhered	  material	  after	  non-­‐specifically	  bound	  molecules	  have	  been	  washed	  of.	  
Regeneration	   phase:	   the	   regeneration	   solution	   (e.g.	   low	   pH	   buffer)	   is	   injected	   to	   remove	   the	  
remaining	  bound	  target	  components.	  
	  After	  this	  phase	  the	  cycle	  is	  completed	  and	  a	  new	  experiment	  can	  start	  by	  establishing	  the	  baseline	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5. Outline	  of	  this	  thesis	  
One	   of	   the	   goals	   of	   the	   research	   project	   described	   in	   this	   thesis	   was	   to	  
demonstrate	  the	  applicability	  and	  usefulness	  of	  the	  newly	  developed	  microarray-­‐
SPR	   imaging	   system	   in	   characterizing	   autoantibody	   profiles	   of	   patients	   with	  
autoimmune	  diseases.	  The	  other	  goal	  was	  to	  find	  new	  autoantibody	  specificities	  
based	  upon	  protein	  modifications	  occurring	  in	  stressed	  cells,	  which	  might	  serve	  as	  
biomarkers	   for	   autoimmune	   diseases	   and	   thus	   might	   be	   incorporated	   into	   the	  
microarray-­‐SPR	  imaging	  assay.	  The	  results	  described	  in	  this	  thesis	  can	  be	  divided	  
into	  two	  parts:	  
Part	  1:	   The	  development	  of	  an	   iSPR	  based	  multiplex	  assay	  for	  characterizing	  the	  
autoantibody	  profile	  of	  autoimmune	  patients.	  
Part	  2:	   Autoreactivity	  of	  cell	  death-­‐associated	  epitopes.	  
In	   Part	   1	   the	   newly	   developed	   microarray-­‐SPR	   imaging	   system	   is	   described,	   as	  
well	  as	  its	  application	  for	  autoantibody	  profiling.	  In	  Chapter	  2	  the	  microarray-­‐SPR	  
imaging	  system	  for	  monitoring	  biomolecular	  interactions	  by	  monitoring	  the	  angle	  
shift	   of	   the	   SPR-­‐dip	   using	   a	   continuous	   angle-­‐scanning	   mode	   is	   described.	   The	  
microarray-­‐SPR	   imaging	   system	  was	   demonstrated	   as	   a	   sensitive,	   accurate,	   and	  
label-­‐free	  detection	  system	  of	  analyst	  binding	  on	  microarrays	  containing	  different	  
molecular	  weight	  ligands.	  In	  Chapters	  3	  and	  4	  the	  potency	  of	  the	  microarray-­‐SPR	  
imaging	  technology	  is	  demonstrated	  by	  automatically	  monitoring	  the	  interactions	  
between	  citrullinated	  peptides	  and	  serum	  antibodies	  of	  rheumatoid	  arthritis	  (RA)	  
patients	   and	   controls.	   In	   Chapter	   3	   it	   was	   investigated	   if	   this	   microarray-­‐SPR	  
technology	   could	   be	   used	   to	  measure	   autoantibody	   reacitivity	   in	   a	   single	   step,	  
without	  the	  need	  of	  a	  secondary	  antibody	  by	  immobilizing	  2	  different	  peptide	  sets	  
and	  probing	  this	  array	  with	  the	  sera	  of	  limited	  set	  of	  RA	  patients	  and	  controls.	  In	  
Chapter	   4	   these	   experiments	  were	   expanded	   to	  monitor	   the	   interactions	   of	   13	  
citrulline	  containing	  peptides	  and	  7	  arginine	  controls	  peptides	  with	  the	  sera	  of	  97	  
RA	   patients	   and	   50	   controls.	   It	   was	   investigated	   if	   the	   RA	   population	   could	   be	  
subclassified	   by	   looking	   at	   specific	   autoantibody	   signatures.	   In	   Part	   2	   the	  
relationship	   between	   cell	   death	   and	   autoimmunity	   was	   further	   investigated.	   In	  
the	  studies	  described	  in	  Chapter	  5	  necrosis	  was	  induced	  in	  Jurkat	  cells	  by	  exposing	  
the	  cells	   to	  hydrogen	  peroxide.	  The	  effects	  of	   this	   treatment	  on	   the	   integrity	  of	  
autoantigenic	   proteins	   was	   analysed.	   The	   implications	   of	   the	   modifications	  
observed	   for	   the	   recognition	   by	   autoantibodies	   was	   investigated	   The	   potential	  
involvement	  of	  virus	  infection	  in	  the	  autoimmune	  response	  associated	  with	  type	  1	  
diabetes	   was	   addressed	   in	   Chapter	   6.	   T1D	   patient	   sera	   were	   analyzed	   for	  
reactivity	  with	  necrotic	   and	   virus	   infected	   cell	   lysates.	   It	   is	   demonstrated	   that	   a	  
very	   small	   portion	   of	   T1D	   patient	   sera	   (3%)	   show	   reactivity	   to	   necrotically	  
modified	   proteins.	   Furthermore,	   more	   T1D	   patient	   sera	   show	   reactivity	   with	  
Coxsackievirus	  cell	   lysates	  than	  control	  sera.	  In	  Chapter	  7	  the	  results	  obtained	  in	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n	   this	   paper	   we	   describe	   the	   use	   of	   a	   Surface	   Plasmon	   Resonance	   (SPR)	  
imaging	   instrument	   for	   monitoring	   the	   binding	   of	   biomolecules	   on	   user-­‐
defined	   regions	   of	   interest	   (ROIs)	   of	   a	  microarray.	   By	  monitoring	   the	   angle	  
shift	   of	   the	   SPR-­‐dip	   using	   a	   continuous	   angle-­‐scanning	   mode	   instead	   of	  
monitoring	  the	  change	  in	  reflectivity	  at	  a	  fixed	  angle,	  a	  linear	  relationship	  with	  
respect	   to	   the	   mass	   density	   change	   on	   the	   surface	   will	   remain	   over	   a	   wide	  
dynamic	   angle	   range	   of	   8	   degrees.	   Peptides	   (2.4	   kDa)	   and	   proteins	   (150	   kDa)	  
were	  both	  spotted	  on	  the	  same	  sensor	  chip	  to	  illustrate	  that	  both,	  low	  and	  high	  
molecular	  weight	  ligands	  with	  initial	  large	  differences	  in	  off-­‐set	  SPR	  angles,	  can	  
be	   applied	   within	   the	   same	   experiment.	   By	   using	   a	   fluorescently	   labeled	  
antibody,	   SPR	   results	   can	   be	   confirmed	   by	  means	   of	   fluorescence	  microscopy	  
after	  completion	  of	  a	  SPR	  experiment.	  SPR	  imaging	  in	  angle-­‐scanning	  operation	  
provides	   sensitive,	   accurate,	   and	   label-­‐free	   detection	   of	   analyte	   binding	   on	  
microarrays	  containing	  different	  molecular	  weight	  ligands.	  
Introduction	  	  
Surface	  Plasmon	  Resonance	   (SPR)	  biosensors	  enable	   today’s	   research	  to	  explore	  
the	  kinetics	  of	  biomolecular	   interactions	   (1).	  The	  use	  of	  SPR	   for	  biosensing,	   first	  
mentioned	   in	   the	   literature	   in	   the	   1980s	   (2,3),	   allows	   label-­‐free	   and	   real-­‐time	  
detection	  of	  various	  biomolecular	  interactions	  (4-­‐6).	  Many	  different	  SPR	  platforms	  
and	   combinations	  of	   technologies	  have	  been	  described	   (7):	   e.g.	   SPR	   imaging	   (8-­‐
10),	   SPR	   microscopy	   (11,12),	   surface	   plasmon	   field-­‐enhanced	   fluorescence	  
spectroscopy	   (SPFS)	   (13,14),	   scanning	   electrochemical	   microscopy-­‐SPR	   (SECM-­‐
SPR)	  (15),	  grating-­‐coupled	  SPR	  (GC-­‐SPR)	  (16-­‐18)	  and	  waveguide-­‐coupled	  SPR	  (WC-­‐
SPR)	   (19).	   The	   SPR	  principle	   is	   based	  on	   the	  excitation	  of	   surface	  plasmons	   in	   a	  
thin	   layer	  (~	  50	  nm)	  of	  a	  metal	  such	  as	  gold,	  using	  p-­‐polarized	   light.	  At	  a	  certain	  
angle	  of	  incidence,	  the	  free	  electron	  oscillation	  in	  gold	  reaches	  a	  maximum	  and	  an	  
evanescent	   field	   is	   being	   enhanced	   by	   at	   least	   a	   factor	   of	   30	   (20,3)	   along	   the	  
liquid-­‐gold	   interface.	   The	   actual	   angle	   of	   the	   so-­‐called	   SPR-­‐dip	   depends	   on	   the	  
wavelength	  of	   the	  used	   light	  and	   the	   refractive	   indexes	  of	   the	   layers	  e.g.	  prism,	  
gold	  and	  liquid	  layer.	  Analyte	  binding	  onto	  the	  sensor	  surface	  will	  induce	  a	  change	  
of	  the	  refractive	  index	  at	  the	  gold-­‐liquid	  interface,	  resulting	  in	  an	  angle	  shift	  of	  the	  
SPR-­‐dip.	  SPR	  measurements	  carried	  out	  in	  a	  fixed	  angle	  mode	  often	  translate	  the	  
angle	  shift	  of	  the	  SPR-­‐dip	  in	  a	  reflectivity	  signal	  calculated	  from	  the	  linear	  part	  of	  
the	   SPR-­‐curve	   (21).	   These	   reflectivity	   signals	   show	   linearity	   up	   to	   5%	   change	   in	  
reflectivity	  (22),	  which	  is	  equal	  to	  a	  50	  mdeg	  angle	  shift	  of	  the	  SPR-­‐dip.	  The	  actual	  
shift	   in	   SPR-­‐dip	   or	   the	   derived	   parameter	   (change	   in	   reflectivity)	   followed	   as	   a	  
function	   of	   time	   is	   plotted	   in	   a	   so	   called	   sensorgram.	   The	   most-­‐common	  
geometries	  of	  SPR	  platforms	  are	  in	  the	  so-­‐called	  Kretschmann	  configuration	  (23),	  
in	  which	  the	   incident	   light	  comes	  from	  the	  high	  refractive	   index	  medium	  (prism)	  
and	   reflects	   at	   the	   gold	   surface	  without	   traveling	   through	   the	   liquid.	   In	   grating-­‐




reflecting	  at	  the	  grating,	  and	  therefore	  sample	  solution	  and	  flow-­‐cell	  need	  to	  be	  
optically	  transparent	  (24).	  Biacore	  AB	  (Uppsala,	  Sweden)	  has	  multiple	  SPR	  systems	  
to	   analyze	   protein	   interaction	   based	   on	   the	   Kretschmann	   configuration	   (25,26).	  
However,	  the	  number	  of	  sensor	  spots	  in	  these	  instruments	  is	  limited	  to	  20	  in	  the	  
A100	   Biacore	   system	   (27).	   With	   the	   FLEXChip,	   a	   grating-­‐coupled	   SPR	   imaging	  
system	  and	  hence	  with	  the	  drawback	  that	  the	  optical	  path	  is	  through	  the	  sample	  
solution,	   it	   is	   possible	   to	   analyze	   400	   interactions	   simultaneously	   (17).	   In	   this	  
paper	   we	   describe	   a	   new	   commercial	   SPR	   imaging	   system	   in	   the	   Kretschmann	  
configuration	   for	   imaging	   a	   50	   mm2	   gold	   surface.	   In	   this	   system,	   biomolecular	  
interactions	   are	   detected	   by	   monitoring	   the	   angle	   shift	   of	   the	   SPR-­‐dip	   using	   a	  
continuous	  angle-­‐scanning	  mode.	  In	  principle	  more	  than	  500	  different	  regions	  of	  
interest	   (ROIs)	   can	  be	  defined	   and	   therefore	  more	   than	  500	   individual	   SPR	  dips	  
can	  be	  measured	  to	  follow	  the	  actual	  SPR	  angles	  from	  the	  imaged	  sensor	  surface,	  
enabling	  simultaneous	  measurement	  of	  multiple	  biomolecular	  interactions.	  
Material	  &	  Methods	  
Reagents	  	  
1-­‐Ethyl-­‐3-­‐(3-­‐dimethylaminopropyl)carbodiimide	   (EDC),	   N-­‐hydroxysuccinimide	  
(NHS),	   ethanolamine,	   phosphate	   buffered	   saline	   (PBS),	   glycine-­‐HCl	   were	  
purchased	  from	  Sigma-­‐Aldrich	  Chemie	  GmbH	  (Steinheim,	  Germany).	  Glycerol	  and	  
Tween-­‐20	  were	  purchased	  from	  Fluka	  Chemie	  GmbH	  (Buchs,	  Switzerland).	  Alexa	  
Fluor®	  488	  labeled	  mouse	  anti-­‐biotin	  IgG	  and	  biotin-­‐XX	  goat	  anti-­‐rabbit	  IgG	  (H+L)	  
were	   purchased	   from	   Molecular	   Probes/Invitrogen	   (Breda,	   The	   Netherlands).	  
Morpholinoethanesulfonic	   acid	   (MES)	   monohydrate	   and	   acetic	   acid	   were	  
purchased	   from	  Merck	   KGaA	   (Darmstadt,	   Germany).	   Refractive	   index	   matching	  
liquid	  n	  =	  1.518	  ±	  0.0002	  and	  n	  =	  1.7200	  ±	  0.0005	  from	  R.P.	  Cargille	  Laboratories	  
Inc.	   (Cedar	   Grove,	   USA).	   VLSI	   Selectipur®	   absolute	   ethanol	  was	   purchased	   from	  
BASF	   Electronic	   Materials	   GmbH	   (Ludwigshafen,	   Germany),	   Assistend®	   optical	  
paper	  was	  purchased	  from	  Omnilabo	  International	  B.V.	  (Breda,	  The	  Netherlands)	  
and	  RBS	  Neutral	  was	  purchased	  from	  Chemical	  Products	  s.a.	   (Brussels,	  Belgium).	  
All	  buffer	  solutions	  were	  prepared	  with	  Milli-­‐Q	  water.	  
SPR	  setup	  
The	  imaging	  Surface	  Plasmon	  Resonance	  Instrument	  for	  Biomolecular	  Interaction	  
Sensing	   (iSPR-­‐IBIS)	   from	   IBIS	   Technologies	   BV	   (Enschede,	   The	   Netherlands)	  
constitutes	  a	  flexible	  SPR	  imaging	  platform	  with	  an	  imaged	  area	  of	  about	  50	  mm2	  
(7x7)	  with	  a	  minimal	  spot-­‐to-­‐spot	  distance	  of	  15	  µm.	  In	  the	  iSPR	  the	  light	  is	  being	  
reflected	   on	   an	   angle-­‐controlled	  mirror	   (range	   8	   deg)	   before	   passing	   through	   a	  
hemispherical	   prism	   to	  enable	   fast	   scanning	  of	   the	  angle	   shift	   of	   the	   SPR-­‐dip	  of	  
the	   individual	   ROIs.	   A	   schematic	   drawing	   of	   the	   iSPR	   optical	   setup	   is	   shown	   in	  
Figure	   1.	   The	   SPR	   angle	   range	   can	   be	   optimized	   by	   manual	   adjustment	   of	   the	  
Angle-­‐scanning	  SPR	  imaging	  for	  detection	  of	  biomolecular	  interactions	  on	  microarrays	  	  
	   41	  
optical	   leverage	   arm,	   between	   66	   deg	   of	   78	   deg.	   A	   bare	   gold	   sensor	   disc	   (IBIS	  
Technologies)	   was	   placed	   carefully	   on	   a	   clean	   hemispheric	   BK7	   prism	   using	   a	  
droplet	  of	  refractive	  index	  matching	  liquid	  (n	  =	  1.518)	  to	  avoid	  entrapment	  of	  air-­‐
bubbles.	  Different	  types	  of	  flow-­‐cells	  are	  available	  for	  addressing	  the	  sample	  over	  
the	  sensor	  surface	  in	  the	  iSPR.	  A	  schematic	  drawing	  of	  the	  liquid	  handling	  system	  
of	  the	  iSPR	  including	  flow	  cell	  is	  shown	  in	  Figure	  2.	  A	  3	  µl	  flow-­‐cell,	  with	  chamber	  
dimensions	   of	   10	   x	   3	   x	   0.1	   mm	   (l	   x	   w	   x	   h),	   is	   being	   placed	   over	   the	   spotted	  
microarray	   and	   sealed	  with	   a	   rubber	   O-­‐ring	   by	   fixing	   the	   screws	   in	   the	   sample	  
rack.	   The	   temperature	   of	   the	   sample	   is	   being	   controlled	   by	   two	   independently	  
controlled	  Peltier	  elements,	  one	  located	  in	  the	  sample	  rack	  and	  the	  other	  one	  in	  
high	  precision	  (<	  0.01°C)	  around	  the	  flow-­‐cell.	  Liquid	  handling	  procedures	  (LHPs)	  
were	   written	   in	   the	   iSPR-­‐software	   to	   navigate	   the	   liquid-­‐handler	   and	   thereby	  
facilitating	   a	   fully	   automated	   performance	   of	   the	   experiment.	   To	   reduce	   the	  
amount	  of	  sample	  needed	  during	  the	  interaction	  time,	  a	  sample	  plug	  was	  guided	  
over	  the	  sensor	  surface	  by	  repeated	  changing	  of	  the	  flow	  direction.	  Depending	  on	  
the	   type	   of	   interaction	   sample	   volumes	   can	   range	   from	   125	   to	   400	   µl,	   with	   a	  
mixing	  (back	  and	  forth)	  volume	  of	  50	  to	  300	  µl	  and	  speed	  of	  2	  µl/sec.	  A	  transient	  
response	  of	  2	  mdeg	  is	  the	  result	  of	  the	  changing	  flow	  direction.	  The	  SPRimager®II	  
from	  GWC	  Technologies	  (Madison,	  WI,	  USA),	  a	  fixed	  angle	  mode	  instrument,	  was	  





Figure	  1:	  Schematic	  representation	  of	  the	  optical	  configuration	  of	  the	  iSPR.	  The	  white	  light	  passes	  
through	   a	   band-­‐pass	   filter	   to	   set	   the	  wavelength	   of	   the	   incident	   light	   at	   840	   nm,	   before	   passing	  
through	   a	   p-­‐polarizer.	   The	   incident	   light	   is	   being	   reflected	   by	   the	   angle	   operated	   mirror	   with	   a	  
maximal	  scanning	  angle	  of	  8	  deg,	  and	  focused	  by	  a	  lens	  before	  reaching	  the	  hemispheric	  BK7	  prism	  
with	  a	  refractive	  index	  of	  n	  =	  1.518	  and	  r	  =	  13	  mm.	  dependent	  on	  the	  application	  the	  Au	  surface	  can	  
be	   coated	   with	   functionalized	   groups	   accordingly.	   The	   reflected	   light	   is	   passed	   through	   another	  
focusing	  lens	  before	  the	  12	  bits	  CCD	  camera	  captures	  at	  least	  10	  different	  images	  per	  second	  which	  







Figure	   2:	   Schematic	   representation	   of	   the	   liquid	   handling	   system	   of	   the	   iSPR.	   Samples	   can	   be	  
collected	  from	  several	  containers	  in	  the	  Peltier	  controlled	  thermostatted	  sample	  rack	  e.g.	  3	  x	  10	  ml	  
containers,	  12	  x	  0.5	  ml	  tubes	  or	  a	  microtiter	  plate,	  using	  the	  needle	  at	  the	  end	  of	  the	  liquid	  handler	  
robot	  arm	  which	  is	  connected	  to	  the	  flow-­‐cell,	  which	  is	  separately	  thermostatted	  in	  high	  precision.	  
The	  mixing	  function	  of	  the	  1	  ml	  syringe	  pump	  facilitates	  a	  continuous	  back-­‐	  and	  forward	  flow	  of	  the	  
sample	   over	   the	   sensor	   surface	   and	   thereby	   reducing	   the	   total	   amount	   of	   sample	   needed.	   The	  
sample	  is	  being	  washed	  away	  with	  buffer	  with	  the	  needle	  positioned	  in	  the	  wash	  station.	  
	  
	  
GWC	   Technologies)	   was	   placed	   carefully	   on	   a	   SF10	   prism	   using	   a	   droplet	   of	  
refractive	  index	  matching	  liquid	  (n	  =	  1.7200).	  The	  standard	  flow-­‐cell	  configuration	  
with	  chamber	  dimensions	  of	  0.5	  x	  13	  mm	  (h	  x	  diameter)	  used	  a	  minimum	  of	  1	  ml	  
sample	  when	  re-­‐circulated	  by	  the	  peristaltic	  pump.	  	  
Refractive	  index	  determination	  
The	   refractive	   indexes	   (∆n)	   of	   glycerol	   dilution	   series,	   from	   0%	   to	   25%	   in	  
PBS/0.03%	   Tween	   20	   (PBST),	   were	   determined	   by	   an	   analog	   laboratory	  
refractometer	   (#354636,	   Carl	   Zeiss/	   JENA,	   Germany)	   at	   20°C.	   Afterwards	   these	  
glycerol	   dilutions	   were	   used	   to	   determine	   the	   angle	   shift	   using	   the	   iSPR	   in	  
combination	  with	   a	   bare	   gold	   sensor	  disc	   from	   IBIS	   Technologies	  BV	   (Enschede,	  
The	   Netherlands)	   and	   the	   reflectivity	   change	   using	   the	   SPRimager®II	   in	  
combination	   with	   a	   bare	   gold	   sensor	   disc	   from	   GWC	   Technologies.	   Both	   SPR	  
measurements	  were	  performed	  at	  20°C.	  	  
Microarray	  fabrication	  
A	   HC200m	   sensor	   disc	   from	   XanTec	   bioanalytics	   GmbH	   (Muenster,	   Germany),	  
functionalized	   with	   a	   carboxylated	   hydrogel	   of	   200	   nm	   thickness	   and	   with	  
medium	  density,	  was	  activated	  by	  shaking	  for	  20	  min	  at	  room	  temperature	  with	  
0.4	   M	   EDC/0.1	   M	   NHS	   in	   MES	   buffer	   (50	   mM,	   pH	   5.4)	   (28,29).	   The	   activated	  
surface	   was	   rinsed	   with	   acetic	   acid	   (50	   mM,	   pH	   3.0)	   and	   dried	   thoroughly	   by	  
applying	   a	   2	   bar	   flow	   of	   nitrogen.	   A	   TopSpot	   device	   in	   combination	   with	   a	   24	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channel	  printhead,	   from	  BioFluidix	  GmbH	  (Freiburg,	  Germany)	   (30),	  was	  used	  to	  
spot	   the	   proteins	   and	   peptides	   in	   a	   non-­‐contact	  manner	   on	   the	   sensor	   surface	  
(layout	  of	  the	  array	  is	  described	  in	  the	  caption	  of	  Fig.	  7A).	  Between	  spotting	  runs	  
the	  printhead	  was	  cleaned	  according	  to	  a	  protocol	  from	  BioFluidix	  with	  a	  5%	  RBS	  
cleaning	  solution	  and	  Milli-­‐Q	  water	  to	  prevent	  cross-­‐contamination.	  The	  24	  spot	  
microarray,	   4	   x	   6,	   on	   top	   of	   the	   sensor	   disc	   consists	   of	   spots	   of	   approximately	  
200	  µm	   in	  diameter	  and	  with	  a	  pitch	  of	  500	  µm.	  The	   sensor	  was	   incubated	   in	  a	  
humidity	   chamber	   at	   room	   temperature,	   to	   prevent	   drying	   of	   the	   spotted	  
1	  nanoliter	   droplets	   during	   the	   1	   hour	   immobilization	   process.	   After	  
immobilization,	  the	  remaining	  active	  groups	  of	  the	  sensor	  surface	  were	  quenched	  
with	  ethanolamine	  (1	  M,	  pH	  8.0)	  for	  10	  min	  at	  room	  temperature.	  The	  sensor	  was	  
stored	  in	  PBS,	  pH	  7.4,	  before	  the	  measurement	  to	  prevent	  drying	  of	  the	  array.	  	  
Detection	   of	   biomolecular	   interactions	   on	   the	   peptide/antibody	  
microarray	  	  
The	  sensor	  containing	  the	  peptide/antibody	  microarray	  was	  mounted	  in	  the	  iSPR	  
and	   equilibrated	  using	   1	  ml	   PBST	   in	   the	   flow-­‐cell	   at	   a	   flow-­‐speed	  of	   2	   µl/sec	   at	  
24°C.	   After	   defining	   the	   ROIs	   of	   150	   µm	   x	   150	   µm,	   the	   SPR-­‐dip	   was	   being	  
determined	  automatically	  by	  the	  software.	  The	  flow-­‐speed	  during	  the	  interactions	  
was	  kept	  at	  2	  µl/sec,	  using	  a	  50	  µl	  mixing	  volume.	  A	  baseline	  was	  made	   in	  PBST	  
followed	   by	   1	   hour	   interactions	   with	   varying	   anti-­‐biotin	   IgG	   concentrations.	  
Signals	   were	   determined	   as	   the	   angle-­‐shift	   between	   PBST	   wash-­‐step	   after	  
incubation	   and	   the	   PBST	   baseline	   before	   the	   interaction.	   The	   sensor	   was	  
regenerated	  with	  10	  mM	  glycine-­‐HCl,	  pH	  1.5	  (500	  µl,	  20	  µl/s)	  between	  the	  various	  
interactions.	   The	   data	   analysis	   was	   performed	   with	   ISPRAD	   software	   from	   IBIS	  
Technologies	  BV	  (Enschede,	  The	  Netherlands).	  	  
Fluorescence	  microscopy	  
After	   completion	   of	   the	   experiment,	   the	   sensor	   disc	   was	   removed	   from	   the	  
hemisphere	  and	  carefully	  placed	  on	  a	  microscope	  slide	  with	   the	   interaction	  side	  
facing	   down	   and	   a	   droplet	   of	   PBST	   in	   between.	   The	   inverted	   Olympus	   IX51	  
microscope	  was	  used	  for	  analysis,	  with	  an	  Olympus	  U-­‐MWB2	  filter	  in	  combination	  
with	   a	   mercury	   lamp.	   Images	   were	   taken	   with	   a	   ColorViewΙΙ	   CCD	   camera	   and	  
analysis®	   FIVE	   software	   from	  Olympus	   Soft	   Imaging	   Solutions	  GmbH	   (Muenster,	  
Germany).	  
Results	  and	  Discussion	  
SPR	  linearity	  
In	   order	   to	   apply	   SPR	   imaging	   for	   quantitative	   adsorption	   experiments,	   it	   is	  
important	  to	  have	  a	   linear	  correlation	  between	  the	  changes	   in	  reflectivity	   (∆%R)	  
and	   changes	   in	   the	   refractive	   index	   (∆n,	   amount	   of	   adsorbed	  molecules	   on	   the	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surface).	  SPR	  systems	  measuring	  at	  a	  fixed	  angle	  positioned	  near	  to	  the	  inflection	  
point	  of	  the	  left-­‐flank	  of	  the	  SPR	  curve,	  can	  only	  apply	  the	  small	  linear	  relationship	  
between	  reflectivity	  and	  mass	  change	  for	  reflectivity	  changes	  of	  less	  than	  5%	  (or	  
50	   mdeg)	   (Nelson	   et	   al.,	   2001)	   due	   to	   the	   shape	   of	   the	   SPR-­‐curve.	   The	   linear	  
correlation	   between	   the	   angle-­‐shift	   of	   the	   SPR-­‐dip	   and	   the	   change	   in	   refractive	  
index	   was	   tested	   by	   varying	   concentrations	   of	   glycerol	   in	   PBST	   (w/v)	   in	   the	  
continuous	   angle-­‐scanning	   mode	   of	   the	   iSPR	   system	   (IBIS)	   and	   the	   fixed	   angle	  
mode	  of	  the	  SPRimager®II	  (GWC).	  The	  repeatability	  was	  tested	  by	  performing	  the	  
experiments	   three	   times	   on	   new	   sensor	   discs;	   the	   obtained	   relative	   standard	  
deviation	   was	   always	   less	   than	   0.5	   units.	   The	   refractive	   indexes	   of	   glycerol	  
samples	   ≤	   0.05%	   were	   calculated	   as	   they	   could	   not	   be	   measured	   with	   the	  
refractive	   index	  meter	  used.	   Figure	  3	   shows	   the	   correlation	  between	   the	  angle-­‐
shift/the	   reflectivity	   and	   the	   refractive	   index	   change	   of	   the	   various	   glycerol	  
concentrations.	   The	   obtained	   linearity	   between	   angle	   shift	   and	   refractive	   index	  
with	   the	   angle-­‐scanning	   mode	   indicates	   a	   dynamic	   range	   of	   more	   than	   2	   deg,	  
corresponding	  to	  a	  refractive	  index	  change	  ≥	  ∆n	  0.03.	  Our	  studies	  also	  showed	  a	  
linearity	   up	   to	   25%	   in	   the	   fixed	   angle	   mode,	   contrary	   to	   the	   5%	   found	   in	   the	  
literature	  (Nelson	  et	  al.,	  2001).	  The	  dynamic	  range	  of	  the	  scanning	  angle	  mode	  is	  
10	  times	   larger	  compared	  to	  the	   fixed	  angle	  mode,	  when	  the	  ability	   to	  measure	  
the	  change	  of	  refractive	  index	  is	  taken	  into	  account.	  The	  maximal	  angle-­‐scanning	  
range	  of	  the	  iSPR	  is	  8	  deg;	  which	  would	  theoretically	  correspond	  with	  a	  maximum	  
refractive	   index	   change	   of	   0.1.	   However,	   with	   the	   prism	   used	   (BK7),	   SPR	   dips	  
cannot	  be	  found	  at	  those	  high	  refractive	  indexes	  as	  the	  necessary	  incident	  angle	  





Figure	  3:	  Linearity	  scanning	  angle	  and	  fixed	  angle	  SPR.	  Relationship	  between	  the	  angle	  shift	  of	  the	  
SPR-­‐dip	   (mdeg)	   and	   the	   change	   in	   refractive	   index,	   in	   the	   scanning	   angle	  mode,	   and	   relationship	  
between	   the	  delta	   reflectivity	  and	   the	  change	   in	   refractive	   index	   in	   the	   fixed	  angle	  mode.	  Twelve	  
serial	  dilutions:	  0.0,	  0.025,	  0.05,	  0.1,	  0.2,	  0.4,	  0.8,	  1.6,	  3.2,	  6.25,	  12.5,	  and	  25%	  glycerol	  in	  PBST	  were	  
used.	   The	   scanning	  angle	   SPR	  measurements	   (black	   line)	   show	  an	   increased	   linear	  dynamic	   range	  
with	  a	  correlation	  coefficient	  of	  0.998	  for	  the	  refractive	  index	  changes	  up	  to	  0.004.	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has	  a	  higher	  refractive	  index	  (1.710)	  compared	  to	  BK7	  (1.510),	  should	  provide	  the	  
possibility	   to	  measure	   refractive	   index	   changes	   up	   to	   1.6,	   as	   was	   calculated	   by	  
applying	  a	  2	  phase	  Fresnel	  reflectivity	  model	  (31).	  	  
Limit	  of	  detection	  
In	   order	   to	   give	   an	   indication	   of	   the	   Limit	   of	   Detection	   (LOD)	   and	   the	   dynamic	  
range	  of	  a	  biomolecular	  system,	  a	  microarray	  containing	  various	  concentrations	  of	  
ligands	   with	   different	   molecular	   weights	   was	   spotted	   on	   a	   sensor	   disc.	   A	   low	  
molecular	  weight	  biotinylated	  peptide	  (2.4	  kDa)	  and	  biotin-­‐XX	  goat	  anti-­‐rabbit	  IgG	  
(H+L)	   (150	  kDa)	  were	  spotted	  on	   the	  same	  sensor	  chip.	  To	  be	  able	   to	  verify	   the	  
biomolecular	   interaction	   with	   a	   fluorescence	   measurement,	   Alexa	   Fluor®	   488	  
labeled	  mouse	  anti-­‐biotin	  IgG	  (150	  kDa)	  was	  applied.	  The	  anti-­‐biotin	  antibody	  will	  
bind	   to	   both	   the	   biotinylated	   groups	   of	   the	   peptide	   and	   the	   immunoglobulin.	  
Regeneration	  of	  the	  sensor	  with	  10	  mM	  glycine-­‐HCl,	  pH	  1.5	  provided	  the	  ability	  to	  
test	   several	   antibody	   concentrations	   on	   one	   sensor	   disc.	   Figure	   4	   shows	   the	  
sensorgram	  of	  the	  interaction	  of	  the	  biotinylated	  peptides	  and	  -­‐proteins	  with	  the	  
anti-­‐biotin	  antibody.	  The	  angle	  shift	   (mdeg)	   is	  shown	  as	  a	  function	  of	  time	  (sec).	  
The	   different	   curves	   represent	   the	   interaction	   with	   the	   various	   amounts	   of	  
biotinylated	  peptide	  spotted.	  The	  curves	  varying	  over	  time	  (x-­‐axis)	  represent	  the	  
different	  concentrations	  of	  the	  analyte,	  anti-­‐biotin	  IgG.	  The	  LOD	  can	  be	  expressed	  
as	  the	  smallest	  change	  in	  refractive	  index	  of	  the	  bulk	  solution	  or	  refractive	  index	  
change	  in	  the	  evanescent	  field	  caused	  by	  accumulated	  mass	  on	  the	  sensor	  surface	  
(9).	   If	   compounds	   with	   an	   increased	   refractive	   index	   replace	   the	   background	  
electrolyte	  buffer	   solution	  a	   linear	   relation	  exists	  between	   the	   surface	   coverage	  
(in	   %)	   and	   the	   molecular	   weight	   of	   the	   adsorbate.	   A	   low	   molecular	   weight	  
compound	  (e.g.	  a	  small	  peptide)	  will	  contribute	  less	  to	  the	  accumulated	  mass	  per	  
surface	   area	   compared	   to	   a	   high	   molecular	   weight	   compound	   (e.g.	   an	  
immunoglobulin).	   In	   literature	   (32)	   it	   is	   indicated	   that	   the	   LOD	   of	   a	   certain	  
biomolecular	   interaction,	   in	   terms	   of	   mass	   per	   square	   surface	   area	   (ng/mm2),	  
depends	   strongly	   on	   the	   affinity	   constant	  of	   a	   specific	   biomolecular	   interaction.	  
Therefore,	   the	   LOD	   should	   be	   expressed	   in	   nanogram	   accumulated	   mass	   per	  
square	  mm.	   The	  molecular	  mass	   of	   the	   analyte	   (in	   this	   case	   the	   anti-­‐biotin	   IgG	  
~150	   kDa)	   gives	   us	   an	   indication	   how	  many	  molecules	   are	   needed	   to	   detect	   a	  
significant	   response	   compared	   to	   the	   signal	   to	   noise	   ratio.	   The	   SPR	   signal	   is	  
related	  to	  the	  accumulated	  mass	  per	  surface	  area.	  (e.g.	  per	  spot)	  the	  immobilized	  
amount	  of	  ligand	  is	  depicted	  in	  femtomole	  and	  the	  analyte	  present	  in	  solution	  in	  
picoMolar	  (pM),	  (Fig.	  5).	  The	  amount	  of	  analyte	  bound	  to	  the	  immobilized	  ligand	  
can	  be	  derived	  from	  the	  measured	  increase	  in	  angle	  shift;	  1	  mdeg	  =	  10.8	  pg/mm2	  
as	  has	  been	  determined	  by	  refractive	  index	  measurements	  which	  are	  dependent	  




Figure	   4:	   Sensorgram	   of	   a	   biotin-­‐antibody	   interaction	   experiment	   with	   different	   ligand	   and	  
analyte	  concentrations.	  An	  injection	  of	  the	  highest	  analyte	  mouse	  anti-­‐biotin	  mouse	  IgG	  (150	  kDa)	  
concentration	   (133	   pM)	   resulted	   in	   a	   gradual	   decrease	   in	   responses	   for	   the	   spots	   loaded	   with	  
different	  ligand	  biotinylated	  peptide	  (2.4	  kDa)	  concentrations	  obtained	  by	  spotting	  of	  417,	  208,	  104,	  
52,	  26	   femtomole	  and	   two	  controls,	  non-­‐biotinylated	  peptide	  and	   the	  background.	  After	   this	   first	  
analysis	   cycle	   a	   lower	  mouse	  anti-­‐biotin	  mouse	   IgG	   (150	   kDa)	   analyte	   concentration	   (53	  pM)	  was	  
injected.	  In	  total	  8	  analysis	  cycles	  were	  carried	  out	  in	  a	  range	  of	  133,	  53,	  13,	  5.3,	  1.3,	  0.53,	  0.13	  and	  
0	   pM	   anti-­‐biotin	  mouse	   IgG.	   Each	   curve	   shows	   the	   transient	   2	  mdeg	   response	   as	   a	   result	   of	   the	  





Figure	  5:	  Response	  curves	  of	  immobilized	  peptide	  in	  femtomole.	  Shows	  the	  response	  curves	  of	  the	  
angle	   shifts	   in	  mdeg	   (linear	   scale)	   which	   can	   be	   derived	   from	   Figure	   4	   from	   the	   various	   peptide	  
concentrations	   immobilized	  on	   the	   sensor	   surface	  and	   its	   interactions	  with	  various	  anti-­‐biotin	   IgG	  
concentrations	  (logarithmic	  scale).	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This	   results	   in	   1.62	   attomole	   in	   case	   of	   a	   ROI	   of	   150	   µm	   x	   150	   µm,	   and	  
64.8	  zeptomole	  or	  4.1	  x	  104	  IgG	  molecules	  bound	  to	  the	  minimal	  ROI	  of	  30	  µm	  x	  
30	  µm.	   Figures	   3	   and	   4	   show	   the	   importance	   of	   both	   ligand	   and	   analyte	  
concentrations	   for	   the	   achievable	   maximum	   angle	   shift.	   Immobilization	   studies	  
showed	  a	  maximum	  shift	  of	  17	  mdeg,	  for	  the	  peptide	  and	  170	  mdeg	  for	  IgG	  with	  
the	  respect	  to	  the	  baseline	  (data	  not	  shown).	  Secondary	  antibodies	  and	  labels	  like	  
latex	   particles	   and	   colloidal	   gold	   (33)	   can	   be	   used	   to	   further	   increase	   the	  mass	  
change	   thereby	   improving	   the	   LOD.	   The	   use	   of	   secondary	   antibodies	   can	   even	  
increase	  the	  specificity	  of	  a	  reaction;	  however	  an	  additional	   interaction	  step	  has	  
to	   be	   included	  which	   overrules	   the	   favorable	   label-­‐free	   one-­‐step	  measurement.	  
The	   results	   in	   Figure	   6A	   and	  B	   show	   the	   images	   taken	  by	   SPR	   and	   fluorescence	  
microscopy,	  respectively.	  The	  results	  in	  Figure	  7	  represent	  the	  signal	  intensities	  of	  
the	   fluorescence	   image	   after	   interaction	  with	   133	   pM	  Alexa	   Fluor®	   488	   labeled	  
mouse	  anti-­‐biotin	  IgG.	  The	  interaction	  at	  the	  lowest	  ligand	  concentration	  is	  barely	  
visible	   compared	   to	   the	   background.	   Comparison	   of	   the	   fluorescence	   results	  
presented	   in	   Figure	   7	   with	   the	   results	   in	   Figure	   4,	   indicates	   that	   SPR	   is	   25-­‐100	  
times	   more	   sensitive	   using	   this	   experimental	   setup.	   This	   is	   determined	   by	   the	  
significant	   signal	   obtained	  of	   the	   lowest	   ligand	   concentration,	   26	   femtomole,	   at	  
different	  analyte	  concentrations.	  Quenching	  of	  the	  fluorescence	  signal	  by	  the	  gold	  
was	  not	  observed,	  which	   is	  probably	  due	  to	  the	   increased	  distance	  between	  the	  






Figure	  6:	  Imaging	  SPR	  vs.	  fluorescence	  microscopy.	  (A)	  Imaging	  SPR	  image	  of	  the	  microarray	  of	  the	  
spotted	  ligands	  after	   interaction	  with	  133	  pM	  Alexa	  Fluor®	  488	  labeled	  mouse	  anti-­‐biotin	  IgG.	  Top	  
two	   rows	   contain	   various	   peptide	   concentrations	   spotted	   in	   twofold:	   417	   femtomole	   of	   a	   non-­‐
biotinylated	  peptide	  as	  a	  negative	  control	  followed	  by	  26,	  52,	  104,	  208,	  and	  417	  femtomole	  of	  the	  
biotinylated	  peptide	  (2.4	  kDa).	  The	  bottom	  two	  rows	  contain	  various	  IgG	  concentrations	  spotted	  in	  
twofold:	   6.67	   femtomole	   of	   a	   non-­‐biotinylated	   IgG	   as	   a	   negative	   control	   followed	   by	   0.42,	   0.83,	  
1.67,	   3.33	   and	   6.67	   femtomole	   of	   biotinylated	   IgG	   (H	   +	   L)	   (150	   kDa).	   (B)	   Fluorescent	  microscopy	  
image	   of	   the	   same	  microarray	   of	   Figure	   6A	   of	   the	   spotted	   ligands	   after	   interaction	  with	   133	   pM	  
Alexa	  Fluor®	  488	  labeled	  mouse	  anti-­‐biotin	  IgG.	  Line	  in	  Figure	  6B	  represents	  place	  on	  sensor	  where	  
intensity	  profile	  of	  Figure	  7	  is	  measured.	  





Figure	   7:	   Intensity	   of	   fluorescence	   signal	   of	   probed	  microarray.	  Fluorescence	   intensity	  profile	  of	  
the	  line	  visible	  in	  Figure	  6B.	  The	  ligand	  concentration	  from	  left	  to	  right	  are:	  0,	  26,	  52,	  104,	  208	  and	  
417	   femtomole	   immobilized	   biotinylated	   peptide	   and	   interaction	   with	   133	   pM	   Alexa	   Fluor®	   488	  
labeled	  mouse	  anti-­‐biotin	  IgG.	  
	  
	  
The	  ability	   to	   run	   the	  SPR	  experiments	   in	  an	  automated	  manner	  by	  using	   liquid	  
handling	   procedures	   (LHPs)	   is	   an	   important	   advantage	   over	   many	   of	   the	  
previously	  described	  systems,	  and	  makes	  it	  suitable	  for	  diagnostic	  purposes.	  Due	  
to	   its	   flexibility,	   in	   terms	   of	   sample	   size	   and	   continuous	   angle-­‐scanning	   mode,	  
remains	   the	   iSPR	   an	   interesting	   tool	   for	   research	   purposes	   as	   it	   can	   meet	  
individual	  needs	  in	  numerous	  applications.	  	  
Conclusion	  
The	   iSPR	   showed	   to	   be	   a	   competent	   and	   sensitive	   instrument	   for	   investigating	  
many	   different	   biomolecular	   interactions	   simultaneously	   because	   of	   its	   large	  
dynamic	   range.	   Compared	   to	   the	   fixed	   angle	   based	   SPR	   imaging	   systems	   the	  
angle-­‐scanning	  mode	  of	   the	   iSPR	  measures	   a	   reliable	   angle-­‐shift	   of	   the	   SPR-­‐dip,	  
resulting	   in	   the	   10-­‐fold	   increased	   linearity.	   The	   angle-­‐scanning	   SPR	   imaging	  
facilitates	   a	   label-­‐free	   and	   real-­‐time	   imaging	   of	   microarray	   interactions	   within	  
50	  mm2	  of	   the	   sensor	   surface,	   thereby	  providing	   the	  possibility	   to	   evaluate	   the	  
interactions	  at	  every	  spot	  of	  the	  microarray	  with	  a	  real-­‐time	  image	  of	  the	  surface.	  
The	  amount	  of	   IgG	  molecules	  bound	   to	   the	  surface	  and	  detected	   in	  a	   label-­‐free	  
manner	   is	   4.1	   x	   104	   molecules	   or	   64.8	   zeptomole.	   Due	   to	   the	   wide	   range	   of	  
operation	   of	   the	   instrument	   both	   peptide	   and	   protein	   interactions	   can	   be	  
measured	  simultaneously.	  The	  obtained	  results	  were	  also	  successfully	  verified	  by	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new	   Surface	   Plasmon	   Resonance	   (SPR)	   imaging	   analysis	   system	  with	   a	  
novel	  SPR-­‐dip	  angle-­‐scanning	  principle	  allows	  the	  measurement,	  without	  
the	   need	   for	   labeling,	   of	   the	   exact	   SPR-­‐dip	   angle.	   With	   this	   system	  
hundreds	   of	   biomolecular	   interactions	   can	   be	   monitored	   on	   microarrays	  
simultaneously	   and	   with	   great	   precision.	   The	   potency	   of	   this	   system	   is	  
demonstrated	   by	   automatically	   monitoring	   the	   interactions	   between	  
citrullinated	  peptides	  and	  serum	  autoantibodies	  of	  50	  rheumatoid	  arthritis	  (RA)	  
patients	   and	  29	   controls	   in	   a	   single	   step.	   The	   smallest	   antibody	   concentration	  
that	  could	  be	  measured	  in	  this	  experimental	  setup	  was	  0.5	  pM.	  
Introduction	  
Some	  of	   the	  outstanding	  questions	   in	   the	   fields	  of	  biology	  and	  medicine	   remain	  
unsolved	   as	   a	   result	   of	   our	   limited	  understanding	  of	   the	   function,	   behavior	   and	  
concerted	  interaction	  of	  many	  significant	  biomolecules.	  To	  obtain	  information	  of	  
complex	   biological	   systems,	   protein	  microarray	   technology	   facilitates	   sensing	   of	  
multiple	  biomolecular	  interactions	  in	  parallel.	  However,	  labeling	  is	  required	  which	  
may	  cause	  additional	  problems	   for	   studying	   structure	   -­‐	   function	   relationships	  of	  
biomolecular	   interactions.	   A	   well-­‐known	   approach	   to	   measure	   the	   binding	   of	  
proteins	  and	  other	  biomolecules	   to	   sensor	   surfaces	   in	  a	   label-­‐less	  and	   real-­‐time	  
manner	   is	  the	  SPR	  imaging	  method	  which	  have	  been	  described	  since	  1988	  (1-­‐4).	  
SPR	  is	  an	  optical	  method	  for	  measuring	  the	  refractive	  index	  of	  material	  absorbed	  
on	  a	  thin	  metal	   layer,	  usually	  gold.	  Photons	  of	  p-­‐polarized	  light	  can	  interact	  with	  
the	  free	  electrons	  of	  the	  metal	   layer;	   inducing	  a	  wave-­‐like	  oscillation	  of	  the	  free	  
electrons	   thereby	   reducing	   the	   reflected	   light	   intensity.	  The	  majority	  of	   systems	  
used	   for	   SPR	   imaging	   represent	   fixed-­‐angle	   instruments.	   These	   instruments	   are	  
based	  on	   a	   relationship	  between	   the	   change	   in	   reflected	   light	   intensity	   and	   the	  
mass	   of	   bound	   analyte,	   i.e.,	   a	   fixed	   incident	   light	   angle	   is	   employed	   and	   mass	  
changes	  are	  estimated	  from	  the	  intensity	  of	  the	  reflected	  light	  (4).	  However,	  the	  
applicable	  range	  of	  this	  linear	  relationship	  is	  limited	  and	  the	  optimal	  angles	  differ	  
considerably	   when	   ligand	   or	   analyte	   panels	   having	   different	   molecular	   weights	  
are	  to	  be	  monitored	  (5).	  The	  use	  of	  only	  one	  fixed	  incident	  light	  angle	  is	  therefore	  
not	  suitable	  for	  the	  monitoring	  of	  multiple	  biomolecular	  interactions	  in	  parallel	  on	  
a	   microarray.	   Most	   commercially	   available	   instruments	   for	   SPR	   imaging	  
measurements,	   such	   as	   instruments	   from	   GWC	   Technologies,	   Genoptics,	   and	  
Kmac,	   although	  with	   different	   technologies	  measure	   at	   fixed	   angles	   to	  monitor	  
the	   interactions.	   In	   systems	   that	   use	   a	   fixed	   wavelength	   the	   most	   reliable	  
parameter	  that	  directly	  reflects	  mass	  changes	  on	  an	  SPR-­‐sensor	  disc	  is	  the	  SPR-­‐dip	  
angle	  shift	  (6,7).	  Thus,	  only	  when	  these	  shifts	  are	  monitored	  for	  all	  the	  spots	  on	  a	  
microarray	   separately,	   the	   magnitude	   and	   affinity	   of	   biomolecular	   interactions	  
can	   be	   reliably	   compared	   amongst	   all	   spots	   of	   any	   microarray.	   The	   use	   of	  
miniaturized	   and	   parallelized	   immunoassays	   in	   a	   microarray	   format	   in	  




Autoimmune	   diseases	   are	   characterized	   by	   the	   presence	   of	   high-­‐affinity	  
autoantibodies	   directed	   against	   self-­‐proteins,	   such	   as	   rheumatoid	   factor	   for	  
rheumatoid	  arthritis	  (RA)	  (8),	  Sm	  for	  systemic	  lupus	  erythemathosus	  (SLE)	  (9)	  and	  
Ro/SS-­‐A	   and	   La/SS-­‐B	   for	   Sjögren’s	   syndrome	   (9).	   Although	   at	   least	   some	  
autoantibodies	   are	   known	   to	   be	   involved	   in	   cell	   and	   tissue	   damage,	   their	  
mechanistic	   role	   in	   the	  pathogenesis	  of	   the	  disease	   is	  generally	  not	  known	  (10).	  
Nevertheless,	   the	  specificity	  of	  autoantibody	  responses	  highlights	  their	  potential	  
as	   important	   tools	   for	   improved	   diagnosis,	   disease	   classification	   and	   prognosis.	  
Miniaturized	  multiplex	  assays	  can	  deliver	  a	  fingerprint	  of	  a	  patient’s	  autoantibody	  
repertoire	   requiring	   only	   a	   limited	   amount	   of	   patient	  material.	   During	   the	   past	  
decade	  various	  research	  groups	  made	  important	  contributions	  to	  the	  application	  
of	  multiplex	  assays	  for	  autoantibody	  detection.	  In	  2002,	  Robinson	  et	  al.	  employed	  
protein	  and	  peptide	  ligand	  arrays,	  representing	  candidate	  autoantigens,	  to	  survey	  
autoantibody	   binding	   (11).	   Arrays	   of	   in	   situ	   synthesized	   peptides	   can	   also	   be	  
generated	   with	   photolithography	   to	   perform	   antibody	   characterization	   (12).	  
Another	  approach	  is	  to	  apply	  ‘virtual	  arrays’	  in	  a	  homogeneous	  assay	  system	  with	  
addressable	   beads	   (13).	   However,	   in	   these	   systems	   at	   least	   one	   of	   the	  
interactants	  must	  be	  labeled,	  which	  may	  disrupt	  the	  binding	  sites	  involved	  in	  the	  
interaction	   leading	   to	   false-­‐negatives.	   In	   addition,	   the	   label	   itself	  might	   interact	  
with	  the	  immobilized	  proteins,	  leading	  to	  false-­‐positives	  (14).	  A	  way	  to	  circumvent	  
these	   problems	   is	   to	   use	   a	   labeled	   secondary	   binding	   molecule,	   which	   might	  
result	  in	  improved	  assay	  sensitivity.	  In	  this	  study	  scanning	  SPR	  microarray	  imaging	  
(IBIS	  Technologies,	  Enschede,	  The	  Netherlands)	   is	  used	  to	  measure	  the	  presence	  
of	  anti-­‐citrullinated	  protein	  antibodies	  (ACPA)	  in	  the	  sera	  of	  RA	  patients.	  Recently,	  
it	   was	   shown	   that	   the	   so-­‐called	   citrulline	   amino	   acid	   (which	   can	   be	   generated	  
posttranslationally	  from	  arginine)	  is	  a	  critically	  important	  moiety	  of	  the	  antigenic	  
determinants	   targeted	   by	   RA-­‐specific	   autoantibodies	   (15).	   Cyclic	   citrullinated	  
peptides	  (CCP)	  are	  widely	  used	  as	  antigenic	  targets	  in	  ELISA-­‐based	  diagnostic	  tests	  
for	  RA.	  The	  sensitivity	  and	  specificity	  are	  71%	  and	  99%	  respectively	  (16).	  	  
Materials	  &	  Methods	  
Serum	  samples	  
The	   sera	   were	   obtained	   from	   the	   Department	   of	   Rheumatology,	   University	  
Hospital	   Nijmegen.	   Sera	   were	   collected	   from	   patients	   visiting	   the	   outpatient	  
clinic,	  who	  had	  been	  diagnosed	  as	  having	  RA	  according	  to	  the	  revised	  criteria	  of	  
the	  American	  College	  of	  Rheumatology.	  To	  further	  assess	  specificity,	  we	  analyzed	  
a	   group	   of	   serum	   samples	   from	   healthy	   individuals	   and	   groups	   of	   sera	   from	  
patients	  with	  osteoarthritis	  and	  SLE,	  obtained	   from	  various	  clinics	  and	  hospitals.	  
Sera	  were	  stored	  at	  -­‐80°C	  until	  used.	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Preparation	  of	  arrays	  
SPR	  detects	  changes	  in	  refractive	  index	  in	  the	  hydrogel	  (200	  nm)	  which	  is	  linked	  to	  
the	   gold	   surface.	   Due	   to	   the	   small	   molecular	   weight	   of	   the	   synthetic	   peptides	  
used	  (~1500	  Da),	  the	  contrast	  of	  the	  immobilized	  array	  to	  the	  background	  is	  not	  
high.	   To	   visualize	   the	   array	   human	   IgG	   was	   spotted	   as	   well.	   The	   peptides	   and	  
human	   IgG	   were	   spotted	   using	   a	   non-­‐contact	   spotter	   (17)	   (1	   nl	   drops	   with	  
spotting	  concentration	  of	  1	  ng/nl	   in	  50	  mM	  Mes,	  pH	  5.4)	  on	  EDC/NHS-­‐activated	  
Xantec	  HC	  200	  nm	  sensor	  discs	  and	  placed	  in	  a	  humidity	  chamber	  at	  RT	  for	  1	  hr.	  
Unreacted	   active	   groups	   were	   blocked	   with	   1	   M	   ethanolamine,	   pH	   8.0	   for	  
10	  minutes.	  The	  sensor	  disc	  was	  rinsed	  with	  PBS	  and	  placed	  on	  a	  hemisphere	  with	  
index-­‐matching	  oil	  and	  inserted	  in	  the	  SPR	  microarray	  imaging	  instrument.	  	  
SPR	  microarray	  interaction	  studies	  
Incubation,	   washing	   and	   regeneration	   were	   performed	   in	   an	   automated	   way	  
using	   liquid	   handling	   procedures	   (LHPs)	   in	   the	   instrument	   for	   biomolecular	  
interaction	  sensing	  (IBIS-­‐iSPR,	   IBIS	  Technologies	  BV,	  Enschede,	  The	  Netherlands).	  
A	  serum	  sample	  plug	  of	  400	  µl	  (diluted	  1:50	  in	  PBS,	  0.03%	  Tween-­‐20)	  was	  guided	  
backward	  and	  forward	  over	  the	  array	  in	  a	  flow-­‐cell	  with	  a	  speed	  of	  1	  μl/sec.	  The	  
serum	  sample	  plug	  was	   surrounded	  by	   two	  air	  plugs	   to	  prevent	   the	  diffusion	  of	  
serum	   components	   into	   the	   buffer.	   Between	   all	   steps	   the	   flow-­‐cell	   was	   rinsed	  
with	   PBS,	   0.03%	   Tween-­‐20.	   The	   array	   was	   regenerated	   by	   injection	   of	   400	   µl	  
10	  mM	   glycine-­‐HCl,	   pH	   1.5	   twice	   for	   30	   seconds.	   Two	   incubation/regeneration	  
cycles	  were	  completed	  before	  applying	  the	  sera	  in	  order	  to	  block	  aspecific	  binding	  
sites	   and	   create	   an	   optimal	   reactive	   sensor	   surface.	   Analysis	   of	   the	   data	   were	  
done	  using	  the	  supplied	  software.	  
Peptide	  ELISA	  
Anti-­‐CCP2	  ELISA	  was	  performed	  by	  IMMUNOSCAN	  RA	  (Euro-­‐Diagnostica,	  Arnhem,	  
the	   Netherlands),	   in	   accordance	   with	   manufacturer’s	   instructions	   with	   the	  
recommended	  25	  U/ml	  cut-­‐off.	  
Results	  
SPR	  experimental	  set-­‐up	  
When	   a	   spot	  meets	   the	   optimal	   SPR	   conditions,	   the	   reflected	   light	   at	   a	   certain	  
region	  of	   interest	   (ROI)	  within	   this	   spot	  will	   reach	  a	  minimal	  value	   resulting	   in	  a	  
dark	   spot.	   Grey	   values	   are	   averaged	   from	   the	   pixels	   in	   predefined	   regions	   of	  
interest	   (ROIs)	   and	   this	   way	   the	   reflected	   light	   intensity	   is	   determined.	   The	  
intensity	   of	   the	   reflected	   light	   is	   plotted	   against	   the	   angle	   of	   the	   incident	   light.	  
SPR	  measurements	  carried	  out	  in	  a	  fixed	  angle	  mode	  often	  translate	  the	  changes	  






Figure	  1:	  Schematic	  representation	  of	  the	  optical	  configuration	  of	  the	  scanning	  angle	  SPR	  imaging	  
instrument.	  Citrullinated	  peptides	  and	  control	  peptides	  are	  chemically	  anchored	  on	  discrete	  spots	  
of	   the	  microarray.	  Autoantibodies	   from	  diluted	   rheumatoid	  arthritis	  patient	   serum	  are	   flown	  over	  
the	  sensor	  chip.	  The	   incident	   light	   is	  being	  reflected	  by	  the	  angle	  operated	  mirror	  before	  reaching	  
the	   hemispheric	   prism	   and	   gold	   sensor,	   and	   the	   microarray	   is	   imaged	   on	   a	   CCD.	   The	   exact	   SPR	  
minimum	   can	   be	   calculated	   from	   multiple	   reflectivity	   images	   and	   monitored	   for	   in	   principle	  
hundreds	  of	  regions	  of	  interests.	  
	  
	  
	  ‘reflectivity	   versus	   angle	   plots’.	   In	   this	   study	   the	   exact	   SPR	   dip-­‐angle	   was	  
measured	   instead	   of	   estimated.	   This	   was	   done	   by	   fast	   incident	   angle	   scanning	  
within	   a	   range	   of	   4	   degrees	   around	   the	   SPR	   dip	   angle	   and	   imaging	   the	  
corresponding	   reflected	   light	   via	   a	   CCD	   camera	   (Fig.	   1).	   Scanning	   is	   performed	  
stepwise,	   e.g.	   an	   angle	   scan	   at	   steps	   of	   50	  mdeg	   of	   incident	   light,	   and	   at	   each	  
angle	  an	  image	  is	  taken.	  By	  curve	  fitting	  the	  “reflectivity	  versus	  angle	  plots”,	  the	  
angle	   of	   the	   exact	   SPR	   dip	   can	   be	   calculated.	   In	   contrast	   to	   fixed-­‐angle	  
instruments,	   which	   measure	   changes	   in	   reflectivity	   at	   one	   defined	   angle,	   the	  
sensorgrams	   generated	   by	   the	   instrument	   used	   in	   this	   study	   represent	   SPR-­‐dip	  
angles	   as	   a	   function	   of	   time	   (Fig.	   2).	   As	   a	   consequence,	   the	   Y-­‐axis	   of	   the	  
sensorgram	  does	  not	   represent	   an	  arbitrary	   reflectivity	  parameter,	   but	   contains	  
the	  exact	  values	  for	  the	  SPR	  angle	  at	  maximal	  resonance.	  These	  exact	  SPR	  angles	  
can	  be	  normalized	  for	  easy	  comparison	  of	  all	  the	  different	  sensorgrams	  of	  all	  the	  
spots	  and	  are	   linearly	  correlated	  with	   the	   refractive	   index,	  corresponding	   to	   the	  
mass	  of	  protein	  bound	  to	  the	  sensor	  surface.	  	  
Monitoring	  the	  interaction	  of	  a	  peptide-­‐array	  with	  serum	  antibodies	  
In	  our	  proof-­‐of-­‐principle	  experiments,	  a	  24-­‐spot	  microarray	  containing	  human	  IgG	  
as	   well	   as	   two	   different	   linear	   citrullinated	   peptides	   (CitA	   and	   CitB)	   and	   the	  
	  





Figure	  2:	  Reflectivity	   images	  at	   four	  different	   incident	  angles	  and	  the	  corresponding	  reflectivity-­‐
versus-­‐angle	   plot.	   Spotted	  array	   contains	   in	   columns	  1and	  6:	   human	   IgG;	   spot	   4P,3Q,2R,1S:	   CitA;	  
2Q,3R,1S,4S:	   arginine	   control	   of	   CitA,	   ArgA;	   spot	   2P,5Q,4R,3S:	   CitB;	   spot	   3P,5P,4Q,5R:	   arginine	  
control	  of	  CitB,	  ArgB.	   Every	  50	  mdeg	  a	   reflectivity	   image	   is	   taken	   from	  which	   the	   intensity	  of	   the	  
reflected	   light	   is	  measured.	   This	   reflected	   light	   intensity	   is	   plotted	   against	   the	   angle	   at	  which	   the	  
image	   is	   taken,	  which	   results	   in	  a	   reflectivity-­‐versus-­‐angle	  plot	   (E).	  A:	   incident	  angle	   is	   -­‐700	  mdeg	  
and	   the	  areas	   surrounding	   the	   spots	  are	   in	   resonance;	  B:	   -­‐200	  mdeg,	  arginine	  control	  peptides	  of	  
both	  citrullinated	  peptides	  are	  in	  resonance;	  C:	  -­‐100	  mdeg,	  citrullinated	  CitB	  is	  in	  resonance;	  D:	  100	  
mdeg,	  citrullinated	  CitA	  is	  in	  resonance.	  Note	  from	  (E)	  that,	  if	  reflectivity	  values	  are	  computed	  only	  




corresponding	   control	   peptides	   (ArgA	   and	   ArgB,	   containing	   arginine	   instead	   of	  
citrulline),	  were	  spotted	  (1	  nl	  per	  spot)	  on	  a	  N-­‐hydroxysuccinimide	  pre-­‐activated	  
polycarboxylate-­‐coated	   gold	   sensor	   surfaces	   using	   a	   non-­‐contact	   spotting	  
instrument	   (17).	   Images	  of	   the	   reflected	   light	  at	   four	  different	   scan	  angles	  after	  
incubation	  of	  the	  24-­‐spot	  array	  with	  serum	  for	  1	  hour	  are	  shown	  in	  Figure	  2A-­‐D.	  
The	   SPR-­‐dip	   of	   each	   ROI	   can	   be	   visualized	   in	   a	   reflectivity-­‐versus-­‐angle-­‐plot	   as	  
shown	   in	   Figure	   2E.	   The	   0	  mdeg-­‐setting	   is	   an	   arbitrary	   value,	  which	   can	   be	   set	  
before	  each	  individual	  experiment	  by	  manual	  adjustment	  to	  obtain	  the	  best	  scan	  
range.	  At	  an	  incident	  angle	  of	  -­‐700	  mdeg	  the	  background	  area	  near	  the	  array	  is	  in	  
resonance	  (A	   in	  Fig.	  2);	  at	   -­‐200	  mdeg	  the	  spots	  coated	  with	  the	  arginine	  control	  
peptides	  ArgA	  and	  ArgB	  are	  in	  resonance	  (B);	  at	  -­‐100	  mdeg	  the	  spots	  coated	  with	  
citrullinated	   CitB	   are	   in	   resonance	   (C)	   and	   at	   100	   mdeg	   the	   spots	   coated	   with	  
citrullinated	  CitA	   are	   in	   resonance	   (D).	   Figure	   2	   demonstrates	   that	   the	   intensity	  
profile	   images	   differ	   considerably	   between	   ROIs	   with	   complexes	   of	   varying	  
masses	  attached	  to	  the	  surface.	  Figure	  3	  shows	  the	  sensorgrams	  obtained	  during	  
incubation	  of	  the	  microarray	  with	  a	  RA	  serum.	  ROIs	  in	  a	  background	  region	  nearby	  
the	   array,	   and	   ROIs	   within	   the	   spots	   of	   immobilized	   human	   IgG	   and	   of	   two	  
arginine-­‐containing	  peptide	   controls	   showed	   relatively	   small	   angle	   shifts	  namely	  
10	   mdeg,	   100	   mdeg,	   18	   mdeg	   and	   30	   mdeg,	   respectively.	   Binding	   to	   the	   two	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corresponding	   citrullinated	   peptides,	   however,	   resulted	   in	   angle	   shifts	   of	   250	  
mdeg	   and	   400	   mdeg,	   respectively.	   The	   noise,	   i.e.,	   the	   baseline	   difference	   in	  
resonance	  angle	  between	   the	  highest	  and	   the	   lowest	  value,	  measured	  over	  100	  
time	  points	  (1000	  sec)	  in	  one	  individual	  ROI,	  was	  1.35	  mdeg,	  making	  angle	  shifts	  
of	  5	  mdeg	  significant.	  In	  Fig.	  3.4	  the	  repeatability	  is	  shown	  for	  various	  injections	  of	  
positive	  RA	  serum	  and	  control	  normal	  sheep	  serum.	  
SPR	  assay	  reproducibility	  
After	  placing	  the	  spotted	  sensor	  disc	  on	  top	  of	  the	  hemisphere	  prism	  in	  the	  flow-­‐
cell	   based	   instrument,	   self-­‐defined	   liquid	  handling	  procedures	   (LHPs)	  were	  used	  
to	   increase	   the	   inter-­‐experiment	   reproducibility.	  Serum	   incubation,	  washing	  and	  
regeneration	  were	  done	  in	  an	  automated	  manner.	  Because	  none	  of	  the	  peptides	  
contained	   lysine-­‐residues,	   coupling	   is	   expected	   to	   occur	   exclusively	   via	   the	   N-­‐
terminal	  primary	  amino	  groups	  thereby	  ensuring	  oriented,	  end-­‐on	  immobilization	  
of	  the	  peptides.	  One	  set	  of	  peptides	  was	  synthesized	  with	  a	  C-­‐terminal	  biotin	  tag.	  
These	   peptides	   were	   used	   to	   investigate	   possible	   differences	   in	   immobilization	  





Figure	  3:	  Typical	  interaction	  of	  RA	  patient	  antibodies	  with	  peptides	  immobilized	  on	  the	  SPR	  sensor	  
disc.	   Sensorgram	   showing	   the	   24	   SPR-­‐dip	   angle	   shifts	   as	   a	   function	   of	   time.	   Baselines	   of	   the	   24	  
regions	   of	   interests	   are	   zeroed.	   After	   the	   association	   phase	   (A),	   the	   array	  was	  washed	  with	   PBS,	  
0.03%	  Tween-­‐20	  (B)	  and	  regenerated	  with	  2	  sequential	  steps	  of	  10	  mM	  glycine-­‐HCl,	  pH	  1.5	  for	  30	  s	  
(C).	  In	  between	  the	  sequential	  glycine-­‐HCl	  steps	  the	  array	  was	  rinsed	  with	  PBS,	  0.03%	  Tween-­‐20	  (D).	  
Blue	   (upper)	   and	   dark	   green	   lines	   (lowest)	   are	   the	   quadruplicates	   of	   CitA	   and	   the	   corresponding	  
arginine	  control,	  respectively;	  light	  green	  (second	  upper)	  and	  purple	  lines	  are	  the	  quadruplicates	  of	  
citrullinated	  CitB	  and	  the	  corresponding	  arginine	  control,	  respectively.	  Red	  lines	  are	  from	  the	  human	  
IgG	   (n=8)	   and	   the	   brown	   lines	   are	   from	   regions	   close	   to	   the	   array	   (blanc	   controls)	   (n=8).	   The	  
enlarged	  section	  shows	  the	  4	  individual	  curves	  from	  the	  quadruplicates	  of	  CitA	  and	  CitB.	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  SPR	  microarray	  imaging	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Figure	  4.	  Reproducibility	  of	   sequential	   interactions.	  Sensorgram	  (raw	  data)	  of	  a	  citrulline	  peptide	  
containing	  spot	  and	  its	  arginine	  control	  spot	  from	  the	  same	  array	  as	  shown	  in	  Fig.	  2.	  The	  array	  was	  
probed	  two	  times	  with	  three	  different	  RA	  sera:	   (B,	  H)	  serum	  1,	   (D,	   J)	  serum	  2,	  and	  (F,	  L)	  serum	  3.	  
Between	  each	   incubation	  with	  RA	  serum	  the	  array	  was	   incubated	  with	  normal	  sheep	  serum	  (NSS)	  
(A,	  C,	  E,	  G,	  I,	  K)	  to	  increase	  the	  number	  of	  regenerations.	  After	  every	  serum	  (RA	  serum	  or	  NSS)	  the	  
sensor	  was	   regenerated	  with	   10	  mM	   glycine-­‐HCl.	   Residual	   serum	   components	   after	   regeneration	  
will	   form	  a	   layer	   that	  blocks	   the	  aspecific	  binding	   sites,	  which	  hardly	   increase	  after	   application	  of	  
more	   sera.	   At	   the	   beginning	   and	   end	   of	   the	   sensorgram	   a	   calibration	   cycle	   (Z)	   is	   performed	   for	  




Figure	   5:	   Autoantibody	   reactivity	   to	   a	   citrullinated	   peptide	  monitored	   by	   SPR	   imaging.	   Fifty	  RA	  
sera	   39	   tested	  positive	   (RA	  CCP+)	   in	   the	  CCP	   ELISA	   and	  11	   tested	  negative	   (RA	  CCP-­‐)),	   10	  normal	  
control	   sera	   (NHS),	   10	   osteoarthritis	   (OA)	   and	   9	   systemic	   lupus	   erythematosus	   (SLE)	   sera	   were	  
tested.	  Sera	  for	  which	  the	  citrulline	   immobilized	  spots	  showed	  an	  angle	  shift	  of	   less	  than	  10	  mdeg	  
are	  depicted	  with	  open	  symbols.	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array	  with	  an	  anti-­‐biotin	  antibody.	  The	  corresponding	  SPR	  angle	  shifts	  were	  211	  ±	  
10	   and	   212	   ±	   12	   mdeg	   for	   the	   citrullinated	   and	   arginine-­‐containing	   peptide,	  
respectively.	  From	  these	  data	  it	  can	  be	  concluded	  that	  there	  was	  no	  difference	  in	  
immobilization	  efficiency	  between	  both	  peptides.	  One	  advantage	  of	  multiplexing	  
the	   monitoring	   of	   protein-­‐protein	   interactions	   is	   the	   ability	   to	   test	   several	  
interactions	  under	  the	  exact	  same	  conditions.	  The	  intra-­‐array	  variation	  in	  the	  iSPR	  
system	   was	   very	   low	   as	   is	   illustrated	   by	   the	   sensorgrams	   of	   the	   quadruplicate	  
interactions	   in	   Figure	   3.	   The	   interaction	   of	   the	   24-­‐spot	   array	   with	   a	   RA	   serum	  
showed	   an	   average	   angle-­‐dip	   shift	   of	   202,5	  mdeg	  with	   a	   standard	   deviation	   of	  
1,3	  mdeg.	  The	   sensor	   chips	   could	  be	  used	   for	  up	   to	  50	   interaction/regeneration	  
cycles	   by	   treatment	   of	   the	   sensor	   surface	   with	   two	   repetitive	   incubations	   with	  
10	  mM	  glycine-­‐HCl,	  pH	  1.5,	  for	  30	  s	  after	  each	  serum	  incubation	  step.	  In	  Figure	  4,	  
the	   repeatability	   of	   12	   injections	   for	   testing	   the	   chip	   performance	   is	   shown.	  
Sequential	  measurements	   of	   patient	   sera	   on	   a	   single	   spot	   showed	   variations	   of	  
less	   than	   5%	   in	   binding	   to	   the	   citrullinated	   peptide,	   even	   when	   6	  
interaction/regeneration	   cycles	   were	   performed	   between	   the	   two	   sequential	  
measurements.	  
Reactivity	  of	  patient	  sera	  in	  SPR	  assay	  
The	   reactivity	  of	   sera	  was	  quantified	  by	   calculating	   the	   ratio	  between	   the	  angle	  
shifts	   observed	   for	   the	   citrullinated	   peptide	   A	   and	   the	   corresponding	   arginine	  
control	   peptide	   (hereafter	   designated	   C/R	   ratio)	   upon	   binding	   of	   serum	  
antibodies.	  The	  results	  for	  50	  RA	  sera	  and	  29	  control	  sera	  (9	  SLE	  patient	  sera;	  10	  
osteoarthritis	   (OA)	   patient	   sera;	   10	   normal	   healthy	   control	   sera)	   are	   shown	   in	  
Figure	  5.	   The	  mean	  C/R	   ratio	   for	   the	  RA	   sera	   tested	  positive	   in	  a	  CCP-­‐ELISA	   (RA	  
CCP+)	   is	  8.6.	  The	  C/R	   ratio	   for	   the	  RA-­‐sera	   tested	  negative	   in	   the	  CCP-­‐ELISA	   (RA	  
CCP-­‐),	  normal	  controls,	  SLE	  patients	  and	  OA	  patients	  are	  0.96,	  1.01,	  1.15	  and	  1.09,	  
respectively.	  Although	   some	  RA	  CCP+	  patients	   showed	  a	  C/R	   around	  1,	  most	   of	  
these	  patients	  were	  only	  weakly	  positive	  in	  the	  anti-­‐CCP	  ELISA.	  Most	  likely	  the	  use	  
of	  a	  linear	  peptide	  in	  the	  SPR	  assay	  leads	  to	  this	  slightly	  reduced	  sensitivity	  as	  the	  
cyclic	  peptides	  used	  in	  the	  anti-­‐CCP	  ELISA	  are	  known	  to	  be	  more	  sensitive.	  	  
Discussion	  
Surface	  plasmon	  microscopy	  and	  SPR	   imaging	  were	   first	  described	   in	  1988	   (1-­‐4)	  
Without	   exceptions,	   the	   systems	   used	   for	   SPR	   imaging	   represented	   fixed-­‐angle	  
instruments,	  i.e.	  the	  mass	  change	  is	  estimated	  from	  the	  intensity	  of	  the	  reflected	  
light	   (4).	   The	   only	   reliable	   and	   underived	   parameter	   that	   directly	   reflects	   the	  
concomitant	  mass	   change	  on	  an	  SPR-­‐sensor	  disc	   is	   the	  SPR-­‐dip	   shift	   (6,7).	   Thus,	  
only	  when	  these	  shifts	  are	  monitored	  for	  all	  the	  spots	  on	  a	  microarray	  separately,	  
the	  magnitude	  and	  affinity	  of	  biomolecular	  interactions	  can	  be	  reliably	  compared	  
amongst	  all	  spots	  of	  any	  microarray.	  The	  innovative	  nature	  of	  the	  approach	  in	  this	  
study	   is	   the	   accurateness	   of	   SPR-­‐dip	   determination	   in	   combination	   with	   the	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unique	   features	   of	   imaging	   the	   sensor	   surface	   and	   real-­‐time	   microarray	   spot	  
monitoring.	   In	   this	  way	   the	   SPR-­‐dip	   of	   each	   spot	   is	  monitored	   real-­‐time	   by	   fast	  
scanning	   the	   angle	   of	   incidence	   and	   imaging	   the	   corresponding	   reflected	   light	  
beam	   via	   a	   CCD	   camera.	   Currently,	   SPR-­‐dip	   angles	   of	   micro-­‐arrays	   of	   up	   to	  
500	  ROIs	  can	  be	  determined	  and	  this	  number	  is	  limited	  by	  the	  current	  computing	  
power,	   since	   collecting	   and	   processing	   the	   images	   including	   the	   fast	   curve-­‐fit	  
calculations	   for	   all	   individual	   ROIs	   require	   a	   huge	   data	   transport.	   Autoimmune	  
diseases	  are	   characterized	  by	   the	  prevalence	  of	   autoantibodies	   recognizing	   self-­‐
proteins.	   Though	  many	   autoantigens	  have	  been	   identified	   and	   characterized,	   to	  
date	  most	   of	   the	   assays	   that	   have	   been	   developed	   to	   detect	   autoantibodies	   to	  
these	   antigens	   are	   ELISA-­‐based,	   thus	   allowing	   only	   separate	   analyses	   for	   each	  
type	  of	  autoantibodies.	  Recent	  observations	  that	   the	  specificity	  of	   the	  detection	  
of	   anti-­‐CCP	   antibodies	   in	   RA	   patient	   sera	   can	   be	   increased	   by	   monitoring	  
reactivities	   with	   both	   the	   citrulline	   and	   arginine-­‐containing	   peptides	   in	   parallel	  
emphasize	   the	   need	   for	   multiplex	   analysis	   systems	   (18).	   and	   that	   the	   ligand-­‐
containing	  sensor	  discs	  can	  be	  efficiently	  regenerated	  and	  re-­‐used.	  In	  most	  of	  the	  
studies	   that	   monitor	   multi-­‐analyte	   protein-­‐protein	   interactions	   a	   secondary	  
antibody	   conjugate	   was	   necessary	   to	   visualize	   bound	   antibodies.	   Here,	   we	  
showed	  that	  SPR	  imaging	  of	  protein/peptide	  microarrays	  provides	  a	  method	  that	  
allows	  a	  one-­‐step	  multi-­‐analyte	  detection	  of	  autoantibodies	  in	  patient	  sera,	  which	  
does	  not	  require	  additional	   reagents	  to	  visualize	  antibody-­‐binding.	  The	  ability	   to	  
measure	   in	   a	   fully	   automated	   fashion	  with	   liquid	  handling	  procedures	   increases	  
reproducibility,	   and	   once	   an	   experiment	   is	   started	   it	   can	   continue	   unattended.	  
The	   ligand-­‐containing	   sensor	   chips	   can	   be	   efficiently	   regenerated	   and	   reused,	  
increasing	   the	   interassay	   reproducibility	   as	   well.	   The	   smallest	   antibody	  
concentration	   that	   could	   be	  measured	  when	   a	   peptide	   concentration	  of	   1ng/nL	  
was	  used	  during	  generation	  of	  the	  array	  was	  0.5	  pM.	  Although	  the	  sensitivity	  of	  
detecting	   RA-­‐specific	   autoantibodies	   by	   the	   scanning	   SPR	   microarray	   imaging	  
system	  under	  the	  conditions	  applied	  in	  this	  study	  is	  slightly	  lower	  than	  that	  of	  the	  
ELISA	   systems,	   we	   expect	   that	   further	   optimization	   will	   lead	   to	   similar	  
sensitivities.	  Moreover,	  for	  the	  low-­‐titered	  sera	  a	  signal	  amplification	  step,	  e.g.	  by	  
using	  a	  (gold-­‐labelled)	  secondary	  antibody,	  may	  raise	  the	  sensitivity	  to	  levels	  that	  
allow	  positive	  signals	  for	  all	  anti-­‐CCP	  autoantibody	  containing	  sera.	  The	  currently	  
most	   widely	   applied	   target	   for	   the	   detection	   of	   anti-­‐citrullinated	   protein	  
antibodies	  (ACPA),	  cyclic	  citrullinated	  peptides,	  are	  only	  recognized	  by	  about	  70%	  
of	   RA	   patients	   (16).	   Due	   to	   the	   heterogeneity	   of	   the	   anti-­‐citrullinated	   protein	  
response	   in	   RA	   (15),	   the	   use	   of	   additional	   citrullinated	   peptides	  may	   allow	   the	  
detection	  of	   such	   antibodies	   in	   patients	   that	   are	  not	   reactive	  with	   the	  peptides	  
used	   in	   the	   CCP2	   ELISA.	   The	   use	   of	  microarrays	  monitored	   by	   SPR	   imaging	  will	  
facilitate	   the	   simultaneous	   detection	   of	   the	   various	   anti-­‐citrullinated	   protein	  
antibodies.	   The	  applicability	  of	   this	  novel	   scanning	   SPR	   technology	   goes	  beyond	  
monitoring	  the	  presence	  of	  autoantibodies	  in	  sera	  of	  autoimmune	  patients.	  Real-­‐
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time	   monitoring	   of	   the	   binding	   allows	   the	   user	   to	   study	   the	   association	   and	  
dissociation	   rate	   constants	   for	   determining	   the	   affinity	   constants	   of	   the	  
biomolecular	   interaction.	   Besides	   kinetic	   studies,	   the	   accurate	  measurement	   of	  
the	  exact	  SPR-­‐dip	  angle	  allows	  the	  accurate	  comparison	  of	  each	  curve,	   including	  
subtraction	  of	  e.g.	  common	  mode	  effect	  (i.e.	  bulk	  shift	  jumps).	  This	  new	  scanning	  
SPR	  technique	  will	  be	  of	  great	  use	  in	  any	  field	  that	  requires	  high-­‐detection	  power	  
and	  high-­‐throughput	  analyses.	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utoantigen	   arrays	   are	   powerful	   tools	   to	   study	   the	   autoantibody	  
repertoires	   found	   in	   patients	   with	   autoimmune	   diseases.	   The	  
autoantibody	   fingerprints	   can	   aid	   the	   diagnosis	   and	   possibly	   also	   the	  
prognosis,	  and	  may	  be	  helpful	  for	  the	  subclassification	  of	  autoimmune	  patients.	  
In	  this	  study	  we	  used	  surface	  plasmon	  resonance	  imaging	  (iSPR)	  of	  biomolecular	  
interactions	   on	   microarrays	   to	   perform	   multiplex	   characterization	   of	  
autoantibody	  responses	  directed	  to	  various	  citrullinated	  peptides	  in	  rheumatoid	  
arthritis	   (RA).	  Microarrays	  were	  generated	  on	   iSPR	   chips	  using	  13	   citrullinated	  
synthetic	   peptides	   and	   the	   arginine-­‐containing	   counterparts	   of	   7	   of	   these	  
peptides.	   Anti-­‐citrullinated	   protein	   antibody	   reactivities	   with	   these	   peptides	  
were	  determined	  for	  97	  RA	  patient	  sera	  and	  sera	   from	  50	  healthy	  and	  disease	  
controls.	   The	   recognition	  of	   some	  peptides	  was	  also	   investigated	  by	  ELISA.	  An	  
automated,	  multiplex	  biomarker	  assay	  was	  developed	  which	  can	  discriminate	  3	  
subclasses	   of	   RA	   patients:	   1)	   patients	   who	   recognize	   peptide	   A,	   which	   is	   a	  
peptide	  isolated	  from	  a	  synthetic	  library	  and	  show	  no	  or	  only	  weak	  reactivities	  
with	  peptides	  E,K	  &	   I,	  which	  also	   represent	  peptides	   isolated	   from	  a	   synthetic	  
library;	   2)	   patients	   who	   recognize	   peptide	   A	   and	   show	   moderate	   reactivities	  
with	  peptides	   E,	   K	   and	   I,	   and	  3)	   patients	  who	  are	  not	  or	   only	  weakly	   reactive	  
with	  peptide	  A	  and	  who	  show	  moderate	  to	  strong	  reactivities	  with	  peptides	  E,	  K	  
and	  I.	  The	  multiplex	  biomarker	  assay	  described	  in	  this	  study	  has	  the	  potential	  to	  
subclassify	   RA	   patients.	   Its	   ability	   to	   identify	   subgroups	   in	   the	   RA	   population	  
could	  be	  of	  great	  help	  in	  the	  development	  of	  assays	  that	  can	  guide	  RA	  therapy.	  	  
Introduction	  
Rheumatoid	   arthritis	   (RA)	   is	   a	   chronic	   inflammatory	   disorder	   associated	   with	  
progressive	   joint	   damage	   which	   may	   lead	   to	   disability.	   Early	   diagnosis	   and	  
treatment	   has	   been	   demonstrated	   to	   interfere	   with	   progression	   and	   leads	   to	  
sustained	  low	  disease	  activity	  or	  even	  remission.	  The	  diagnosis	  of	  RA	  is	  relatively	  
easy	   in	   advanced	   stages	   of	   the	   disease,	   when	   the	   lesions	   are	   clinically	   and	  
radiologically	  apparent,	  but	  more	  difficult	  in	  the	  initial	  or	  early	  phases,	  when	  the	  
institution	  of	  the	  appropriate	  therapy	  would	  be	  most	  useful.	  Recently,	  it	  became	  
evident	  that	  RA	  patients	  can	  be	  classified	  into	  distinct	  disease	  subgroups,	  differing	  
at	   the	   genetic	   (1),	   immunological	   (2)	   and	   prognostic	   levels	   and	   responding	  
differently	   to	   drug	   treatment	   (3).	   The	   two	   serological	   markers	   that	   are	   most	  
extensively	   applied	   in	   RA	   diagnosis	   are	   rheumatoid	   factor	   (RF)	   and	   anti-­‐
citrullinated	   protein	   antibodies	   (ACPA).	   Although	   these	   markers	   display	  
comparable	  sensitivities,	  the	  specificity	  of	  ACPA	  is	  significantly	  higher	  than	  that	  of	  
RF.	   Recently,	   ACPA	   have	   been	   included	   as	   an	   important	   parameter	   in	   the	   new	  
ACR/EULAR	   criteria	   for	   the	   classification	   of	   RA	   (4).	   ACPA,	   which	   are	   most	  
frequently	  detected	  by	  the	  cyclic	  citrullinated	  peptide	  (CCP)	  test,	  are	  detectable	  in	  




individuals	  and	   in	  about	  5%	  of	   inflammatory	  disease	  controls	   (5).	  Because	  ACPA	  
positivity	   in	   sera	   from	   non-­‐RA	   inflammatory	   diseases	   is	   often	   not	   citrulline-­‐
specific,	   in	  contrast	  to	  that	   in	  RA	  sera	  (6),	  testing	  with	  both	  citrullinated	  and	  the	  
corresponding	   non-­‐citrullinated	   antigens	   will	   further	   increase	   the	   specificity.	  
ACPA	   are	   often	   detectable	   in	   RA	   patients	   years	   before	   the	   onset	   of	   clinical	  
symptoms	   (7,8)	   and	   are	   therefore	   very	   suitable	   for	   the	   early	   detection	   of	   RA.	  
ACPA	   may	   be	   present	   in	   up	   to	   40%	   of	   RF-­‐negative	   sera	   (9,10).	   Lee	   and	  
collaborators	   determined	   that	   the	   sensitivity	   for	   RA	   by	   detecting	   either	  
rheumatoid	   factor	   (RF)	  or	  anti-­‐CCP	   reactivity	  was	   increased	   to	  81.4%,	  compared	  
to	   71.6%	   and	   66.0%,	   respectively,	   for	   these	   tests	   alone	   (11).	   Although	   anti-­‐CCP	  
antibodies	   represent	   the	   vast	   majority	   of	   ACPA,	   several	   studies	   have	  
demonstrated	   that	   the	   ACPA	   response	   is	   very	   heterogeneous	   (6,12,13).	   This	   is	  
further	   substantiated	   by	   the	   reactivities	   observed	   with	   the	   growing	   number	   of	  
citrullinated	  antigens	   that	   are	  used	   for	   their	   detection:	   e.g.	   fibrin(ogen)	   (14,15),	  
alpha-­‐enolase	   (16)	   and	   (mutated)	   vimentin	   (17-­‐19).	   The	   (potentially)	  differential	  
association	  of	  distinct	   types	  of	  ACPA	  with	  specific	  clinical	   features	   increased	   the	  
need	  for	  multiplexed	  systems	  for	  ACPA	  detection.	  During	  the	  last	  decade,	  several	  
systems	   for	   the	   simultaneous	   detection	   of	   multiple	   autoantibodies	   have	   been	  




Figure	  1:	  iSPR	  sensorgram.	  Schematic	  illustration	  of	  the	  changes	  of	  the	  iSPR	  resonance	  angle	  in	  time	  
as	  a	  result	  of	  antibody	  binding	  to	  peptides	  immobilized	  on	  the	  sensor	  disc.	  The	  analysis	  cycle	  starts	  
with	  measuring	  a	  baseline	  (A).	  After	  injection	  of	  a	  serum	  the	  antibodies	  can	  bind	  to	  the	  immobilized	  
peptides	   resulting	   in	   a	   resonance	   angle	   shift	   (B).	   Subsequently,	   the	   non-­‐specifically	   bound	   serum	  
proteins	  are	   removed	  by	  changing	   to	  a	  buffer	   flow	  and	  the	  dissociation	  phase	  starts	   (C).	  The	   iSPR	  
signal	   can	   be	   calculated	   by	   subtracting	   the	   iSPR	   angle	   found	   at	   baseline	   (A)	   from	   the	   iSPR	   angle	  
obtained	   after	   the	   removal	   of	   non-­‐specifically	   bound	  material	   (C).	   Finally,	   the	   sensor	   disc	   can	   be	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developed	   (20).	   Thirteen	   antigens	   were	   simultaneously	   tested	   for	   binding	   with	  
serum	  antibodies.	  Another	  approach	  is	  to	  apply	  ‘virtual	  arrays’	  in	  a	  homogeneous	  
assay	  system	  with	  fluorescent	  addressable	  beads,	  as	  was	  described	  by	  Fulton	  and	  
colleagues	  already	   in	  1997	   (21).	  An	  approach	  similar	   to	   that	  of	   the	   fluorescently	  
labeled	  beads	  is	  an	  immunoassay	  with	  bar-­‐coded	  particles	  (22).	  In	  2002	  Robinson	  
and	   collaborators	   analyzed	   protein	   and	   peptide	   microarrays	   on	   poly-­‐L-­‐lysine-­‐
coated	  glass	  microscope	  slides	  for	  autoantibody	  binding	  with	  fluorescence-­‐based	  
detection	  methods	   (23).	  We	   have	   developed	   an	   alternative	  multiplexed	   system	  
for	   monitoring	   ACPA	   reactivities	   in	   RA	   sera	   using	   surface	   plasmon	   resonance	  
imaging	   (iSPR)	  of	  protein/peptide	  microarrays	   (24).	   iSPR	   is	  an	  optical	  method	   to	  
measure	  protein	  binding	   in	   real-­‐time,	  without	   the	  need	   for	   labeling	   (Fig.	  1)	   (25-­‐
27).	   Besides	   the	   multiplexing,	   miniaturization	   and	   automation	   features	   of	   this	  
system,	  major	  advantages	  are	  that	  antibody	  detection	  does	  not	  require	  additional	  
reagents,	   like	   fluorescently	   labeled	  secondary	  antibody-­‐conjugates,	  and	   that	   the	  
arrays	  can	  be	  regenerated,	  allowing	  the	  analysis	  of	  multiple	  sera	  on	  a	  single	  array.	  
In	   the	   present	   study,	   the	   applicability	   of	   this	   system	   for	   the	   simultaneous	  
detection	   of	   various	   ACPA	   in	   RA	   and	   control	   sera	   and	   the	   presence	   of	   specific	  
ACPA	  profiles	  were	  investigated	  using	  microarrays	  containing	  citrullinated	  and	  the	  
corresponding	  non-­‐citrullinated	  peptides.	  	  
Methods	  
Patient	  sera	  
The	   sera	   were	   obtained	   from	   the	   Department	   of	   Rheumatology,	   Radboud	  
University	   Nijmegen	  Medical	   Center.	   Sera	   were	   collected	   from	   patients	   visiting	  
the	  outpatient	  clinic,	  who	  had	  been	  diagnosed	  with	  RA	  according	   to	   the	   revised	  
criteria	   of	   the	   American	   College	   of	   Rheumatology	   (28).	   As	   controls,	   serum	  
samples	   from	   9	   healthy	   individuals	   and	   from	   18	   patients	   with	   systemic	   lupus	  
erythematosus	   (SLE),	   14	  with	   Sjögren’s	   syndrome	   (SS)	   and	   9	  with	   osteoarthritis	  
(OA),	  obtained	  from	  various	  clinics	  and	  hospitals,	  were	  used.	  Sera	  were	  stored	  at	  
-­‐80°C	  until	  used.	  
Microarray	  preparation	  	  
The	   24-­‐spot	  microarray	   containing	   4	   human	   IgG	   spots	   (to	   visualize	   the	   spotted	  
microarrays),	   7	   peptide	   sets	   (citrulline-­‐containing	   peptides	   and	   corresponding	  
arginine-­‐containing	   peptides)	   and	   6	   additional	   citrullinated	   peptides	   were	  
generated	  using	  EDC/NHS-­‐activated	  carboxymethyldextran	  hydrogel	  sensor	  discs	  
(80m,	  XanTec,	  Muenster,	  Germany)	  by	  the	  Topspot	  microarray	  printer	  (Biofluidics	  
GmbH,	   Freiburg).	   The	   sequences	   of	   the	   7	   peptides	   were	   derived	   from	   human	  
vimentin	   (D),	   human	   fibrinogen	   (one	   peptide	   from	   the	   α-­‐chain	   (F)	   and	   one	  
peptide	  from	  the	  β-­‐chain	  (C))	  (12),	  or	  corresponded	  to	  the	  cfc1-­‐cyc	  sequence	  (B)	  
(6),	   or	   to	   the	   sequence	  of	  peptides	   isolated	   from	   synthetic	   citrullinated	  peptide	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libraries	   (A,	   E,	   G)	   (29;	   patent	   PCT/WO	   03/050542).	   One	   of	   the	   additional	   six	  
peptides	  was	  derived	  from	  α-­‐enolase	  (H)	  (12),	  the	  other	  5	  were	  also	  selected	  from	  
synthetic	   citrullinated	   peptide	   libraries	   (I-­‐M	   (patent	   PCT/WO	   03/050542).	   The	  
peptides	   and	   human	   IgG	  were	   spotted	   (30)	   as	   1	   nl	   droplets	   containing	   1	   ng/nl	  
peptide	   in	  50	  mM	  Mes,	  pH	  5.4,	  after	  which	   the	  discs	  were	  placed	   in	  a	  humidity	  
chamber	  at	  room	  temperature	  for	  1	  hr.	  Unreacted	  reactive	  groups	  were	  blocked	  
with	  1	  M	  ethanolamine,	  pH	  8.0	  for	  10	  minutes.	  The	  sensor	  discs	  were	  rinsed	  with	  
PBS	  and	  placed	  on	  a	  hemisphere	  with	  index-­‐matching	  oil	  and	  inserted	  in	  the	  iSPR	  
instrument.	  	  
SPR	  microarray	  interaction	  studies	  
Incubation,	   washing	   and	   regeneration	   were	   performed	   in	   an	   automated	   way	  
using	  liquid	  handling	  procedures	  (LHPs)	  in	  the	  iSPR	  instrument,	  version	  2007	  (IBIS	  
Technologies	   BV,	   Enschede,	   The	   Netherlands).	   A	   serum	   sample	   plug	   of	   400	   µl	  
(diluted	  1:50	  in	  PBS,	  0.03%	  Tween-­‐20)	  was	  flowed	  forward	  and	  backward	  over	  the	  
array	  in	  a	  flow-­‐cell	  with	  a	  speed	  of	  1	  μl/sec.	  The	  serum	  sample	  plug	  was	  flanked	  
on	   both	   sides	   by	   air-­‐plugs	   to	   prevent	   the	   diffusion	   of	   serum	   components	  	  
into	   the	   buffer.	   Between	   all	   steps	   the	   flow-­‐cell	   was	   rinsed	   with	   PBS,	   0.03%	  	  
Tween-­‐20.	   The	   array	   was	   regenerated	   by	   two	   sequential	   injections	   of	   400	   µl	  
10	  mM	   glycine-­‐HCl,	   pH	   1.5,	   both	   for	   30	   seconds	  with	   a	   speed	   of	   1	   μl/sec.	   Two	  
incubation/regeneration	  cycles	  with	  healthy	  control	  sera	  were	  completed	  before	  
applying	  the	  patient	  sera	  in	  order	  to	  block	  nonspecific	  binding	  sites	  and	  to	  create	  
an	   optimal	   sensor	   surface.	   The	   data	   were	   analyzed	   using	   SPRint	   software	   (IBIS	  
Technologies,	  Enschede,	  The	  Netherlands).	  
Peptide	  ELISA	  
Anti-­‐CCP2	   ELISA	   was	   performed	   using	   the	   IMMUNOSCAN	   RA	   test	   (Euro-­‐
Diagnostica,	   Arnhem,	   the	   Netherlands),	   in	   accordance	   with	   the	   manufacturer’s	  
instructions	  with	   the	   recommended	  25	  U/ml	   cut-­‐off.	  Maxisorb	  microtitre	   plates	  
(NUNC)	  were	  coated	  with	  peptide	  G	  (containing	  either	  citrulline	  or	  arginine)	  at	  a	  
concentration	  of	  1	  μg	  per	  well	  in	  100	  μl	  50	  mM	  NaHCO3,	  pH	  9.6,	  overnight	  at	  4⁰C.	  
Non-­‐specific	  binding	  sites	  were	  blocked	  with	  150	  μl	  5%	  skimmed	  milk,	  PBS,	  0.05%	  
Tween-­‐20	   (MPBST)	   per	   well	   at	   room	   temperature	   for	   two	   hours.	   Sera	   were	  
diluted	  1:100	  in	  MPBST	  and	  100	  μl	  was	  added	  at	  room	  temperature	  for	  one	  hour.	  
The	  plates	  were	  washed	  tree	  times	  with	  PBS,	  0.05%	  Tween-­‐20	  and	  subsequently	  
HRP-­‐conjugated	   anti-­‐human	   immunoglobulin	   antibody	   (anti-­‐IgG,	   -­‐IgA,	   -­‐IgM,	  	  
-­‐kappa,	   -­‐lambda;	   P212,	   Dako,	   Glostrup,	   Denmark)	   was	   added	   at	   a	   1000-­‐fold	  
dilution	  in	  MPBST,	  followed	  by	  an	  incubation	  at	  room	  temperature	  for	  one	  hour.	  
Plates	  were	  washed	   three	   times	  with	  PBS,	   0.05%	  Tween-­‐20	   and	  once	  with	  PBS.	  
Bound	  HRP-­‐conjugated	   antibodies	  were	  detected	  by	   TMB	   conversion.	   Reactions	  
were	  stopped	  with	  1	  M	  H2SO4	  and	  the	  absorbance	  was	  measured	  at	  450	  nm.	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Data	  analysis	  
Figure	   1	   shows	   a	   sensorgram	   for	   the	   interaction	   of	   serum	   antibodies	   with	   a	  
peptide	   on	   a	   microarray.	   The	   extent	   of	   antibody	   (and	   possibly	   other	   serum	  
molecules)	  binding	  to	  the	  peptide	  was	  established	  by	  determining	  the	  difference	  
in	   resonance	   angle	   before	   and	   after	   the	   binding	   (after	   washing	   and	   at	   the	  
baseline)	  (24,25).	  To	  control	  for	  non-­‐specific	  reactivities	  (e.g.	  to	  other	  parts	  of	  the	  
citrullinated	   peptides),	   control	   peptides	   were	   included	   in	   which	   the	   citrulline	  
residue	  is	  replaced	  by	  an	  arginine	  residue.	  In	  the	  arrays	  used	  in	  these	  experiments	  
7	  control	  peptides	  were	  included.	  The	  mean	  of	  the	  arginine	  control	  peptides	  was	  
determined	   for	   each	   sample,	   and	   these	  mean	   values	  were	   subtracted	   from	   the	  
signals	   obtained	   for	   the	   citrulline	   peptides	   for	   each	   individual	   sample.	   Sera	  
displaying	   standard	   deviations	   of	   30	   mdeg	   or	   more	   for	   the	   arginine-­‐containing	  
peptides	  were	   excluded	   from	   the	   analysis.	   A	   cut-­‐off	   angle	   shift	   for	   positivity	   of	  
20	  mdeg	   was	   derived	   from	   the	   background	   signals	   obtained	   with	   sera	   from	  
normal	  healthy	  controls.	  The	  reactivities	  of	  the	  RA	  sera	  with	  these	  peptides	  were	  
categorized	   as	   negative	   (angle	   shifts	   to	   20	   mdeg),	   weak	   (angle	   shifts	   of	  	  
20	  -­‐	  30	  mdeg),	  moderate	   (angle	  shifts	  of	  30	   -­‐	  50	  mdeg)	  or	  strong	  (angle	  shifts	  of	  
50	   mdeg	   or	   more).	   Cluster	   and	   principal	   component	   analysis	   were	   performed	  
using	  SPSS	  for	  Windows,	  version	  14.0,	  and	  R,	  version	  2.13.0	  (31).	  	  
Results	  and	  Discussion	  
Autoantibody	  monitoring	  by	  microarray	  iSPR	  
The	  methodology	   used	   in	   this	   study	   to	  monitor	   autoantibodies	   in	   patient	   sera,	  
iSPR	  of	  biomolecular	  interactions	  on	  microarrays,	  was	  introduced	  recently	  (24,25).	  
Interactions	  are	  measured	  by	  changes	  in	  the	  SPR	  angle	  over	  time	  and	  are	  plotted	  
in	  a	  sensorgram	  as	  shown	   in	  Figure	  1.	  After	  determining	  the	  baseline	  resonance	  
angle,	   a	  diluted	   serum	  was	  applied	   to	  allow	  binding	   to	   the	   immobilized	  peptide	  
antigens	  for	  1	  hour,	  followed	  by	  a	  washing	  step	  to	  remove	  non-­‐specifically	  bound	  
material.	  The	  sensor	  disc	  was	  subsequently	  regenerated	  by	  a	  pH	  shock	  (pH	  1.5),	  
after	   which	   the	   next	   serum	   was	   injected.	   The	   difference	   in	   resonance	   angle	  	  
after	   washing	   and	   at	   the	   baseline	   is	   correlated	   with	   the	   mass	   increase	  	  
on	   the	   sensor	   surface	   due	   to	   the	   binding	   of	   antibodies	   (and	   possibly	  	  
other	   molecules).	   To	   demonstrate	   the	   applicability	   of	   the	   microarrays	   for	  	  
ACPA	   profiling,	   an	   array	   of	   3	   peptide	   sets	   (citrulline-­‐	   and	   corresponding	  	  
arginine-­‐containing	   peptides)	   was	   probed	   with	   3	   anti-­‐CCP-­‐positive	   RA	   sera.	  	  
Figure	   2A	   shows	   the	   sensorgrams	   for	   each	   of	   these	   6	   peptides.	   The	   results	  
demonstrate	   that	   sera	   1,	   2	   and	   3	   show	   reactivity	   with	   one	   (peptide	   A),	   two	  
(peptides	  A	   and	  B)	   and	   three	   citrullinated	   peptides	   (peptides	  A-­‐C),	   respectively.	  
The	  results	  of	  previous	  experiments	  showed	  that	  the	  intra-­‐assay	  variation	  is	  very	  





	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2:	  Sensorgrams	  of	  three	  peptide	  sets	  with	  three	  different	  RA	  sera.	  Three	  distinct	  peptides	  
(A-­‐C),	  each	  containing	  either	  citrulline	  (Cit)	  or	  arginine	  (Arg),	  were	  immobilized	  on	  sensor	  discs	  and	  
successively	  incubated	  with	  three	  different	  RA	  sera.	  Resonance	  angles	  were	  recorded	  with	  the	  iSPR	  
equipment.	  A)	  Sensorgram	  of	  raw	  data.	  The	  sharp	  resonance	  angle	  peaks	  with	  negative	  values	  are	  
due	   to	   differences	   in	   refractive	   indices	   of	   the	   glycine	   buffer	   and	   the	   incubation	   buffer.	  	  
B)	   Sensorgram	   of	   processed	   data,	   the	   arginine-­‐peptide	   signals	   are	   subtracted	   from	   the	  
corresponding	  citrulline-­‐peptide	  signals.	  A	  serum	  is	  scored	  positive	  when	  the	  resonance	  angle	  shift	  
observed	  for	   the	  citrullinated	  peptide	  after	  removing	  non-­‐specifically	  bound	  serum	  components	   is	  
at	  least	  20	  mdeg	  larger	  than	  that	  observed	  for	  the	  corresponding	  arginine-­‐containing	  peptide.	  
	  
	  
peptide	  showed	  a	  mean	  SPR	  angle	  shift	  of	  202.5	  mdeg	  with	  a	  standard	  deviation	  
of	   1.3	   mdeg.	   The	   peptide-­‐containing	   sensor	   chips	   could	   be	   used	   for	   up	   to	  
30	  cycles	   without	   a	   significant	   reduction	   of	   performance,	   as	   monitored	   by	   the	  
analysis	  of	  the	  same	  reactive	  serum	  every	  tenth	  cycle	  (24,25).	  
Microarrays	  containing	  multiple	  citrullinated	  antigens	  	  
Differences	   in	  ACPA	  specificities	  are	  most	   likely	  due	  to	  the	   identity	  of	  the	  amino	  
acids	  flanking	  the	  citrulline	  in	  the	  protein/peptide	  target.	  To	  detect	  various	  ACPA	  
in	   the	   sera	   of	   RA	   patients	   simultaneously,	   microarrays	   containing	   13	   different	  
citrullinated	   peptides	   were	   generated.	   For	   7	   of	   these	   peptides	   also	   the	  
corresponding	  arginine-­‐containing	  peptides	  were	  immobilized	  on	  the	  arrays.	  The	  
citrullinated	  peptides	  were	  selected	  based	  upon	  their	  recognition	  by	  ACPA	  in	  RA	  
sera	  as	  revealed	  by	  previous	  ELISA	  experiments.	  The	  sequences	  of	  these	  peptides	  
are	  derived	  from	  filaggrin,	  vimentin,	  fibrinogen	  α-­‐chain,	  fibrinogen	  β-­‐chain,	  and	  α-­‐
enolase	   or	   correspond	   to	   the	   sequences	   of	   peptides	   that	   were	   isolated	   from	  
synthetic	   citrullinated	   peptide	   libraries.	   The	   peptides	   were	   immobilized	   on	   the	  
surface	  of	  EDC/NHS	  activated	  carboxymethyldextran-­‐containing	  iSPR	  sensor	  discs	  
by	   covalent	   coupling	   to	   primary	   amines	   of	   the	   peptides.	   Previously,	   we	  
demonstrated	   that	   the	   charge	   difference	   between	   the	   citrullinated	   and	  
corresponding	   arginine-­‐containing	   peptides	   did	   not	   affect	   their	   immobilization	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Figure	  3:	  Correlation	  diagrams	  for	  non-­‐specific	  binding	  corrections.	  The	  iSPR	  resonance	  angle	  shifts	  
obtained	  with	  the	  citrullinated	  peptides	  were	  either	  corrected	  for	  non-­‐citrulline-­‐dependent	  binding	  
by	  subtracting	  the	  shifts	  observed	  for	  the	  corresponding	  arginine-­‐containing	  peptides	  (x-­‐axis)	  or	  by	  
subtracting	   the	   mean	   of	   the	   shifts	   observed	   for	   6	   arginine-­‐containing	   peptides	   (y-­‐axis).	   A.	  
Correlation	   between	   the	   correction	   procedures	   for	   peptides	   A-­‐F.	   B.	   Correlation	   between	   the	  
correction	  procedures	  for	  peptide	  G.	  
	  
	  
microarray	  to	  control	  for	  non-­‐specific	  binding.	  To	  test	  if	  the	  mean	  values	  obtained	  
with	   these	   peptides	   could	   be	   used	   to	   correct	   for	   non-­‐specific	   binding	   to	   the	  
citrulinated	   peptides,	   the	   correlation	   between	   the	   values	   obtained	   after	  
correction	   with	   either	   the	   mean	   values	   obtained	   for	   the	   arginine-­‐containing	  
peptides	  or	  with	  the	  values	  observed	  for	  each	  corresponding	  arginine-­‐containing	  
peptide	  was	  determined	  (Fig.	  3).	  For	  peptide	  G	  no	  correlation	  between	  the	  values	  
after	  ‘peptide-­‐specific’	  and	  the	  ‘7-­‐peptide-­‐mean’	  correction	  was	  observed	  and	  the	  
remaining	   values	   were	   all	   very	   small,	   in	   particular	   when	   the	   correction	   was	  
performed	   with	   the	   values	   obtained	   with	   the	   arginine	   variant	   of	   this	   peptide	  
(Fig.	  3B).	  This	  might	  be	  explained	  by	  the	  presence	  of	  another	  epitope	   in	  peptide	  
G,	   the	   recognition	   of	  which	   is	   not	   dependent	   on	   the	   citrulline	   residue.	   For	   that	  
reason	   peptide	   G	   was	   excluded	   from	   the	   correction	   method.	   The	   correlation	  
between	   the	  mean	   values	   for	   the	   other	   six	   peptides	   (A-­‐F)	   appeared	   to	   be	   high	  
(correlation	   coefficient	  0.918;	   Figure	  3A),	  which	   justifies	   the	   correction	  with	   the	  
mean	  of	  the	  remaining	  six	  peptides	  (A-­‐F).	  	  
Reactivities	  with	  arginine-­‐containing	  peptides	  
The	  binding	  efficiency	  of	  serum	  components	   to	   the	  arginine-­‐containing	  peptides	  
was	  generally	  low,	  as	  illustrated	  by	  the	  examples	  in	  Figure	  2.	  However,	  the	  signals	  
obtained	   for	   one	   of	   the	   arginine-­‐containing	   peptides	   (peptide	   G)	   were	   often	  
relatively	  high	  with	  RA	  sera	  compared	  to	  signals	  for	  the	  control	  sera	  and	  similar	  to	  
those	  observed	  for	  the	  corresponding	  citrulline-­‐containing	  peptide.	  To	  investigate	  















































Figure	  4:	  The	   recognition	  of	  peptide	  G	  by	  RA	  sera	   is	   citrulline-­‐independent.	  A.	   iSPR	  and	  B.	  ELISA	  
results	   for	   both	   the	   citrullinated	   and	   the	   arginine-­‐containing	   peptide	   G.	   RA:	   rheumatoid	   arthritis	  
sera;	  Control:	  sera	  from	  15	  systemic	   lupus	  erythematosus;	  12	  Sjögren’s	  syndrome;	  9	  osteoarthritis	  
patients	  and	  10	  healthy	  individuals.	  
	  
	  
that	  the	  iSPR	  signals	  were	  due	  to	  antibody	  binding,	  the	  recognition	  of	  this	  peptide	  
was	  also	  analyzed	  by	  ELISA.	  The	  reactivity	  of	  96	  RA	  and	  48	  control	  sera	  (SLE,	  SS,	  
OA	   and	   normal	   human	   sera)	   was	   determined.	   The	   results	   of	   both	   the	   iSPR	  
analyses	   and	   the	   ELISA	   analyses	   (Fig.	   4)	   show	   that	   both	   the	   citrulline	   and	   the	  
arginine	  peptide	  G	  were	  significantly	  more	  reactive	  with	  RA	  sera	  than	  with	  control	  
sera	  in	  both	  assays.	  When	  the	  reactivities	  of	  control	  sera	  were	  used	  to	  determine	  
a	  cut-­‐off	  value,	  45%	  and	  44%	  of	  the	  RA	  sera	  were	  reactive	  with	  the	  citrulline-­‐	  and	  
arginine-­‐contaning	   peptide	   G,	   respectively,	   in	   iSPR,	   whereas	   these	   percentages	  
were	  57%	  and	  59%	  in	  ELISA.	  The	   increased	  recognition	  of	  peptide	  G	   irrespective	  
of	   the	   presence	   of	   citrulline	   suggests	   that	   the	   epitope	   in	   this	   peptide	   is	  
independent	   of	   the	   citrulline	   residue.	   Further	   experiments	   will	   be	   required	   to	  
investigate	   the	  diagnostic	  and/or	  prognostic	   value	  of	  antibodies	   recognizing	   this	  
peptide.	  
ACPA	  profiling	  by	  iSPR	  
Using	   the	   microarrays	   containing	   13	   citrullinated	   peptides	   and	   7	   arginine-­‐
containing	   peptides	   described	   above,	   97	   RA	   sera	   and	   50	   control	   sera	   were	  











Figure	   5:	   Reactivity	   RA	   and	   non-­‐RA	   sera	   with	   an	   array	   containing	   13	   citrullinated	   peptides.	  
Peptides	   A	   through	  M	  were	   immobilized	   on	   iSPR	   sensor	   discs	   and	   incubated	  with	   RA	   (both	   anti-­‐
CCP2-­‐positive	   (CCP2+)	   and	   -­‐negative	   (CCP2-­‐)),	   SLE,	   SS,	   OA,	   and	   normal	   human	   (NHS)	   sera.	   The	  




sera	   was	   categorized	   in	   4	   groups:	   no	   reactivity	   (angle	   shifts	   smaller	   than	  
20	  mdeg),	   weak	   reactivity	   (angle	   shifts	   of	   20	   -­‐	   30	   mdeg),	   moderate	   reactivity	  
(angle	  shifts	  of	  30	  -­‐	  50	  mdeg)	  and	  strong	  reactivity	  (angle	  shifts	  of	  more	  than	  50	  
mdeg).	   As	   expected,	   the	   citrullinated	   peptides	   displayed	   various	   patterns	   of	  
recognition	  by	  the	  RA	  sera	  and	  the	  citrullinated	  epitope-­‐specific	  reactivities	  were	  
indeed	   found	  to	  be	  most	  prevalent	   in	   the	  anti-­‐CCP2	  positive	  group.	  Most	  of	   the	  
reactivities	   found	   in	   the	   RA	   sera	   were	   directed	   to	   peptide	   A,	   which	   was	  
recognized	  by	  38%	  of	  the	  RA	  sera.	  All	  of	  these	  sera	  were	  anti-­‐CCP2-­‐positive.	  This	  
peptide	  was	  not	  recognized	  by	  any	  of	  the	  control	  sera.	  Another	  peptide	  that	  was	  
frequently	  recognized	  by	  the	  RA	  sera	  was	  peptide	  E	  (recognized	  by	  40%	  of	  the	  RA	  
sera),	  but	  this	  peptide	  was	  also	  recognized	  by	  6	  control	  sera	  (12%),	  although	  the	  
reactivity	  of	  the	  latter	  sera	  was	  generally	  weak.	  Interestingly,	  also	  24%	  of	  the	  anti-­‐
CCP2-­‐negative	   sera	   appeared	   to	   be	   reactive	   with	   this	   peptide.	   The	   same	   holds	  
true	  for	  peptide	  I,	  which	  was	  recognized	  by	  36%	  of	  the	  RA	  sera	  (35	  out	  of	  97	  sera	  
reacted	  with	  this	  peptide),	  whereas	  it	  was	  recognized	  by	  only	  10%	  of	  the	  control	  
sera.	  Peptide	  M	  showed	  more	  reactivity	  with	  sera	  of	  patients	  with	  SLE	  (39%)	  and	  
SS	  (36%)	  than	  with	  RA	  sera	  (5%).	  Recently,	  it	  became	  clear	  that	  RA	  patients	  can	  be	  
classified	   into	   two	  major	   subsets,	   those	  who	   have	  ACPA	   and	   those	  who	   do	   not	  
(32).	  Some	  peptides	  on	  our	  array	  were	  recognized	  by	  anti-­‐CCP2	  negative	  RA	  sera,	  
but	  the	  reactive	  antibodies	  were	  either	  rare,	  or	  only	  weakly	  reactive	  (peptides	  B,	  
C	  and	  F),	  or	  not	  RA-­‐specific,	   since	   they	  also	  showed	  reactivity	  with	  a	  number	  of	  





















recognition	  pattern	  was	  observed.	  This	  peptide	  was	  particularly	  reactive	  with	  sera	  
from	   SLE	   and	   SS	   patients,	   whereas	   hardly	   any	   reactivity	   was	   observed	  with	   RA	  
sera.	   To	   reveal	   potential	   correlations	   between	   the	   recognition	   patterns	   of	  
individual	   peptides,	   the	   data	   were	   subjected	   to	   a	   principal	   component	   analysis	  
(PCA).	  PCA	  is	  a	  variable	  reduction	  procedure,	  which	  can	  be	  used	  to	  convert	  a	  set	  
of	  possibly	  correlated	  variables	  into	  a	  set	  of	  uncorrelated	  variables	  called	  principal	  
components.	  These	  principal	   components	  will	  account	   for	  most	  of	   the	  observed	  
variances.	  For	  instance,	  when	  the	  recognition	  of	  two	  different	  peptides	  by	  patient	  
sera	  is	  similar,	  the	  use	  of	  only	  one	  of	  these	  would	  be	  sufficient	  for	  autoantibody	  
profiling.	  The	  PCA	  analysis	  on	  the	  tested	  sera	  did	  not	  reveal	  any	  redundancy	  in	  the	  
reactivities	  with	  the	  different	  citrullinated	  peptides,	  suggesting	  that	  the	  peptides	  
used	   do	   not	   contain	   identical	   or	   highly	   similar	   citrullinated	   epitopes.	   Taken	  
together,	   these	   data	   confirm	   the	   frequent	   recognition	   of	   various	   citrullinated	  
peptides	  by	  RA	  sera,	  especially	  anti-­‐CCP2-­‐positive	  sera,	  but	  also	  demonstrate	  the	  
diversity	   of	   citrullinated	   peptide	   recognition	   among	   different	   patients.	   Both	   the	  
number	   of	   reactive	   peptides	   and	   the	   reactivity	   profiles	   of	   individual	   sera	   vary	  
extensively.	  
Analysis	  of	  ACPA	  profiles	  
The	  identification	  of	  ACPA	  reactivity	  profiles	  based	  upon	  the	  ACPA	  fine-­‐specificity	  
of	   individual	   sera	   may	   allow	   the	   subclassification	   of	   RA	   patients	   and	   lead	   to	   a	  
more	   accurate	   prognosis	   and	   to	   more	   focused	   and	   better	   tailored	   therapies.	  
Indeed	   the	   group	   of	   Robinson	   showed	   that	  multiplex	   analysis	   of	   biomarkers	   in	  
early-­‐stage	  RA	  allowed	  the	  stratification	  of	  patients	  with	  clinically	  identifiable	  RA	  
subtypes	  (33,34).	  To	  investigate	  whether	  common	  autoantibody	  reactivity	  profiles	  
could	  be	  discerned	  in	  the	  dataset	  obtained	  by	  the	  iSPR	  analyses,	  a	  cluster	  analysis	  
was	  performed.	  The	  results,	  shown	  in	  Figure	  6,	  confirmed	  that	  the	  recognition	  of	  
peptide	   A	   was	   associated	   with	   anti-­‐CCP2	   positivity	   and	   also	   show	   that	   the	  
autoantigenicity	  of	  peptide	  A	  is	  completely	  distinct	  from	  that	  of	  all	  other	  peptides.	  
The	  other	  most	  frequently	  reactive	  peptides,	  E,	  K	  and	  I	  were	  clustered	  in	  a	  group,	  
the	  reactivity	  of	  which	  seemed	  to	  be	  inversely	  correlated	  with	  that	  of	  peptide	  A.	  
These	   data	   suggest	   that	   the	   citrullinated	   epitope	   in	   peptides	   E,	   K	   and	   I	  may	   be	  
partially	   related.Clustering	   of	   the	   patients	   revealed	   3	  major	   groups:	   1)	   patients	  
who	  recognize	  peptide	  A	  and	  show	  no	  or	  only	  weak	  reactivities	  with	  peptides	  E,	  K	  
and	   I;	  2)	  patients	  who	  recognize	  peptide	  A	  and	  show	  moderate	   reactivities	  with	  
peptides	   E,	   K	   and	   I,	   and	   3)	   patients	   who	   are	   not	   or	   only	   weakly	   reactive	   with	  
peptide	  A	  and	  who	  show	  moderate	  to	  strong	  reactivities	  with	  peptides	  E,	  K	  and	  I.	  
All	   the	   sera	   in	   the	   first	   two	   groups	   were	   anti-­‐CCP2-­‐positive,	   whereas	   the	   third	  
cluster	   comprised	   both	   anti-­‐CCP2-­‐positive	   and	   anti-­‐CCP2-­‐negative	   patients.	   The	  
reactivities	  against	  peptides	  E,	  K	  and	   I	  were	  not	   restricted	   to	  RA;	  peptide	  E	  was	  
recognized	  by	  6,	  peptide	  I	  by	  5	  and	  peptide	  K	  by	  2	  diseased	  controls.	  Only	  one	  of	  	  
	  





Figure	   6:	   Cluster	   analysis	   of	   anti-­‐citrullinated	   peptide	   iSPR	   data.	   The	   dataset	   obtained	   with	  
peptides	  A	  through	  M	  and	  both	  the	  RA	  (97)	  and	  control	  (50)	  sera	  was	  subjected	  to	  a	  cluster	  analysis,	  
the	   results	  of	  which	  are	  presented	   in	   a	  heat	  map.	  High	   signals	   are	   shown	   in	  blue,	  whereas	  no	  or	  
weak	  signals	  are	  shown	  in	  red.	  A.	  Heat	  map	  for	  the	  RA	  sera;	  anti-­‐CCP2-­‐positive	  sera	  are	  marked	  by	  
the	  green	  bars,	  while	  anti-­‐CCP2-­‐negative	  sera	  are	  marked	  by	  the	  yellow	  bars.	  B.	  Heat	  map	  for	  the	  
control	  sera.	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these	   sera	   (from	   a	   SS	   patient)	   had	   antibodies	   against	   all	   3	   peptides.	   Cluster	  
analysis	  was	  also	  performed	  with	  the	  data	  obtained	  for	  the	  control	  sera	  (Fig.	  6B).	  
No	   or	   hardly	   any	   correlation	   was	   observed	   between	   the	   clustering	   of	   patients	  
(and	   healthy	   controls)	   and	   the	   different	   diseases.	   In	   2009,	   Van	   der	   Linden	   and	  
coworkers	   showed	   that	   the	   combination	   of	   two	   or	  more	   highly	   sensitive	   ACPA	  
tests	   does	   not	   improve	   the	   diagnostic	   value	   (35).	   These	   tests	   contain	   antigenic	  
targets	   which	   had	   been	   selected	   based	   upon	   their	   high	   sensitivity	   for	   ACPA	  
detection	   and	   therefore	   are	   suited	   to	   differentiate	   between	   ACPA-­‐positive	   and	  
ACPA-­‐negative	   RA	   patients.	   In	   this	   study	   we	   generated	   a	  multiplex	   assay	   using	  
citrullinated	  autoantibody	  targets	  that	  are	  less	  frequently	  found	  in	  the	  sera	  of	  RA	  
patients	   which	   allows	   the	   detection	   of	   ACPA	   subtype	   profiles.	   The	   question	  
whether	   these	   profiles	   can	   be	   used	   to	   stratify	   patients	   with	   different	   clinical	  
features	  awaits	   further	  analyses	  with	   larger	   cohorts	  of	   clinically	  well-­‐defined	  RA	  
patients.	  	  
Conclusion	  
This	   study	   shows	   that	   microarray-­‐iSPR	   is	   a	   suitable	   technology	   for	   the	  
simultaneous	   detection	   of	   ACPA	   fine-­‐specificities	   and	   the	   visualization	   of	   ACPA	  
profiles.	  The	  RA	  patients	  could	  be	  subclassified	   into	  3	  main	  groups	  based	  on	  the	  
differential	   reactivity	   with	   4	   peptides	   as	   revealed	   by	   a	   cluster	   analysis.	   The	  
analysis	   of	   many	   clinically	   well-­‐characterized	   sera	   will	   be	   required	   to	   elucidate	  
correlations	  between	  ACPA	  profiles	  and	  clinical	   features,	   such	  as	   the	   severity	  of	  
disease	  progression	  and	  the	  responsiveness	  to	  specific	  therapies.	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utoimmune	   diseases	   are	   believed	   to	   develop	   due	   to	   a	   loss	   of	  
immunological	   tolerance,	   which	   may	   result	   in	   the	   formation	   of	  
autoantibodies	   and/or	   the	   destruction	   of	   tissue.	   Posttranslational	  
modifications	   of	   autoantigens	   have	   been	   proposed	   to	   play	   a	   role	   in	   the	  
generation	   of	   autoantibodies.	   In	   addition	   to	   apoptosis-­‐	   or	   necrosis-­‐induced	  
modifications,	  oxidative	  stress-­‐induced	  modifications	  are	  also	  believed	  to	  play	  a	  
role	   in	   the	   generation	   of	   such	   neo-­‐epitopes.	   To	   investigate	  whether	   oxidative	  
stress	  leads	  to	  the	  modification	  of	  autoantigenic	  proteins	  in	  SLE,	  PM/Scl	  overlap	  
syndrome	   and	  myositis,	  we	   analyzed	   these	   proteins	   from	   oxidatively	   stressed	  
Jurkat	  cells	  as	  well	  as	  their	  purified	  recombinant	  equivalents	  by	  SDS-­‐PAGE	  and	  
immunoblotting.	   A	   time	   and	   H2O2-­‐concentration	   dependent	   retarded	  
electrophoretic	  mobility	  was	  observed	  for	  all	  analyzed	  proteins.	  In	  vitro	  oxidized	  
recombinant	   U1A	   and	   Jo-­‐1	   proteins	   resulted	   in	   mobility	   shifts	   that	   were	  
comparable	   with	   those	   observed	  with	   H2O2-­‐treated	   Jurkat	   cells.	   The	   retarded	  
migration	  of	  U1A,	  Rrp40,	  Rrp41,	  Ro60,	  La,	  and	  Jo-­‐1	  in	  SDS-­‐PAGE	  can	  result	  from	  
the	   oxidative	   modification	   of	   these	   proteins	   upon	   H2O2	   treatment.	   Hydroxyl	  
radicals	  are	  suggested	  to	  be	  involved	  in	  the	  oxidative	  modification,	  because	  we	  
observed	  similar	  results	  with	  hypochlorite	  treated	  Jurkat	  cells	  and	  recombinant	  
proteins.	   These	   modifications	   may	   result	   in	   the	   increased	   autoantigenicity	   of	  
the	   protein	   to	   which	   the	   immune	   response	   in	   the	   respective	   autoimmune	  
diseases	  is	  directed.	  
Introduction	  
Neo-­‐epitopes	   generated	   by	  modification	   of	   self-­‐proteins	  may	   trigger	   the	   loss	   of	  
immunological	   tolerance	   in	   autoimmune	   diseases.	   Since	   this	   hypothesis	   was	  
formulated,	  researchers	  have	  focused	  on	  finding	  processes	  which	  may	  cause	  such	  
alterations	   in	   self	   proteins.	   Cell	   death	   is	   a	   process	   often	   accompanied	   by	  
posttranslational	  modifications.	   Both	   apoptotic	   and	   necrotic	  modifications	   have	  
been	  reported	  to	  occur	  in	  a	  variety	  of	  autoantigens	  (1,2).	  Reactive	  oxygen	  species	  
(ROS)-­‐mediated	  reactions,	  which	  can	  be	  associated	  with	  necrosis,	  may	  also	  be	  of	  
importance	  for	  the	  modification	  of	  self	  proteins.	  One	  of	  the	  mechanisms	  that	  are	  
used	   by	   the	   innate	   immune	   system	   to	   destroy	   foreign	   pathogens	   is	   the	   rapid	  
release	   of	   ROS,	   a	   process	  which	   is	   called	   oxygen-­‐	   or	   respiratory	   burst.	   ROS	   are	  
oxygen-­‐based	  molecules	  which	  are	  highly	  reactive	  and	  include	  superoxide	  (O2•-­‐),	  
hydroxyl	   radicals	   (OH•)	   and	   hydrogen	   peroxide	   (H2O2).	   ROS	   can	   be	   formed	  
intracellularly,	  in	  for	  example	  the	  mitochondria,	  as	  a	  natural	  byproduct	  of	  oxygen	  
metabolism.	   Under	   stress	   conditions	   ROS	   levels	   can	   increase	   dramatically	   and	  
damage	  cellular	  structures,	   including	  DNA,	  proteins	  and	   lipids	  (3-­‐5).	  Cell	  damage	  
often	   results	   in	   apoptosis	   or	   necrosis.	   Antigens	   in	   a	   variety	   of	   autoimmune	  
diseases,	   including	   systemic	   lupus	   erythematosus	   (SLE),	   type	   1	   diabetes	   (T1D),	  
and	  rheumatoid	  arthritis	   (RA)	  have	  been	  shown	  to	  be	  oxidatively	  modified	  (6,7).	  




can	   be	   diverse.	   For	   example,	   Ro60,	   a	   60	   kDa	   antigenic	   target	   for	   antibodies	  
present	   in	   a	   subset	  of	   SLE	  patients,	   can	  be	  modified	  by	   lipid	  oxidation	  products	  
resulting	  in	  the	  formation	  of	  aldehydes,	  mainly	  4-­‐hydroxy-­‐2-­‐alkenals.	  In	  addition,	  
during	   inflammation	  non-­‐enzymatic	  reactions	  can	  result	   in	  the	  production	  of	  so-­‐
called	   “advanced	   glycation	   end”	   products	   (AGE),	   which	   can	   be	   associated	   with	  
proteins	   (8).	   AGE-­‐modified	   antibodies	   are	   found	   amongst	   others	   in	   rheumatoid	  
arthritis	   patients	   and	   are	   believed	   to	   be	   the	   result	   of	   inflammation	   and/or	  
oxidative	   stress	   (9).	   The	   generation	  of	   anti-­‐IgG-­‐AGE	   appears	   to	   be	   specific	   for	   a	  
subset	   of	   RA	   patients	   suggesting	   that	   the	   modification	   of	   distinct	   proteins	   can	  
result	   in	   different	   clinical	   phenotypes	   (10).	   To	   further	   investigate	   whether	  
oxidative	   stress	   conditions	   are	   able	   to	   cause	   distinct	   posttranslational	  
modifications	   (PTM)	   of	   autoantigenic	   proteins,	   we	   studied	   the	   effects	   of	   ROS-­‐
inducing	  compounds	  on	  intracellular	  proteins.	  	  
Materials	  and	  Methods	  
Cell	  lines	  
Jurkat	  (human	  T	  cell	  lymphoma)	  cells	  were	  cultured	  in	  RPMI	  1640	  GlutaMAXTM-­‐I	  
(Gibco-­‐BRL)	   supplemented	   with	   10%	   heat-­‐inactivated	   fetal	   calf	   serum	   (Gibco-­‐
BRL),	  25	  mM	  Hepes-­‐KOH,	  pH	  8.0,	  1	  mM	  penicillin,	  1	  mM	  streptomycin,	  and	  1	  mM	  
sodium	  pyruvate.	  The	  cells	  were	  grown	  in	  a	  humidified	  37°C	  incubator	  containing	  
5%	  CO2	  and	  maintained	  at	  a	  cell	  density	  of	  0.5	  to	  1.2	  x	  106	  cells/ml.	  
Induction	  of	  oxidative	  stress	  and	  cell	  extract	  preparation	  
Oxidative	   stress	   was	   generally	   induced	   by	   incubation	   of	   Jurkat	   cells	   in	   culture	  
medium	   supplemented	  with	   48	  mM	  H2O2	   (Acros	  Organics;	   Geel,	   Belgium)	   for	   5	  
hours,	  or	  as	  indicated.	  Alternatively,	  Jurkat	  cells	  were	  subjected	  for	  the	  indicated	  
periods	   of	   time	   to	   15	   mM	   NaOCl	   in	   culture	   medium.	   Cells	   were	   harvested	   by	  
centrifugation	  and	  resuspended	  in	  sonication	  buffer	  (20	  mM	  Hepes-­‐KOH,	  pH	  7.4,	  
100	   mM	   KCl,	   0.5	   mM	   PMSF,	   0.1%	   NP-­‐40,	   2	   mM	   EDTA,	   1	   mM	   DTE)	   at	   a	  
concentration	   of	   108	   cells/ml	   and	   lysed	   by	   sonication	   on	   ice.	   Cell	   debris	   was	  
removed	  by	  centrifugation	  for	  15	  min	  at	  16,000xg	  and	  supernatants	  were	  stored	  
at	  -­‐20°C	  until	  use.	  
In	  vitro	  oxidative	  modification	  	  
Recombinant	  U1A	  and	  Jo-­‐1	  proteins	  were	  purified	  as	  described	  below,	  after	  which	  
the	  buffer	  was	  exchanged	  with	  KRB-­‐buffer	  (20	  mM	  Hepes-­‐KOH,	  pH	  7.4,	  127	  mM	  
NaCl,	  5.5	  mM	  KCl,	  10	  mM	  glucose,	  1	  mM	  CaCl2,	  and	  2	  mM	  MgSO4)	  using	  overnight	  
dialysis	   at	   4°C	   in	   10	   kDa	   cut-­‐off	   Spectra/Por®	   6	   tubes	   (VWR).	   Recombinant	  
proteins	  were	  subjected	  to	  oxidative	  conditions	  generated	  by	  the	  Fenton	  reaction	  
by	  incubation	  with	  100	  µM	  Fe(SO4)	  and	  1.7	  mM	  ascorbic	  acid	   in	  KRB-­‐buffer	  with	  
or	   without	   13	   mM	   H2O2	   for	   30	   minutes.	   The	   reaction	   was	   stopped	   by	   adding	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10	  mM	  EDTA.	  Alternatively,	  recombinant	  U1A	  and	  Jo-­‐1	  protein	  was	  subjected	  for	  
up	  to	  30	  minutes	  to	  1.5	  mM	  NaOCl	  in	  KRB-­‐buffer.	  
Gel	  electrophoresis	  and	  immunoblotting	  
Extracts	   from	  normal	  or	  oxidized	   Jurkat	  cells	  and	  material	   from	  mock	  or	   in	  vitro	  
oxidized	   recombinant	   proteins	   were	   separated	   by	   electrophoresis	   in	  
polyacrylamide	   gels	   and	   stained	   with	   colloidal	   Coomassie	   Brilliant	   Blue	   (CBB;	  
0.08%	   CBB	   G250,	   1.6%	   ortho-­‐phosphoric	   acid,	   8%	   ammonium	   sulfate	   and	   20%	  
methanol)	   or	   transferred	   to	   nitrocellulose	   membranes	   by	   electroblotting.	  
Membranes	   were	   blocked	   with	   5%	   non-­‐fat	   dried	   milk	   in	   PBS	   containing	   0.05%	  
Tween-­‐20	   (MPBST).	   Mouse	   monoclonal	   antibodies	   (anti-­‐U1A,	   9A9,	   anti-­‐Ro60,	  
1D11,	   and	   anti-­‐La,	   SW5),	   rabbit	   polyclonal	   antibodies	   (anti-­‐Rrp40,	   H70,	   anti-­‐
Rrp41,	   H71)	   and	   human	   patient	   sera	   (anti-­‐Jo-­‐1,	   anti-­‐U1-­‐70k	   and	   anti-­‐
topoisomerase	   I)	   were	   diluted	   in	   MPBST	   prior	   to	   the	   detection	   of	   proteins	   on	  
western	  blot.	  As	   secondary	   antibody,	   horseradish	  peroxidase-­‐conjugated	   rabbit-­‐
anti	   mouse	   IgG,	   swine	   anti-­‐rabbit	   IgG	   or	   rabbit-­‐anti	   human	   IgG	   (Dako	  
Immunoglobulins)	   were	   used,	   respectively,	   in	   MPBST.	   Bound	   antibodies	   were	  
visualized	  by	  chemiluminescence.	  	  
Recombinant	  protein	  production	  and	  purification	  
The	  recombinant	  U1A	  and	  Jo-­‐1	  proteins	  were	  expressed	  in	  E.	  coli	  and	  purified	  as	  
described	   previously	   (11,12).	   The	   purified	   proteins	   were	   pooled	   and	   stored	   at	  
-­‐80°C	  until	  use.	  	  
Results	  
Autoantigens	  are	  modified	  in	  oxidatively	  stressed	  Jurkat	  cells	  
Reactive	  oxygen	  species	  such	  as	  OH•,	  O2•-­‐,	  and	  H2O2	  are	  able	  to	  induce	  cell	  death.	  
Saito	   and	   colleagues	   describe	   apoptotic	   and	   necrotic	   phenotypes	   in	   Jurkat	   cells	  
that	  were	  exposed	   to	   low	  or	  high	  concentrations	  of	  H2O2,	   respectively	   (13).	  The	  
radicals	  generated	  during	  oxidative	  stress	  may	  lead	  to	  distinct	  cleavage	  products	  
(Hof	  unpublished	  results)	  or	  oxidation	  specific	  modifications	  in	  biomolecules	  that	  
trigger	   an	   immune	   response.	   Jurkat	   cells	   were	   subjected	   to	   similar	   levels	   of	  
oxidative	   stress	   as	   described	   by	   Casiano	   et	   al.,	   by	   adding	   48	   mM	   H2O2	   to	   the	  
medium	   followed	   by	   culturing	   for	   5	   hours	   (1).	   Cell	   lysates	   were	   prepared	   and	  
analyzed	   by	   SDS-­‐PAGE	   and	   immunoblotting.	   For	   all	   autoantigenic	   proteins	  
analyzed	  (Ro60,	  La,	   Jo-­‐1,	  U1A)	  a	  retarded	  electrophoretic	  mobility	  was	  observed	  
(Fig.	   1A).	   In	   addition,	   a	   mobility	   shift	   was	   observed	   for	   two	   exosome	   core	  
proteins,	   Rrp40	   and	  Rrp41	   (lanes	   8,	   10).	   Interestingly,	   in	   the	   case	   of	   Rrp41	   two	  
retarded	   species	   were	   observed.	   For	   the	   Ro60	   antigen	   and	   possibly	   the	   La	  
protein,	  not	  all	  molecules	  appeared	  to	  be	  modified	  after	  5	  hours	  in	  the	  presence	  
of	  H2O2,	   since	  a	   signal	   similar	   to	   the	  non-­‐modified	   sample	   could	  be	  detected	  as	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well	   (lanes	   2,	   6).	   Because	   the	   migration	   of	   all	   proteins	   analyzed	   by	  
immunoblotting	   appeared	   to	   be	   affected,	   cells	   were	   subjected	   to	   H2O2-­‐induced	  
oxidative	   stress	   for	   various	   periods	   of	   time	   and	   the	   migration	   of	   all	   proteins	  
detectable	  by	  total	  protein	  staining	  of	  the	  SDS-­‐PAGE	  gels	  was	  examined.	  A	  highly	  
similar	  staining	  pattern	  was	  observed	  up	  to	  180	  min,	  after	  which	  several	  changes	  
became	   apparent	   (Fig.	   1B).	   These	   data	   indicate	   that	   after	   several	   hours	   of	  
oxidative	  stress	  many	  proteins	  undergo	  changes	  that	  affect	  their	  electrophoretic	  
mobility	  in	  SDS-­‐PAGE.	  To	  investigate	  the	  rate	  of	  modification	  of	  the	  autoantigenic	  
proteins,	  their	  electrophoretic	  mobility	  was	  determined	  after	  different	  incubation	  
times	   with	   48	   mM	   H2O2.	   The	   results	   revealed	   strong	   differences	   between	   the	  
rates	   by	   which	   the	   different	   proteins	   were	  modified.	   At	   180	  minutes	   the	   Ro60	  
antigen	   shows	   a	   transition	   of	   the	   non-­‐modified	   to	   the	   oxidized	   protein	   (Fig.	   2),	  
and	   after	   240	   minutes	   the	   conversion	   is	   virtually	   complete.	   The	   Jo-­‐1	   and	   U1A	  
proteins	   were	   completely	   modified	   after	   120	   and	   180	   min,	   respectively.	   Rrp41	  
was	  shifted	  completely	  after	  120	  min,	  whereas	  the	  second	  retarded	  Rrp41	  species	  
appeared	   only	   after	   180	   min.	   The	   monoclonal	   antibody	   that	   was	   used	   for	   the	  
detection	  of	  U1A	  is	  cross-­‐reactive	  with	  the	  U2B’’	  protein	  (14).	  Also	  U2B”	  appeared	  
to	   be	   shifted,	   which	   was	   already	   detectable	   after	   15	   minutes	   and	   became	  




Figure	   1:	   Hydrogen	   peroxide-­‐induced	   autoantigen	   modification	   in	   Jurkat	   cells.	   (A)	   Extracts	   of	  
Jurkat	  cells	  which	  were	  treated	  for	  5	  hours	  with	  0.15%	  H2O2	  (H2O2)	  or	  extracts	  of	  non-­‐treated	  Jurkat	  
cells	  (Ctrl)	  were	  analyzed	  by	  immunoblotting.	  Western	  blots	  containing	  the	  respective	  extracts	  were	  
incubated	  with	  patient	  sera	  containing	  antibody	  reactivities	  against	  U1A	  or	  Jo-­‐1,	  mouse	  monoclonal	  
antibodies	   reactive	  with	   Ro60	   and	   La	   or	  with	   rabbit	   antibodies	   directed	   to	   the	   exosome	  proteins	  
Rrp40	  and	  Rrp41.	  The	  positions	  of	  the	  modified	  proteins	  are	  indicated	  with	  asterisks.	  (B)	  Jurkat	  cells	  
were	   cultured	   for	   0	   -­‐	   360	  min	   after	   the	   addition	   of	   H2O2	   to	   a	   final	   concentration	   of	   0.15%.	   Cell	  
extracts	  were	  separated	  by	  SDS-­‐PAGE	  and	  stained	  with	  Coomassie	  Brilliant	  Blue.	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Figure	  2:	  Kinetics	  of	  autoantigen	  modification	  in	  oxidatively	  stressed	  Jurkat	  cells.	  Jurkat	  cells	  were	  
treated	  with	   0.15%	  H2O2	   for	   the	   indicated	   periods	   of	   time.	   Cell	   extracts	  were	   separated	   by	   SDS-­‐
PAGE	   and	   specific	   proteins	   were	   visualized	   by	   immunoblotting	   using	   a	   patient	   serum	   containing	  
antibodies	  directed	  against	  Jo-­‐1,	  mouse	  monoclonal	  antibodies	  to	  the	  U1A	  and	  Ro60	  proteins,	  and	  a	  
rabbit	  polyclonal	  antibody	  against	  Rrp41.	  The	  anti-­‐U1A	  monoclonal	  antibody	  cross-­‐reacts	  with	   the	  
U2B’’	  protein.	  Modified	  proteins	  are	  indicated	  with	  asterisks.	  
	  
	  
with	  material	   from	  cells	   exposed	   for	  more	   than	  180	  minutes	   to	  H2O2	   tended	   to	  
decrease,	  which	  may	  result	  from	  the	  loss	  of	  membrane	  integrity	  and	  intracellular	  
content	  or	  from	  the	  disruption	  of	  the	  epitopes	  recognized	  by	  the	  antibodies	  used	  
(Fig.	  2).	  	  
Concentration-­‐dependent	  modification	  of	  autoantigens	  
To	   investigate	  whether	   similar	   oxidative	  modifications	  were	   observed	   at	  milder	  
conditions,	   Jurkat	   cells	   were	   treated	   with	   different	   concentrations	   of	   H2O2,	  
ranging	  from	  0.03	  mM	  to	  48	  mM,	  for	  5	  hours.	  Only	  at	  the	  higher	  concentrations,	  
32	   mM	   and	   48	   mM	   H2O2,	   a	   mobility	   shift	   for	   the	   U1A	   protein	   was	   observed	  
(Fig.	  3).	   The	   migration	   of	   U2B”	   was	   also	   affected	   at	   the	   higher	   H2O2	  
concentrations,	  although	  this	  did	  not	  seem	  to	  be	  as	  pronounced	  as	  that	  of	  U1A.	  
The	   relatively	   high	   concentrations	   of	   H2O2	  may	   induce	   cell	   death	   and	   therefore	  
the	  migration	  alterations	  observed	  may	  be	  associated	  with	  cell	  death.	  Hydrogen	  
peroxide	  has	  been	  reported	  to	  induce	  necrosis	  (1),	  and	  therefore	  the	  induction	  of	  
necrosis	  was	  monitored	  by	  the	  cleavage	  of	  topoisomerase	  I	  (Topo	  I),	  which	  leads	  
to	  a	  characteristic	  45	  kDa	  cleavage	  product.	   Indeed,	  the	  Jurkat	  cells	  appeared	  to	  
become	  necrotic	  after	  exposure	  to	   the	  H2O2	  concentrations	   that	   led	  to	  U1A	  and	  
U2B”	   modification	   (Fig.	   3)	   (1).	   In	   contrast,	   relatively	   low	   H2O2-­‐concentrations	  
(0.03	  mM	   -­‐	   0.3	  mM)	   induced	   apoptosis,	   as	   demonstrated	   by	   the	   specific	  





Figure	  3:	  Hydrogen	  peroxide	  concentration-­‐dependent	  autoantigen	  modification.	  Jurkat	  cells	  were	  
cultured	  in	  the	  presence	  of	  various	  concentrations	  of	  H2O2	  for	  5	  hours,	  after	  which	  cell	  extracts	  were	  
analyzed	  by	  immunoblotting	  (lanes	  4-­‐11).	  Western	  blots	  containing	  extracts	  of	  untreated	  (Ctrl)	  and	  
treated	   cells	   were	   incubated	   with	   patient	   sera	   containing	   autoantibodies	   against	   DNA	  
topoisomerase	  I	  (Topo	  I)	  or	  U1-­‐70k.	  U1A	  was	  detected	  with	  a	  monoclonal	  antibody	  that	  cross-­‐reacts	  
with	   the	   U2B’’	   protein	   (top	   panel).	   The	   modified	   protein	   signals	   are	   indicated	   with	   asterisks.	   As	  
additional	  controls,	  cells	  were	  treated	  with	  0.15%	  H2O2	  for	  5	  hours	  to	  induce	  necrosis	  (lane	  2),	  or	  8	  
hours	  with	  40	  μM	  anisomycin	  to	  induce	  apoptosis	  (lane	  3).	  The	  induction	  of	  necrosis	  was	  monitored	  
by	  the	  appearance	  of	  the	  45	  kDa	  cleavage	  product	  of	  Topo	  I,	  Topo	  I	  CL	  (middle	  panel),	  whereas	  the	  
induction	  of	  apoptosis	  was	  monitored	  by	  the	  appearance	  of	  the	  40	  kDa	  cleavage	  product	  of	  U1-­‐70k,	  
U1-­‐70k	   CL	   (bottom	   panel).	   Note	   that	   Topo	   I	   in	   apoptotic	   cells	   is	   cleaved	   into	   a	   70	   kDa	   product	  
(arrowhead),	  in	  agreement	  with	  previous	  observations.	  
	  
	  
detectable	   mobility	   shift	   of	   the	   U1A	   and	   U2B’’	   proteins.	   Jurkat	   cells	   rendered	  
apoptotic	  by	  anisomycin	  treatment	  were	  analyzed	  in	  parallel	  as	  a	  reference.	  Note	  
that,	  as	  reported	  previously	  (1),	  also	  the	  Topo	  I	  protein	  was	  cleaved	  in	  apoptotic	  
cells,	   resulting	   in	  a	  cleavage	  product	   that	   is	  different	   from	  that	   in	  necrotic	   cells.	  
These	   data	   suggest	   that	   the	   observed	   oxidative	   modification	   of	   antigens	   is	  
primarily	  associated	  with	  H2O2	  concentrations	  that	  induce	  necrosis.	  
In	  vitro	  oxidation	  of	  purified	  recombinant	  autoantigenic	  proteins	  	  
The	  exposure	  of	  Jurkat	  cells	  to	  H2O2	  results	   in	  the	  elevation	  of	  both	  extracellular	  
and	   intracellular	  ROS	   levels.	  To	   investigate	  whether	  hydroxyl	   radicals,	  which	  are	  
the	   main	   direct	   ROS	   emerging	   from	   H2O2,	   are	   involved	   in	   the	   modification	  
reactions,	  purified	  recombinant	  autoantigenic	  proteins	  were	  exposed	  to	  hydroxyl	  
radicals	   generated	   by	   the	   Fenton	   reaction	   (15-­‐18).	   In	   this	   reaction	   ferrous	   iron	  	  
	  
Modification	  of	  autoantigenic	  proteins	  in	  oxidatively	  stressed	  Jurkat	  cells	  	  
95	  
	  
Figure	   4:	   In	   vitro	   oxidation	   of	   recombinant	   Jo-­‐1	   and	   U1A.	   Recombinant	   Jo-­‐1	   (recJo-­‐1)	   and	   U1A	  
(recU1A)	   proteins	   (Ctrl)	   were	   incubated	   under	   oxidative	   conditions	   generated	   by	   the	   Fenton	  
reaction.	   Material	   from	   reactions	   supplemented	   with	   H2O2	   is	   indicated	   with	   +	   (lane	   2),	   whereas	  
material	   from	  reactions	  without	  H2O2	   is	   labeled	  -­‐	  (lane	  3).	  Proteins	  were	  visualized	  using	  a	  patient	  
serum	   containing	   anti-­‐Jo-­‐1	   or	   a	   monoclonal	   anti-­‐U1A	   antibody.	   The	   positions	   of	   the	   retarded	  
proteins	  (lane	  2)	  are	  indicated	  with	  asterisks.	  
	  
	  
(Fe2+)	   is	  oxidized	  by	  H2O2	   to	  yield	   ferric	   iron	   (Fe3+),	  a	  hydroxyl	  anion	   (OH−)	  and	  a	  
hydroxyl	  radical	  (OH•).	  Both	  U1A	  and	  Jo-­‐1	  were	  oxidized	  in	  vitro,	  after	  which	  the	  
proteins	  were	  analyzed	  by	   immunoblotting	  using	   a	  mouse	  monoclonal	   anti-­‐U1A	  
antibody	  and	  a	  anti-­‐Jo-­‐1	  positive	  patient	  serum.	  The	  recombinant	  proteins	  were	  
incubated	   under	   conditions	   generated	   by	   the	   Fenton	   reaction	   either	   in	   the	  
presence	  of	  or	   the	  absence	  of	  H2O2	   (Fig.	   4).	  After	   incubation	   in	   the	  presence	  of	  
H2O2	   the	  migration	  of	  both	  U1A	  and	  Jo-­‐1	   in	  SDS-­‐PAGE	  appeared	  to	  be	  retarded,	  
very	   similar	   to	   what	   was	   observed	   for	   these	   proteins	   from	  H2O2	   treated	   Jurkat	  
cells.	   The	   mobility	   shift	   was	   not	   observed	   when	   the	   proteins	   were	   incubated	  
without	  H2O2.	  The	   results	   suggest	   that	   the	  observed	  protein	  modifications	  are	  a	  
direct	  effect	  of	  H2O2	  or	  its	  products	  generated	  in	  the	  Fenton	  reaction.	  	  
Oxidative	  stress-­‐induced	  protein	  modification	  is	  O2•-­‐	  independent	  
To	  obtain	  more	  insight	  into	  the	  ROS	  species	  that	  are	  responsible	  for	  the	  detected	  
modifications	   in	   Jurkat	   cells,	   we	   incubated	   these	   cells	   with	   two	   other	   ROS	  
generators,	  menadione	  and	  paraquat,	  which	  generate	  O2•-­‐	  inside	  the	  cell	  (19,20).	  	  
	  
	  
	  	  	   	  
Figure	  5:	  The	  effect	  of	  superoxide-­‐induced	  oxidative	  stress	  on	  autoantigenic	  proteins.	  Jurkat	  cells	  
were	   treated	   for	   2	   hours	  with	   various	   concentrations	   of	  menadione	   (A)	   or	   24	   hours	  with	   various	  
concentrations	   of	   paraquat	   (B).	   Cell	   extracts	   were	   separated	   by	   SDS-­‐PAGE	   and	   analyzed	   by	  
immunoblotting	   using	   an	   anti-­‐Jo-­‐1	   positive	   patient	   serum	   or	   a	   monoclonal	   anti-­‐U1A/anti-­‐U2B”	  
antibody.	  
A	   B	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Jurkat	   cells	   treated	   with	   up	   to	   0.4	   mM	  menadione	   (Fig.	   5A)	   or	   up	   to	   0.4	   mM	  
paraquat	  (Fig.	  5B)	  were	  lysed	  and	  analyzed	  by	  immunoblotting	  and	  FACS	  analysis.	  
After	   treatment	   intracellular	   superoxide	   anion	   levels	   were	   monitored	   in	   Jurkat	  
cells	   using	   FACS	   analysis	   and	   the	   fluorescent	   hydroethidine	   probe	   (data	   not	  
shown).	   Although	   both	   menadione	   and	   paraquat	   treatment	   did	   result	   in	   an	  
increase	   in	   the	   intracellular	   superoxide	  anion	   concentration,	   neither	  menadione	  
nor	  paraquat	  led	  to	  the	  detectable	  modification	  of	  the	  U1A	  and	  Jo-­‐1	  proteins.	  	  
Hypochlorous	  acid-­‐induced	  autoantigen	  modification	  
Since	   H2O2	  may	   lead	   to	   the	   production	   of	   OH•	   in	   cells,	   it	   is	   possible	   that	   H2O2-­‐
derived	  OH•	  plays	  a	  role	  in	  the	  observed	  modification	  of	  proteins.	  Neutrophils	  and	  
monocytes	   express	   the	   enzyme	   myeloperoxidase	   (MPO),	   which	   plays	   a	   pivotal	  
role	   in	   the	   destruction	   of	   pathogens.	  MPO	   produces	   hypochlorous	   acid	   (HOCl),	  
which	  can	  react	  with	  many	  biomolecules,	  e.g.	  oxidize	  thiols,	  damage	  side-­‐chains,	  
or	  induce	  the	  fragmentation	  or	  aggregation	  of	  proteins	  (21).	  However,	  through	  its	  
reaction	  with	  O2•-­‐	  or	  Fe2+,	  HOCl	  also	   is	  a	  potent	  generator	  of	   the	  highly	  reactive	  
OH•	   radical	   (22).	   To	   investigate	   whether	   OH•	   is	   involved	   in	   electrophoretic	  
mobility	  shifts	  of	  proteins	  as	  have	  been	  observed	  after	  exposure	   to	  H2O2,	   Jurkat	  
cells	   or	   recombinant	   proteins	  were	   subjected	   to	   the	   alternative	   OH•	   generator,	  
HOCl.	   Subsequent	   to	   0.1%	   or	   0.01%	   NaOCl	   treatment	   of	   Jurkat	   cells	   or	  
recombinant	   proteins,	   respectively,	   samples	  were	   analyzed	   via	   immunoblotting.	  
Both	   Jo-­‐1	  and	  U1A	  proteins	   from	  Jurkat	  cells	   showed	  a	  mobility	  shift	  already	  30	  
min	   after	   the	   addition	   of	   NaOCl,	   which	   resulted	   in	   a	   similar	   electrophoretic	  
mobility	  as	  observed	  after	  H2O2	  exposure	   (Fig.	  6A).	  RecJo-­‐1	  and	   recU1A	  became	  
modified	   upon	   NaOCl	   treatment	   as	   well	   (Fig.	   6B).	   A	   migration	   shift	   that	   was	  	  
	  
	  
	  	  	  	  	  	  	  	  	   	  
Figure	  6:	  The	  effect	  of	  hypochlorous	  acid	  on	  Jo-­‐1	  and	  U1A.	  (A)	  Jurkat	  cells	  were	  treated	  with	  0.1%	  
NaOCl	  for	  the	  indicated	  periods	  of	  time	  (minutes;	  lanes	  2-­‐4),	  after	  which	  cell	  extracts	  were	  prepared	  
and	   analyzed	   by	   immunoblotting	   using	   monospecific	   anti-­‐Jo-­‐1	   or	   anti-­‐U1A	   antibodies.	   In	   lane	   1	  
material	   from	   untreated	   cells	  was	   loaded	   (Ctrl).	   Lane	   5	   contains	   extract	   of	   Jurkat	   cells	   that	  were	  
treated	  for	  2	  hours	  with	  0.15%	  H2O2.	  The	  positions	  of	  modified	  proteins	  are	  marked	  with	  asterisks.	  
(B)	  Recombinant	  Jo-­‐1	  (recJo-­‐1)	  and	  U1A	  (recU1A)	  proteins	  were	  treated	  either	  for	  5	  or	  30	  min	  with	  
0.01%	  NaOCl	  and	  visualized	  by	  immunoblotting	  as	  in	  panel	  A.	  The	  positions	  of	  recJo-­‐1	  and	  recU1A	  in	  
treated	  samples	  are	  indicated	  with	  asterisks.	  
A	   B	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comparable	   to	   that	  upon	  H2O2,	  exposure	  was	  already	  detected	  after	  a	  5	  minute	  
incubation	   in	   the	   presence	   of	   NaOCl.	   Since	   mobility	   shifts	   in	   NaOCl	   treated	  
samples	   were	   highly	   similar	   to	   those	   observed	   under	   H2O2	   conditions	   and	   the	  
chemical	   nature	   of	   radicals	   after	   H2O2	   and	   NaOCl	   decomposition	   resemble,	  
suggest	  that	  OH•	  are	  responsible	  for	  the	  observed	  electrophoretic	  differences.	  
Discussion	  
The	  posttranslational	  modification	  of	  proteins	  can	  generate	  neo-­‐epitopes,	  which	  
in	  predisposed	  individuals	  can	  initiate	  an	  immune	  response	  and	  eventually	  lead	  to	  
the	   loss	   of	   immunological	   tolerance	   and	   autoimmunity.	   Here	   we	   report	   that	  
autoantigenic	  proteins	  associated	  with	  various	  autoimmune	  diseases	  are	  modified	  
upon	  their	  exposure	  to	  OH•.	  Oxidative	  modifications	  can	  have	  a	  variety	  of	  effects	  
on	   the	   affected	   biomolecule,	   e.g.	   loss	   or	   gain	   of	   function.	   In	   rabbits	   that	   have	  
been	  immunized	  with	  oxidized	  Ro60	  an	  accelerated	  disease	  process	  was	  reported,	  
in	  contrast	  to	  their	  non-­‐oxidized	  counterparts	  (23).	  A	  similar	  mechanism	  might	  be	  
involved	   in	   the	   loss	   of	   immunological	   tolerance	   in	   autoimmune	   patients.	   The	  
altered	   electrophoretic	  mobility	   of	   Jo-­‐1	   is	   in	   agreement	  with	   the	   results	   of	   our	  
previous	  studies	  on	  the	  oxidative	  modification	  of	  Jo-­‐1	  in	  H2O2-­‐treated	  Jurkat	  cells	  
(Van	   Dooren	   et	   al.	   manuscript	   submitted	   for	   publication).	   The	   effects	   of	   H2O2	  
treatment	   were	   less	   pronounced	   for	   the	   Rrp40	   and	   La	   proteins,	   which	  may	   be	  
explained	  by	  differences	  in	  the	  number	  or	  microenvironment	  of	  amino	  acids	  that	  
can	  be	  oxidized.	  In	  addition,	  oxidative	  modification	  of	  one	  residue	  could	  result	  in	  
a	   conformational	   change	   of	   the	   protein	   and	   a	   concomitant	   increased	  
susceptibility	   to	  oxidation	  of	  other	  amino	  acids.	  This	  could	  explain	  the	  step-­‐wise	  
modification	  as	  observed	  for	  Rrp41.	  The	  total	  protein	  analysis	  of	  the	  H2O2-­‐treated	  
Jurkat	  cell	  extracts	  revealed	  that	  particularly	  after	  three	  hours	  of	  oxidative	  stress	  
important	   changes	   were	   observed,	   which	   at	   least	   in	   part	   will	   be	   due	   to	   the	  
induction	   of	   necrosis	   as	   indicated	   by	   the	   appearance	   of	   the	   specific	  
topoisomerase	  I	  cleavage	  product,	  but	  to	  oxidative	  protein	  modifications	  as	  well,	  
as	  is	  evident	  from	  the	  western	  blot	  analyses.	  The	  number	  of	  proteins	  that	  appear	  
to	   become	  modified	   upon	   H2O2	   exposure	   implies	   that	   oxidative	  modification	   is	  
not	  a	  unique	  feature	  of	  autoantigenic	  proteins.	  Remarkably,	  the	  modifications	  of	  
Ro60,	   Jo-­‐1,	   Rrp41,	   and	   U1A	   did	   not	   occur	   simultaneously,	   and,	   although	  
differences	   in	   the	   rate	   by	   which	   these	   proteins	   are	   oxidized	   clearly	   exist,	   all	  
autoantigenic	  proteins	  analyzed	  appeared	  to	  be	  modified	  prior	  to	  the	  initiation	  of	  
the	   major	   changes	   affecting	   the	   total	   protein	   pattern.	   It	   will	   be	   interesting	   to	  
investigate	   whether	   autoantigenic	   proteins	   tend	   to	   be	   modified	   relatively	   fast	  
(Fig.	  2).	  Importantly,	  only	  concentrations	  of	  H2O2	  that	  are	  able	  to	  induce	  necrosis	  
result	   in	  oxidatively	  modified	  proteins,	  which	   implies	  that	  the	  modifications	  may	  
also	   be	   caused	   by	   necrosis-­‐associated	   activities.	   Another	   open	   question	   is	  
whether	   the	   oxidatively	   modified	   autoantigenic	   proteins,	   in	   contrast	   to	   other	  
proteins,	   are	   exposed	   to	   the	   immune	   system	   and	   lead	   to	   a	   modification-­‐
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dependent	  immune	  response.	  For	  such	  studies,	  techniques	  that	  allow	  the	  specific	  
detection	  of	  modified	  epitope	   targeting	   autoantibodies	   are	  needed.	   Since	  H2O2-­‐
induced	  necrosis	  might	  be	  involved	  in	  the	  observed	  modifications,	  the	  possibility	  
existed	   that	   intracellular	   ROS	   (e.g.	   from	  mitochondria)	   played	   a	   role.	   However,	  
none	  of	  the	  alternative	  necrosis	  induction	  methods	  (e.g.	  the	  exposure	  to	  ethanol,	  
HgCl2	   or	   heat)	   (24-­‐26),	   which	   are	   associated	   with	   mitochondrial	   damage,	   nor	  
generators	  of	  intracellular	  superoxide	  radicals	  (19,20)	  led	  to	  modifications	  with	  a	  
similar	  retarded	  electrophoretic	  mobility	  (data	  not	  shown	  and	  Fig.	  5).	  Because	  the	  
alternative	   necrosis	   induction	   methods,	   through	   mitochondrial	   damage,	   also	  
mainly	   generate	   intracellular	   superoxide	   anion	   radicals,	   we	   conclude	   that	  
superoxide	  radicals	  do	  not	  play	  a	  major	  role	   in	  the	  oxidative	  modification	  of	  the	  
autoantigenic	  proteins.	  The	  hydroxyl	  radical,	  OH•,	  on	  the	  other	  hand,	  appears	  to	  
be	   strongly	   involved	   in	   the	   oxidative	  modification	   of	   the	   proteins	   studied	   here,	  
since	   both	   the	   in	   vitro	   oxidation	   of	   recombinant	   proteins	   and	   the	   treatment	   of	  
Jurkat	  cells	  or	  recombinant	  proteins	  with	  NaOCl	  resulted	  in	  a	  mobility	  shift	  similar	  
to	  that	  observed	  in	  H2O2	  treated	  material	  (Fig.	  4	  &	  6).	  The	  exact	  chemical	  nature	  
of	  the	  modifications	  caused	  by	  the	  exposure	  to	  hydroxyl	  radicals	  requires	  further	  
investigation,	  e.g.	  by	  the	  isolation	  of	  modified	  proteins	  and	  their	  analysis	  by	  mass	  
spectrometry.	   Taken	   together,	   our	   data	   show	   that	   the	   exposure	   to	   hydroxyl	  
radicals	   leads	   to	   rapid	   oxidative	   modifications	   of	   autoantigenic	   proteins,	   which	  
can	   be	   monitored	   via	   their	   altered	   electrophoretic	   mobility	   in	   SDS-­‐PAGE	   gels.	  
These	  modifications	  are	  probably	  not	  unique	  for	  autoantigenic	  proteins,	  although	  
differences	   in	   the	   rate	   of	   modification	   may	   exist.	   The	   questions	   whether	  
autoantigenic	   proteins	   are	   generally	   modified	   faster	   than	   non-­‐autoantigenic	  
proteins	   and	  whether	   the	  oxidative	  modifications	   lead	   to	   the	   formation	  of	  neo-­‐
epitopes,	  require	  further	  investigations.	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ype	   1	   diabetes	   (T1D)	   is	   an	   autoimmune	   disease	   characterized	   by	   the	  
destruction	   of	   the	   insulin	   producing	   beta	   cells	   in	   the	   pancreas.	   Years	  
before	  the	  onset	  of	  clinical	  symptoms,	  the	  destructive	  process	  of	  beta	  cells	  
may	  have	   started	  and	   the	  humoral	   response	   to	   islet	  beta	   cell	   antigens	   can	  be	  
demonstrated.	   It	   is	  not	   fully	  understood	  yet	  why	  an	   immune	  response	  to	  beta	  
cell	   antigens	   is	   generated	   in	   T1D	   patients;	   one	   model	   hypothesizes	   the	  
involvement	  of	  cryptic	  epitopes,	  which	  might	  be	  generated	  by	  or	  exposed	  as	  a	  
result	  of	  posttranslational	  modifications.	  To	  test	  this	  hypothesis	  two	  conditions	  
that	   involve	   alterations	   in	   posttranslational	   modifications	   and	   are	   associated	  
with	   T1D,	   necrosis	   and	   enterovirus	   infection,	   were	   induced	   in	   a	   murine	  
pancreatic	   beta	   cell-­‐line	   (Min6)	   and	   the	   reactivity	   of	   T1D	   patient	   sera	   with	  
antigens	  in	  lysates	  of	  these	  cells	  was	  studied	  by	  western	  blotting.	  The	  results	  did	  
not	   reveal	   antibody	   reactivities	   with	   material	   from	   necrotic	   Min6	   cells	   that	  
frequently	   occur	   in	   T1D	   and	   not	   in	   the	   control	   sera.	   Using	   material	   from	  
Coxsackievirus	   B3-­‐infected	   cells,	   both	   T1D	   sera	   and	   control	   sera	   had	   a	   high	  
prevalence	   (80-­‐96%)	   of	   antibodies	   reactive	   with	   the	   viral	   coat	   protein	   VP-­‐1,	  
indicative	   of	   previous	   enteroviral	   infections	   in	   both	   groups.	   A	   Mr	  100,000	  
protein	   from	   Coxsackievirus-­‐infected	   cells	   was	   recognized	   by	   63%	   of	   the	   T1D	  
sera	   and	   only	   10%	   of	   sera	   from	   healthy	   controls.	   The	   possibility	   that	   this	  
Mr	  100,000	   protein	   is	   a	   Min6	   protein	   modified	   upon	   infection	   with	  
Coxsackievirus	   and	   the	   putative	   role	   of	   this	   modified	   self-­‐protein	   in	   the	  
pathogenesis	  of	  T1D	  will	  be	  discussed.	  
Introduction	  
Diabetes	  mellitus,	   a	   family	   of	   disorders	   characterized	  by	   chronic	   hyperglycemia,	  
can	  be	  divided	  in	  type	  1	  diabetes	  (T1D)	  and	  type	  2	  diabetes.	  T1D	  results	  from	  the	  
decline	   in	   insulin	   production	   by	   destruction	   of	   the	   insulin	   producing	   beta	   cells,	  
while	   type	   2	   diabetes	   results	   from	   the	   combination	   of	   insulin	   resistance	   and	  
insulinopenia.	   The	   presence	   of	   autoantibodies	   directed	   towards	   beta	   cell	  
antigens,	  like	  insulin,	  glutamic	  acid	  decarboxylase	  (GAD)	  or	  IA-­‐2	  distinguishes	  T1D	  
from	   type	   2	   diabetes.	   Accumulating	   evidence,	   a.o.	   from	   twin-­‐studies,	   indicates	  
that	   genetic	   factors	   are	   important	   for	   the	   development	   of	   T1D	   (1).	   Yet,	   genetic	  
factors	   alone	   can	   hardly	   explain	   the	   rapid	   increase	   in	   incidence	   among	   children	  
and	  adolescents	  as	  well	  as	  the	  decrease	  in	  patient	  age	  at	  diagnosis.	  These	  trends	  
support	   a	   critical	   role	   of	   exogenous	   factors	   in	   the	   development	   of	   T1D	   (2).	  
Environmental	   factors	   like	   toxins,	   food	   allergens	   and	   viral	   infections	   (3)	   can	  
directly	   or	   indirectly	   induce	   cell	   death.	   Dying	   cells	   and	   cell	   death	   associated	  
processes	   produce	   proteins	   with	   unusual	   modifications.	   A	   hypothesis	   that	   is	  
increasingly	  supported	  by	  experimental	  data	  proposes	  an	  important	  role	  for	  such	  
posttranslational	   modifications	   in	   breaking	   tolerance	   to	   self	   antigens.	   These	  
altered	  proteins	  may	  be	  recognized	  by	  the	  immune	  system	  as	  non-­‐self,	  which	  may	  




the	   U1-­‐70K	   protein	   in	   apoptotic	   cells.	   The	   40	   kDa	   cleavage	   product	   of	   U1-­‐70K,	  
which	   is	   targeted	   by	   the	   immune	   system	   in	   systemic	   lupus	   erythematosus	   and	  
mixed	   connective	   tissue	   disease,	   contains	   neo-­‐epitopes	   that	   are	   preferentially	  
reactive	   with	   early	   serum	   samples	   of	   these	   patients	   (4,5).	   Epitope	   spreading	  
following	  the	  initial	  response	  has	  been	  suggested	  to	  lead	  to	  an	  extended	  immune	  
response	   targeting	   also	   the	   native	   protein	   and	   to	   a	   chronic	   autoimmune	  
response.	  There	  is	  accumulating	  evidence	  for	  the	  involvement	  of	  reactive	  oxygen	  
species	  (ROS)	  in	  the	  autoimmune	  destruction	  of	  beta	  cells	  (6).	  The	  production	  of	  
ROS	   is	   often	   associated	   with	   necrosis	   and	   can	   be	   produced	   by	   the	   beta	   cells	  
themselves	   or	   by	   the	   infiltrating	   macrophages	   (6-­‐8).	   Trigwell	   and	   colleagues	  
reported	   on	   an	   oxidative	   modification	   of	   GAD65	   which	   leads	   to	   the	  
oligomerization	  of	  this	  T1D	  autoantigen	  (9).	  Antibodies	   in	  T1D	  patient	  sera	  were	  
able	   to	   bind	   to	   these	   complexes	   and	   appeared	   to	   bind	   more	   efficiently	   to	   the	  
larger	  complexes	  than	  to	  the	  smaller	  oligomers	  or	  the	  native	  protein.	  Enteroviral	  
infections	   have	   been	   reported	   to	   be	   associated	   with	   the	   generation	   of	   T1D	  
(10,11).	  Enteroviruses	  are	  small	  non-­‐enveloped	  viruses	  that	  are	  composed	  of	  four	  
capsid	   proteins,	   VP1-­‐4,	   and	   a	   single-­‐stranded	   RNA	   genome.	   Associations	   with	  
several	   Coxsackieviruses	   (11)	   have	   been	   reported.	   Already	   in	   1969	   researchers	  
noted	  that	  anti-­‐Coxsackievirus	  antibodies	  were	  found	  more	  frequently	  in	  patients	  
with	  T1D	  than	  in	  control	  subjects	  (12).	  About	  10	  years	  later,	  Yoon	  and	  coworkers	  
demonstrated	   that	   Coxsackievirus	   B4	   (CVB4)	   was	   able	   to	   replicate	   in	   cultured	  
human	  islets	  (13)	  and	  in	  situ	  hybridization	  studies	  have	  provided	  evidence	  for	  the	  
selective	   replication	   of	   CVB4	   in	   insulin-­‐producing	   beta	   cells	   of	   the	   human	  
pancreas.	  In	  1979,	  a	  CVB4	  was	  isolated	  from	  the	  pancreas	  of	  a	  patient	  who	  died	  of	  
diabetic	  ketoacidosis	  (14).	  The	  latter	  viral	  strain,	  when	  transferred	  to	  susceptible	  
mice,	  led	  to	  hyperglycemia	  with	  inflammation	  of	  the	  pancreatic	  Langerhans	  islets,	  
as	   well	   as	   beta	   cell	   necrosis,	   and	   provoked	   the	   appearance	   of	   autoantibodies	  
(anti-­‐GAD	   antibodies)	   and	   hyperglycemia	   six	   weeks	   post-­‐infection	   (14,15).	  
Andreoletti	   and	   coworkers	   were	   able	   to	   detect	   CVB	   RNA	   in	   the	   blood	   of	   T1D	  
patients	   at	   the	   onset	   and	   during	   the	   course	   of	   T1D	   (16).	   CVB	   isolated	   from	  
children	   with	   acute-­‐onset	   diabetes	   was	   able	   to	   induce	   T1D	   when	   injected	   into	  
mice	   (17).	  Beta	  cell	   infection	  by	  enteroviruses	  can	  destroy	   the	   insulin-­‐producing	  
cells	  directly	  by	  cytolysis	  (18,	  19).	  Another	  mechanism	  of	  beta	  cell	  destruction	  is	  a	  
bystander	   effect	   of	   the	   enterovirus-­‐induced	   inflammatory	   reaction	   (20).	   This	  
reaction	   may	   induce	   tissue	   damage	   and	   the	   release	   of	   (altered)	   self	   antigens,	  
leading	   to	   enhanced	   antigen	   presentation	   and	   activation	   of	   antigen	   presenting	  
cells.	   In	   addition	   to	   stimulating	   the	   release	   of	   (altered)	   self-­‐antigens,	  
autoimmunity	  may	  also	  result	   from	  molecular	  mimicry,	  which	   is	  based	  on	  cross-­‐
reactivity	  between	  self	  antigens	  and	  viral	  antigens	  (21).	  Self-­‐reactive	  T	  cells	  might	  
be	  activated	  by	  encountering	  viral	  proteins	  containing	  epitopes	  that	  are	  identical	  
or	  very	  similar	  to	  those	  of	  self	  proteins.	  Indeed	  it	  was	  shown	  that	  the	  P2C	  protein	  
of	   CVB4	   shares	   sequence	   similarity	   with	   human	   GAD	   (21-­‐24).	   To	   investigate	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whether	  T1D	  patient	  sera	  contain	  antibodies	  that	  specifically	  recognize	  unusually	  
modified	   antigens,	   murine	   pancreatic	   beta	   cells	   (Min6	   cell-­‐line)	   were	   cultured	  
under	   different	   circumstances.	   The	   effects	   of	   both	   necrosis	   and	   infection	   with	  
Coxsackievirus	   B3	   (CVB3)	   on	   the	   recognition	   of	   cellular	   proteins	   by	   T1D	   patient	  
antibodies	  were	  studied.	  	  
Methods	  
Patient	  sera	  and	  antibodies	  
T1D	   sera,	   systemic	   lupus	   erythematosus	   (SLE)	   sera	   and	   primary	   Sjögren’s	  
syndrome	  (SS)	  sera	  were	  collected	  at	   the	  Departments	  of	   Internal	  Medicine	  and	  
Rheumatology	   of	   the	   Radboud	   University	   Nijmegen	   Medical	   Centre	   (The	  
Netherlands).	   Sera	   from	   healthy	   individuals	   were	   purchased	   from	   the	   Sanquin	  
Bloodbank	  Nijmegen.	  Sera	  were	  stored	  in	  aliquots	  at	  -­‐80°C	  until	  use.	  The	  need	  for	  
ethical	   approval	   to	   use	   these	   sera	   for	   autoantibody	   studies	   was	   waived	   by	   the	  
local	  ethics	  committee;	  patients	  provided	  informed	  consent.	  The	  anti-­‐enteroviral	  
VP-­‐1	  antibody	  was	  purchased	  from	  Dako.	  
Cell	  lines,	  induction	  of	  cell	  death	  and	  extract	  preparation	  
Min6	  cells	  (murine	  pancreatic	  beta	  cells	  (25)	  were	  a	  gift	  from	  Dr.	  Merja	  Roivainen	  
and	   Dr.	   Per	   Bendix	   Jeppesen	   and	   were	   cultured	   in	   Dulbecco’s	  modified	   Eagle’s	  
medium	  (Gibco)	  supplemented	  with	  10%	  heat-­‐inactivated	  fetal	  calf	  serum	  (Gibco-­‐
BRL),	  50	  μM	  β-­‐mercaptoethanol,	  10	  mM	  Hepes-­‐KOH,	  pH	  8.0,	  100	  U/ml	  penicillin	  
and	   100	   mg/ml	   streptomycin.	   The	   cells	   were	   cultured	   in	   a	   humidified	   37°C	  
incubator	   containing	   5%	   CO2	   until	   they	   reached	   ~70%	   confluency.	  Necrosis	  was	  
induced	  with	   0.15%	  H2O2	   for	   5	   hours	   unless	   indicated	   otherwise.	   The	   adherent	  
cells	  were	  detached	  by	   treatment	  with	  5	  mM	  EDTA	   for	  1	  min	  and	  harvested	  by	  
centrifugation.	  After	  washing	  with	  phosphate-­‐buffered	  saline	  (PBS)	  the	  cells	  were	  
resuspended	   in	   sonication	   buffer	   (25	  mM	   Tris-­‐HCl,	   pH	   7.6,	   100	  mM	   KCl,	   1	  mM	  
EDTA,	  1	  mM	  DTT,	  10%	  glycerol)	  and	  lysed	  by	  sonication	  on	  ice.	  The	  lysates	  were	  
centrifuged	  for	  15	  min	  at	  10,000g	  to	  remove	  cellular	  debris.	  Virus	   infected	  Min6	  
cells	   (see	   below)	   were	   lysed	   in	   SDS-­‐PAGE	   loading	   buffer	   (2%	   SDS,	   5%	   β-­‐
mercaptoethanol,	   10%	   glycerol,	   0.005%	   bromophenol	   blue,	   62.5	   mM	   Tris-­‐HCl,	  
pH	  6.8)	  and	  stored	  at	  -­‐20°C.	  CVB3	  Nancy	  virus	  was	  kindly	  provided	  by	  R.	  Kandolf	  
(University	  of	  Tübingen,	  Germany).	  Production	  of	  virus	  stocks	  was	  performed	  as	  
previously	   described	   (26).	   Briefly,	   Buffalo	   green	   monkey	   cells	   were	   grown	   in	  
minimal	   essential	   medium	   (Gibco)	   supplemented	   with	   10%	   fetal	   bovine	   serum,	  
100	  U/ml	  penicillin	  and	  100	  mg/ml	  streptomycin	  at	  37°C	   in	  a	  5%	  CO2	   incubator.	  
After	   infection,	   cells	   were	   incubated	   until	   complete	   cytopathic	   effect	   was	  
observed.	  Virus	  was	   released	  by	   three	  successive	  cycles	  of	   freezing	  and	  thawing	  





Figure	   1:	   Hydrogen	   peroxide-­‐induced	   necrosis	   in	   Min6	   cells.	   Extracts	   of	  Min6	   cells	   which	   were	  
treated	  with	  0.15%	  hydrogen	  peroxide	  (+)	  or	  extracts	  of	  non-­‐treated	  Min	  6	  cells	  (-­‐)	  were	  analyzed	  by	  
immunoblotting.	   Western	   blots	   containing	   the	   respective	   extracts	   were	   incubated	   with	   a	  
scleroderma	  patient	   serum	  containing	  antibodies	   to	   topoisomerase	   I.	   The	  position	  of	   the	  necrotic	  




Figure	   2:	   Reactivity	   of	   T1D	   sera	  with	  necrotic	  Min6	   lysates.	  Western	  blots	  containing	  extracts	  of	  
Min6	  cells	  which	  were	  treated	  with	  0.15%	  hydrogen	  peroxide	  (+)	  or	  extracts	  of	  non-­‐treated	  Min	  6	  
cells	  (-­‐)	  were	  incubated	  with	  T1D	  patient	  sera.	  The	  arrows	  mark	  the	  positions	  of	  polypeptides	  that	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~70%	  confluency	  were	  infected	  with	  CVB3	  at	  a	  multiplicity	  of	  infection	  of	  1	  or	  10	  
in	  culture	  medium.	  After	  incubation	  for	  8	  hrs,	  16	  hrs,	  24	  hrs	  and	  48	  hrs,	  cells	  were	  
washed	   three	   times	   with	   PBS.	   The	   adherent	   cells	   were	   detached	   by	   treatment	  
with	  5	  mM	  EDTA	  for	  1	  min	  and	  harvested	  by	  centrifugation	  at	  800g	  for	  5	  min	  at	  
room	   temperature.	   Cells	   were	   lysed	   in	   SDS-­‐PAGE	   loading	   buffer	   and	   stored	   at	  	  
-­‐20˚C.	  	  
Gel	  electrophoresis	  and	  immunoblotting	  
Proteins	   from	   normal,	   necrotic	   and	   virus-­‐infected	   Min6	   cell	   extracts	   were	  
separated	   by	   SDS-­‐PAGE	   using	   10%	   polyacrylamide	   gels	   and	   transferred	   to	  
nitrocellulose	   membranes	   by	   electroblotting.	   The	   blots	   were	   blocked	   with	   5%	  
non-­‐fat	  dried	  milk	   in	  PBS	  containing	  0.05%	  Tween-­‐20	  (MPBST)	  and	  subsequently	  
incubated	   with	   patient	   sera,	   1,000-­‐fold	   dilution	   in	   MPBST.	   As	   a	   secondary	  
antibody,	   horseradish	   peroxidase-­‐conjugated	   rabbit-­‐anti	   human	   IgG	   (Dako	  
Immunoglobulins)	   was	   used	   at	   a	   5,000-­‐fold	   dilution	   in	   MPBST.	   The	   anti-­‐
enteroviral	  VP-­‐1	  antibody	  was	  diluted	  500-­‐fold	  in	  MPBST	  and	  subsequently	  with	  a	  
secondary	   antibody,	   horseradish	   peroxidase-­‐conjugated	   rabbit-­‐anti	   mouse	   IgG	  
(Dako)	  which	  was	  used	  at	  a	  1,000-­‐fold	  dilution	  in	  MPBST.	  Bound	  antibodies	  were	  
visualized	  by	  chemiluminescence.	  
Results	  
Reactivity	  of	  T1D	  patient	  sera	  with	  necrotic	  Min6	  cell	  antigens	  
Necrosis	  was	   induced	   in	  Min6	  cells	  by	  adding	  H2O2	   to	   the	  culture	  medium	  (final	  
concentration	  0.15%).	  After	   incubation	   for	  5	  hours	   cells	  were	   lysed	  and	   the	   cell	  
lysates	   were	   analysed	   by	   immunoblotting	   (Fig.	   1).	   The	   cleavage	   of	  
topoisomerase	  I	   into	  an	   immunoreactive	   fragment	  of	  approximately	  45	  kDa	   (27)	  
indicates	   that	   necrosis	  was	   effectively	   induced.	   Immunoblots	   containing	   normal	  
and	   necrotic	  Min6	   lysates	   were	   probed	   with	   103	   T1D	   patient	   sera,	   5	   Sjögren’s	  
syndrome	  (SS)	  sera,	  5	  systemic	  lupus	  erythematosus	  (SLE)	  sera	  and	  10	  sera	  from	  
healthy	  individuals.	  A	  comparison	  of	  the	  data	  did	  not	  lead	  to	  the	  identification	  of	  
an	  antigen	  in	  the	  necrotic	  cell	  material	  that	  was	  frequently	  recognized	  by	  the	  T1D	  
patients,	   but	   not	   by	   the	   controls.	   Several	   proteins	   recognized	   by	   patient	   sera	  
showed	  a	  slightly	  retarded	  migration	  in	  SDS-­‐PAGE	  gels	  (Fig.	  2,	  lysates	  probed	  with	  
T1D3	  and	  T1D14),	  which	  is	  reminiscent	  of	  observations	  made	  with	  material	  from	  
necrotic	   Jurkat	   cells	   and	   is	   likely	  due	   to	  oxidative	  modification	  of	   the	   respective	  
proteins	   (28).	  Two	  out	  of	   the	  103	  T1D	  sera	   showed	   reactivities	  with	  antigens	  of	  
the	   necrotic	   cell	   extracts	   distinct	   from	   the	   retarded	   migration	   pattern	   (Fig.	   2,	  
T1D1	  and	  T1D29).	  T1D29	  has	  antibodies	  recognizing	  a	  necrotic	  Mr	  40,000	  protein,	  
which	  might	   be	   a	   cleavage	   product	   of	   the	  Mr	  45,000	   protein	   recognized	   in	   the	  
control	   extract.	   T1D1,	   which	   did	   not	   show	   any	   reactivity	   with	   proteins	   in	   the	  




Figure	  3:	  Apoptosis	   induced	  by	  CVB3	   infection	   in	  Min6	   cells.	  Extracts	  of	  Min6	  cells	   infected	  with	  
CVB3	  for	  8,	  24	  or	  48	  hrs	  or	  cultured	  for	  48	  hrs	  under	  similar	  conditions	  (mock,	  M)	  were	  separated	  by	  
SDS-­‐PAGE	  and	   transferred	   to	   nitrocellulose	  membranes.	   The	  blots	  were	  probed	  with	   patient	   sera	  
containing	  antibodies	  to	  topoisomerase	  I	  and	  U1-­‐70K.	  The	  Mr	  70,000	  and	  Mr	  45,000	  topoisomerase	  I	  
cleavage	  products,	  which	  appear	   in	  apoptotic	  and	  necrotic	   cells,	   respectively,	  are	  marked	  with	  an	  
asterisk	  (*),	  the	  apoptosis-­‐specific	  Mr	  40,000	  U1-­‐70K	  cleavage	  product	  is	  marked	  with	  two	  asterisks	  





Figure	   4:	   Reactivity	   of	   T1D	   sera	  with	  CVB3-­‐infected	  Min6	   lysates.	  Extracts	  of	  Min6	  cells	   infected	  
with	   CVB3	   for	   8,	   24	   or	   48	   hrs	   or	   cultured	   for	   48	   hrs	   under	   similar	   conditions	   (mock,	   M)	   were	  
separated	  by	  SDS-­‐PAGE	  and	  transferred	  to	  nitrocellulose	  membranes.	  The	  blots	  were	  probed	  with	  
T1D	  patient	  sera.	  Reactive	  polypeptides	  of	  Mr	  33,000,	  Mr	  100,000	  and	  Mr	  28,000	  are	  marked	  with	  
one,	  two	  and	  three	  asterisks,	  respectively.	  
M 8 24 48 M 8 24 48











M 8 24 48 M 8 24 48 M 8 24 48 





* * * 
** 
*** 
Reactivity	  of	  T1D	  sera	  with	  antigens	  from	  necrotic	  and	  Coxsackievirus-­‐infected	  pancreatic	  beta	  cells	  
	   109	  
Cell	  death	  induction	  by	  CVB3	  infection	  of	  Min6	  cells	  
The	  murine	  pancreatic	  beta	  cell	  line	  Min6	  was	  infected	  with	  CVB3	  virus.	  Similar	  to	  
previous	  observations	  (29)	  the	  first	  effects	  were	  observed	  after	  24	  hrs,	  when	  the	  
cells	  became	  more	  rounded	  and	  started	  to	  detach	  from	  the	  bottom	  of	  the	  culture	  
plates.	  To	  investigate	  whether	  these	  changes	  might	  be	  associated	  with	  apoptotic	  
and/or	  necrotic	  phenomena,	   the	   lysates	   from	  virus-­‐infected	   cells	  were	  analysed	  
for	   the	   presence	   of	   protein	   modifications	   which	   occur	   specifically	   during	  
apoptosis	  and	  necrosis,	  the	  cleavage	  of	  U1-­‐70K	  and	  topoisomerase	  I,	  respectively.	  
Only	   weak	   signals	   were	   observed	   for	   the	   apoptotic	   degradation	   products	   of	  
U1-­‐70K	  (Mr	  40,000)	  (Fig.	  3),	  suggesting	  that	  only	  a	  small	  fraction	  of	  the	  Min6	  cells	  
is	   apoptotic	   at	   this	   stage.	   Both	   the	   anti-­‐topoisomerase	   I	   and	   the	   anti-­‐U1-­‐70K	  
patient	   sera	   showed	   prominent	   reactivities	   with	   a	   Mr	   33,000	   protein	   upon	  
infection	  of	  the	  Min6	  cells.	  	  
Reactivity	  of	  T1D	  patient	  sera	  with	  antigens	  from	  CVB3-­‐infected	  Min6	  
cells	  
To	  investigate	  the	  (auto)antibody	  reactivity	  of	  T1D	  sera	  with	  proteins	  from	  CVB3-­‐
infected	  Min6	  cells,	  cells	  were	  harvested	  8,	  24	  and	  48	  hours	  post-­‐infection.	  As	  a	  
control,	  cells	  were	  only	  treated	  with	  PBS	  without	  CVB3.	  Immunoblots	  with	  mock-­‐
infected	  and	  CVB3-­‐infected	  Min6	  lysates	  were	  probed	  with	  sera	  from	  T1D	  and	  SS	  
patients	  and	  from	  healthy	  controls.	  Figure	  4	  shows	  three	  blots	  probed	  with	  T1D	  
sera;	  the	  reactivities	  found	  in	  the	  T1D	  and	  control	  sera	  are	  summarized	  in	  Table	  1.	  
Twenty	  three	  out	  of	  24	  T1D	  sera	  (96%)	  showed	  reactivity	  with	  a	  Mr	  33,000	  band,	  
which	  was	   reminiscent	  of	   the	  band	  observed	  also	  with	   the	  anti-­‐topoisomerase	   I	  
and	  the	  anti-­‐U1-­‐70K	  antibodies	  (see	  above).	  This	  reactivity	  was	  also	  found	  in	  4	  out	  
of	  5	  SS	  sera	  and	  8	  out	  of	  10	  healthy	  control	  sera.	  Importantly,	  this	  band	  was	  not	  
or	  hardly	  detected	  in	  the	  material	  from	  the	  cells	  harvested	  8	  hours	  post	  infection	  




Table	  1:	  Reactivity	  of	  T1D	  and	  control	  sera	  with	  the	  Mr	  28,000,	  Mr	  33,000	  and	  Mr	  100,000	  proteins	  

































































(e.g.	  T1D54)	  also	  showed	  reactivity	  with	  a	  polypeptide	  with	  a	  molecular	  weight	  of	  
approximately	   100,000	   (15	   out	   of	   24	   patients,	   63%),	   which	  was	   less	   frequently	  
observed	   with	   the	   other	   sera;	   only	   1	   of	   the	   SS	   patients	   and	   1	   of	   the	   normal	  
control	   sera	   displayed	   this	   reactivity.	   Two	   of	   the	   T1D	   patients	   (e.g.	   T1D9)	   also	  
showed	  reactivity	  with	  a	  Mr	  28,000	  protein,	  which	  was	  not	  recognized	  by	  any	  of	  
the	  control	  sera.	  None	  of	  these	  antigens	  were	  detectable	   in	  material	   from	  mock	  
infected	  cells.	  	  
Comigration	  of	  the	  Mr	  33,000	  antigen	  with	  the	  viral	  coat	  protein	  VP-­‐1	  	  
The	  appearance	  of	  antigens	   targeted	  by	  T1D	  and	  control	   sera	  upon	   infection	  by	  
CVB3	  raised	  the	  question	  whether	  these	  antigens	  represent	  host	  cell	  proteins,	  the	  
reactivity	  of	  which	  is	  changed	  as	  a	  result	  of	  the	  infection,	  or	  viral	  proteins	  that	  are	  
expressed	  during	  the	  course	  of	  infection.	  To	  investigate	  this,	  a	  mouse	  monoclonal	  
antibody	  to	  the	  33	  kDa	  viral	  coat	  protein	  VP-­‐1	  was	  used	  to	  stain	  an	  immunoblot	  
that	  was	  simultaneously	  stained	  with	  a	  patient	  serum	  reactive	  with	  the	  Mr	  33,000	  
species	   (Fig.	   5).	   The	   antigen	   targeted	   by	   the	   patient	   serum	   indeed	   co-­‐migrated	  
with	   the	   VP-­‐1	   protein,	   strongly	   suggesting	   that	   this	   patient	   serum	   contains	  




Figure	  5:	  The	  Mr	  33,000	  protein	  recognized	  by	  patient	  sera	  co-­‐migrates	  with	  the	  viral	  VP-­‐1	  protein.	  
Western	   blots	   containing	   extracts	   of	   non-­‐	   or	   CVB3-­‐infected	   Min6	   cells	   (48	   hrs	   post-­‐infection;	  
indicated	  with	   -­‐	  and	  +,	   respectively)	  were	  probed	  with	  a	  T1D	  patient	   serum	  containing	  antibodies	  
towards	   the	  Mr	   33,000	   protein	   (left	   panel)	   or	   a	  monoclonal	   antibody	   recognizing	   the	   CVB3	   VP-­‐1	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Discussion	  
In	   this	   study	   the	   reactivity	   of	   T1D	   sera	   with	   antigens	   from	   necrotic	   and	   CVB3-­‐
infected	   murine	   insulinoma	   cells	   was	   assessed	   by	   immunoblotting.	   The	   most	  
frequently	  found	  antibody	  reactivities	  in	  T1D	  sera	  are	  antibodies	  to	  GAD65	  (84%),	  
IA-­‐2	  (74%)	  and	  insulin	  (49%-­‐92%,	  higher	  frequency	  in	  young	  children)	  (30).	  None	  
of	  these	  reactivities	  were	  found	  in	  these	  experiments,	  which	  may	  at	  least	  in	  part	  
be	  explained	  by	  the	  importance	  of	  conformational	  aspects	  for	  the	  recognition	  of	  
GAD65	   (31)	   and	   IA-­‐2	   (32)	   by	   autoantibodies,	   and	   the	   disruption	   of	   protein	  
conformation	   during	   SDS-­‐PAGE.	   The	   experimental	   approach	   did	   not	   allow	   the	  
detection	   of	   antibodies	   to	   insulin,	   since	   the	  molecular	  weights	   of	   the	   relatively	  
small	  insulin	  polypeptide	  chains	  are	  beyond	  the	  separation	  range	  of	  the	  gels	  used.	  
Several	   proteins	   from	   hydrogen	   peroxide	   treated,	   necrotic	   Min6	   cells	   that	   are	  
recognized	  by	  T1D	  antibodies	   showed	  a	   retarded	  migration	   in	  SDS-­‐PAGE.	  This	   is	  
reminiscent	  of	  observations	  made	  with	  material	  from	  hydrogen	  peroxide	  treated,	  
necrotic	  Jurkat	  cells	   (28).	  The	  retarded	  migration	   is	  probably	  due	  to	  oxidation	  of	  
amino	  acid	  side	  chains	  by	  ROS	  resulting	   from	  hydrogen	  peroxide	   (28).	  Oxidation	  
may	  lead	  to	  the	  formation	  of	  neo-­‐epitopes	  which	  could	  be	  involved	  in	  triggering	  
the	  autoimmune	  response	   in	  T1D.	  A	  comparison	  of	   the	  data	  did	  not	   lead	   to	   the	  
identification	   of	   an	   antigen	   in	   the	   necrotic	   cell	   material	   that	   was	   frequently	  
recognized	   by	   the	   T1D	   patients,	   but	   not	   by	   the	   controls.	   This	   suggests	   that	   the	  
observed	   oxidative	   modifications	   do	   not	   seem	   to	   play	   a	   major	   role	   in	   the	  
generation	   of	   autoantibodies	   towards	   neo-­‐epitopes,	   although	   these	   results	  
should	   be	   interpreted	   with	   care,	   because	   all	   T1D	   sera	   were	   from	   adult	   T1D	  
patients.	  The	  possibility	  that	  such	  neo-­‐epitopes	  play	  a	  role	  in	  the	  very	  early	  stages	  
of	  the	  disease	  cannot	  be	  completely	  excluded.	  During	  progression	  of	  the	  disease	  
epitope	   spreading	  may	  occur,	  which	   can	  not	  only	   result	   in	   the	  generation	  of	   an	  
immune	  response	  to	  multiple	  epitopes	  of	  one	  or	  more	  antigens	  (33,34),	  but	  also	  
in	  the	  disappearance	  of	  autoantibodies	  that	  are	  reactive	  with	  the	  initial	  triggering	  
epitope.	   Another	   explanation	   might	   be	   related	   to	   the	   use	   of	   the	   immortalized	  
Min6	   cell	   line	   in	   these	  experiments.	   it	   is	  possible	   that	   reactivities	  with	  modified	  
targets	   are	   missed	   due	   to	   differences	   in	   protein	   expression	   (levels)	   between	  
cultured	  cell	  lines	  and	  human	  beta	  cells.	  For	  that	  reason	  the	  Min6	  cell	  line	  might	  
not	   be	   the	   best	   source	   of	   (modified)	   targets	   for	   human	   autoantibodies	   and	   it	  
would	   be	   interesting	   to	   study	   the	   autoantibody	   profiles	   of	   T1D	   patients	   using	  
human	  islet	  cells.	  However,	  for	  obvious	  reasons	  large	  quantities	  of	  such	  cells	  are	  
not	  readily	  available.	  The	  infection	  of	  murine	  Min6	  cells	  with	  CVB3	  did	  result	  in	  an	  
altered	  reactivity	  pattern	  for	  most	  T1D	  sera,	  the	  most	  prominent	  of	  which	  is	  the	  
recognition	  of	  three	  protein	  bands	  in	  the	  material	  from	  infected	  cells,	  but	  not	   in	  
that	  of	  the	  non-­‐infected	  cells.	  A	  Mr	  33,000	  protein	  was	  recognized	  by	  96%,	  a	  Mr	  
100,000	  protein	  by	  63%	  and	  a	  Mr	  28,000	  protein	  by	  8%	  of	  the	  T1D	  sera.	  Since	  viral	  
proteins	  will	  be	  produced	  during	  the	  course	  of	  the	  infection	  and	  since	  anti-­‐CVB3	  
Chapter	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protein	  antibodies	  are	  known	  to	  occur	  frequently	  in	  human	  sera	  (21),	  reactivities	  
with	   viral	   proteins	   were	   expected	   with	   the	   material	   from	   CVB3-­‐infected	   Min6	  
cells.	  The	  Mr	  33,000	  protein	  probably	  represents	  the	  CVB3	  viral	  coat	  protein	  VP-­‐1	  
as	   suggested	   by	   the	   comigration	   in	   SDS-­‐PAGE	   and	   the	   time	   course	   of	   the	  
appearance	  of	  this	  protein	  after	  infection	  of	  the	  cells.	  The	  situation	  for	  the	  other	  
two	   bands	   is	   less	   clear.	   The	   Mr	   28,000	   protein	   might	   represent	   the	   viral	   coat	  
protein	  VP-­‐2	  or	  VP-­‐3	  (26	  and	  25	  kDa,	  resp.),	  based	  on	  the	  migration	  in	  SDS-­‐PAGE,	  
but	  it	  can	  also	  be	  a	  Min6	  cellular	  protein	  which	  is	  modified	  as	  a	  result	  of	  the	  CVB3	  
infection	  and,	  as	  a	  consequence,	  is	  reactive	  with	  some	  T1D	  sera.	  The	  Mr	  100,000	  
species	   is	   even	   more	   likely	   to	   be	   a	   neo-­‐epitope	   containing	   host	   cell	   protein,	  
because	   none	   of	   the	   fully	   processed	   viral	   proteins	   migrates	   at	   Mr	   100,000.	  
Because	   CVB3	   proteins	   are	   translated	   as	   one	   prepropeptide,	   which	   is	   rapidly	  
proteolytically	   processed	   into	   several	   propeptides	   and	   subsequently	   into	   the	  11	  
viral	   structural	   and	   non-­‐structural	   proteins,	   the	   possibility	   that	   the	  Mr	   100,000	  
represents	  a	   viral	  propeptide,	  e.g.	  P1	   (96	  kDa),	   cannot	  be	   ruled	  out	   completely.	  
However,	   (i)	   the	   lack	   of	   a	   strong	   correlation	   between	   the	   recognition	   of	   the	  
33,000	  and	  100,000	  bands,	  (ii)	  the	  failure	  of	  the	  anti-­‐VP-­‐1	  monoclonal	  antibody	  to	  
bind	  to	  the	  100,000	  species	  (VP-­‐1	  is	  part	  of	  the	  P1	  propeptide),	  and	  (iii)	  the	  lower	  
frequency	   of	   antibodies	   against	   this	   protein	   in	   control	   sera	   argue	   against	   this	  
possibility.	  The	  elucidation	  of	  the	  molecular	  identity	  of	  the	  Mr100,000	  protein	  will	  
be	   required	   to	   answer	   the	   question	   whether	   this	   is	   indeed	   a	   neo-­‐epitope	  
containing	  Min6	  protein.	  The	  results	  of	  our	  study	  demonstrated	  that	  antibodies	  in	  
some	   T1D	   sera	   can	   be	   directed	   to	   antigens	   that	   are	   exclusively	   detected	   in	  
hydrogen	   peroxide	   induced	   necrotic	   insulinoma	   cell	   material.	   Our	   data	   do	   not	  
support	  a	  major	  role	  for	  these	  modified	  self	  proteins	  in	  the	  immune	  response	  of	  
T1D.	  Many	  T1D	  and	  control	  sera	  contain	  antibodies	  towards	  enteroviral	  proteins,	  
such	  as	  the	  Mr	  33,000	  protein,	  which	  most	  likely	  is	  the	  viral	  protein	  VP-­‐1.	  The	  high	  
antibody	  prevalence	  corresponds	   to	   the	  high	   frequency	  of	  enteroviral	   infections	  
in	   the	   population	   (35).	   Although	   the	   frequency	   of	   recognition	   of	   the	  Mr	   33,000	  
protein	  did	  not	  markedly	  differ	  between	  sera	  from	  T1D	  patients	  and	  from	  control	  
subjects,	  antibodies	   to	  a	  Mr	  100,000	  protein	  were	  more	   frequently	   found	   in	   the	  
T1D	  sera	  (63%)	  than	  in	  the	  healthy	  control	  (10%)	  and	  SS	  sera	  (20%).	  Although	  the	  
identity	  of	  this	  Mr	  100,000	  protein	  was	  not	  established	  in	  these	  experiments,	  it	  is	  
tempting	   to	   speculate	   that	   this	   protein	   is	   a	  Min6	  protein	   that	   is	  modified	   upon	  
infection	  with	  CVB3.	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Part	  1:	   The	  development	  of	  an	  iSPR-­‐based	  multiplex	  assay	  for	  
characterizing	  the	  autoantibody	  profile	  of	  autoimmune	  patients	  
Multiplexed	  detection	  of	  autoantibody	  biomarkers	  	  
Many	  autoantibodies	  are	  included	  as	  key	  components	  of	  the	  diagnostic	  algorithm	  
for	  many	   autoimmune	   diseases,	   such	   as	   rheumatoid	   arthritis	   (RA)	   (1),	   systemic	  
lupus	   erythematosus	   (SLE)	   (2)	   and	  mixed	   connective	   tissue	   disease	   (MCTD)	   (3).	  
The	  spectrum	  of	  autoantibodies	  in	  autoimmune	  diseases	  is	  continually	  expanding.	  
For	  example,	   in	  autoimmune	  disease	  with	  multi-­‐organ	   involvement,	  such	  as	  SLE,	  
more	   than	   100	   different	   autoantibodies	   have	   been	   described	   (4)	   and	   over	   20	  
autoantibodies	  have	  been	   found	   in	   scleroderma	   (5,6).	  Diagnostic	   tests	   currently	  
used	  by	  clinicians	  are	  almost	  all	  based	  on	  the	  detection	  of	  a	  single	  autoantibody,	  
which	  may	  not	  be	  present	  exclusively	  in	  one	  disease	  (e.g.	  anti-­‐snRNP	  antibodies	  in	  
SLE	  and	  MCTD)	  or	  which	   is	  present	   in	  a	  subset	  of	  patients	   (e.g.	  anti-­‐citrullinated	  
protein	   antibodies	   (ACPA)	   in	   RA).	   Multiplex	   analysis	   of	   a	   patient’s	   antibody	  
repertoire	  might	  provide	  information	  to	  diagnose	  and	  subclassify	  patients,	  which	  
may	  lead	  to	  a	  better	  treatment	  strategy.	  As	  is	  described	  in	  Chapter	  1	  several	  new	  
techniques	   have	   been	   designed	   for	   the	   multiplex	   analysis	   of	   autoantibody	  
repertoires	  in	  autoimmune	  sera	  (7).	  Some	  of	  these	  novel	  techniques	  are	  based	  on	  
label-­‐free	  detection	  of	  biomolecular	   interactions.	  These	   techniques	  can	   result	   in	  
less	   false	   positives	   or	   false	   negatives,	   higher	   throughput,	   and	   an	   increased	  
sensitivity	   and	   specificity.	   One	   of	   these	   is	   surface	   plasmon	   resonance	   (SPR)	  
imaging,	  an	  optical	  method	  to	  measure	  refractive	  indices	  near	  a	  sensor	  surface.	  	  
Fixed	  angle	  configuration	  versus	  angle	  scanning	  configuration	  
Chapter	  2	  demonstrates	  the	  differences	  in	  dynamic	  range	  between	  two	  different	  
optical	   SPR	   configurations:	   1)	   fixed	   angle	   configuration	   and	   2)	   angle	   scanning	  
configuration.	  In	  fixed	  angle	  configuration,	  the	  angle	  of	  incident	  light	  is	  fixed	  and	  
the	   intensity	   of	   the	   reflected	   light	   is	   measured.	   Because	   of	   the	   non-­‐linear	  
relationship	  between	  reflected	  light	  intensity	  and	  the	  SPR	  angle	  dip	  the	  change	  in	  
SPR	  angle	  dip	  as	  a	  result	  of	  a	  biomolecular	  interaction	  cannot	  be	  derived	  from	  the	  
measured	   reflected	   light	   intensity	   only.	   An	   angle	   scanning	   configuration,	   as	  
applied	  in	  this	  thesis,	  detects	  the	  reflected	  light	  intensities	  at	  different	  angles	  very	  
fast	  for	  the	  ROIs,	  creating	  a	  full	  SPR	  curve	  for	  each	  ROI.	  The	  angle	  scanning	  system	  
of	   IBIS	   Technologies	   produces	   250	   full	   SPR	   curve	   scans	   per	   second.	   By	   applying	  
SPR	  curve	  fitting	  routines	  the	  actual	  SPR	  angle	  dip	  is	  then	  calculated	  for	  each	  ROI	  
with	   great	   accuracy	   (resolution	   is	   better	   than	   0.1	   mdeg).	   The	   conversion	   of	  
reflected	   light	   intensity	  to	  SPR	  angle	  dip	  at	  a	  fixed	  angle	   is	  only	  applicable	  when	  
the	   relationship	   between	   these	   parameters	   is	   linear.	   In	   practice	   this	   linear	  
relationship	   appears	   to	   be	   valid	   for	   a	   range	   of	   50	  mdeg	   (8).	   However,	   because	  
every	  spot	  contains	  in	  principle	  a	  different	  ligand	  (and	  a	  different	  ligand	  density),	  
every	  SPR	  curve	  obtained	  from	  these	  spots	  shows	  from	  the	  start	  of	  an	  experiment	  
Chapter	  7	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already	  more	   than	  50	  mdeg	   (sometimes	  >	  500	  mdeg),	  and	  as	  a	  consequence	  an	  
optimal	   SPR	   angle	   for	  measuring	   the	   linear	   relation	  of	   reflected	   light	   intensities	  
for	  all	  spots	  cannot	  be	  set.	   In	  Chapter	  2	  the	  dynamic	  range	  of	  both	  the	  scanning	  
angle	   configuration	   and	   fixed	   angle	   configuration	   is	   assessed	   with	   samples	   of	  
increasing	  refractive	  indices.	  The	  results	  show	  a	  10	  times	  larger	  dynamic	  range	  for	  
the	   angle	   scanning	   compared	   to	   the	   fixed	   angle	   configuration.	   In	   the	   angle	  
scanning	  configuration	  all	  spots	  on	  a	  microarray	  can	  be	  monitored	  independently	  
with	  a	   large	  dynamic	  range,	  allowing	  the	  measurement	  of	  peptide/protein	  spots	  
with	  different	  molecular	  masses	  or	  affinities	  simultaneously.	  This	  makes	  the	  angle	  
scanning	  configuration	  the	  preferred	  configuration	  for	  the	  reliable	  measurement	  
of	   the	  magnitude	  and	  kinetics	  of	  peptide/protein	  arrays	  with	  biological	   samples	  
such	  as	  sera.	  
Detection	  of	  autoantibodies	  in	  sera	  by	  SPR	  imaging	  
The	   one-­‐step	   multi-­‐analyte	   detection	   of	   autoantibodies	   in	   patient	   sera	   by	   SPR	  
imaging	  (iSPR)	   is	  described	   in	  Chapter	  3.	  The	  spotted	  sensor	  discs	  could	  be	  used	  
up	   to	   30	   analysis	   cycles	  with	   less	   than	   5%	   variation	   in	   absorption	   signal	   of	   the	  
same	   serum.	   Due	   to	   the	   microarray	   format	   reference	   peptides	   and	   control	  
peptides	   can	   be	   included	   and	   assayed	   under	   the	   same	   conditions	   as	   the	   target	  
peptides.	   These	   characteristics	   of	   iSPR	   allow	   the	   consistent	   measurement	   of	  
antibody	   reactivities	   in	   patient	   and	   control	   sera.	   Although	   the	   sensitivity	   of	  
detecting	   RA-­‐specific	   autoantibodies	   by	   the	   scanning	   SPR	   imaging	   system	   is	  
slightly	  lower	  than	  that	  of	  the	  ELISA	  systems,	  we	  expect	  that	  further	  optimization	  
will	   lead	   to	   similar	   sensitivities.	   Increasing	   ligand	   density	   could	   be	   a	   way	   of	  
improving	  the	  sensitivity.	   In	  the	  experiments	  described	  in	  this	  thesis	  microarrays	  
were	  made	  by	  a	  piezoactuator,	  which	  dispenses	   the	   ligand	  spotting	   fluid	  on	   the	  
surface	   in	  1	  nl	  small	  droplets.	  The	  sizes	  of	   the	  spots	  are	  dependent	  on	  fluid	  and	  
surface	   properties.	   Efforts	   to	   increase	   ligand	   density	   by	   increasing	   the	  
concentration	  of	   ligand	  in	  the	   ligand	  spotting	  fluid	  for	  some	  peptides	  resulted	  in	  
increased	  hydrophilicity	  and	  in	  the	  “touching”	  and	  “flooding”	  of	  separate	  spots.	  A	  
contact	  spotter,	  a	  device	  which	  is	  applied	  to	  the	  sensor	  surface	  and	  defines	  sensor	  
spots	  size	  and	  place,	  would	  be	  helpful	   to	   increase	   ligand	  concentration	   in	   ligand	  
spotting	   fluid.	   This	   could	   a.o.	   be:	   atomic	   force	   microscope	   tips	   (AFM	   tips)	   (9),	  
microfabricated	   fountain	   pens	   (10),	   or	   polydimethylsiloxane	   (PDMS)	  
microspotters	  (11).	  Ligand	  density	  could	  also	  be	  increased	  by	  applying	  the	  ligands	  
in	  a	  continuous	  flow	  to	  the	  sensor	  surface,	  which	  makes	  it	  possible	  to	  expose	  each	  
spot	   to	   a	   larger	   sample	   volume	   than	  would	   be	   possible	  with	   printing	  methods.	  
Continuous	  flow	  would	  be	  best	  applied	  as	  a	  laminar	  flow	  because	  mass	  transport	  
introduced	  by	  circular	  flow	  introduced	  by	  suction/dispensing	  methods	  would	  lead	  
to	   inhomogeneous	   spots.	   Another	  way	   of	   improving	   the	   sensitivity	  might	   be	   by	  
optimizing	   the	   length	   of	   the	   linker	   to	   which	   the	   ligands	   are	   bound.	   During	   the	  
experiments	  we	   changed	   from	  a	   sensor	  disc	  with	  no	  dextran	  hydrogel	   to	   a	   disc	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with	  a	  200	  nm	  hydrogel.	  We	  anticipated	  that	  the	  close	  proximity	  of	  the	  ligands	  to	  
the	   sensor	   surface	   would	   lead	   to	   sterical	   hindrance.	   Indeed	   the	   change	   to	   this	  
new	  type	  of	  sensor	  improved	  the	  signal	  strength	  and	  led	  to	  the	  results	  described	  
in	   Chapter	   3.	   Further	   optimization	   of	   linker	   length	   might	   lead	   to	   better	   ligand	  
accessibility	   and	   thus	   to	   improved	   assay	   sensitivity.	   The	   peptides	   were	  
immobilized	  by	  covalent	  linkage	  of	  the	  primary	  amine	  residues	  and	  the	  EDC/NHS	  
activated	   carboxylic	   groups	   on	   the	   sensor	   surface.	   This	   type	   of	   coupling	   is	  
different	   from	   the	   passive	   absorption	   coupling	   which	   is	   used	   in	   ELISA	  
experiments.	   The	   differences	   in	   coupling	   chemistry	   between	   these	   techniques	  
might	   result	   in	   differences	   in	   orientation	   of	   the	   antigenic	   molecules	   and	   as	   a	  
result	   in	   differences	   among	   the	   accessibility	   of	   the	   epitopes,	  which	   can	   lead	   to	  
differences	   in	   sensitivity.	   Sensitivity	   may	   also	   be	   improved	   by	   optimizing	   the	  
regeneration	   protocol	   of	   the	   sensor	   discs.	   Repetitive	   probing	   of	   the	   discs	   with	  
three	   different	   sera	   resulted	   in	   comparable	   angle	   shifts,	   suggesting	   binding	   of	  
similar	   amounts	   of	   serum	   immunoglobulins	   to	   the	   sensor	   surface.	   However,	  
probing	  of	   regenerated	  sensor	  discs	  with	  a	  secondary	  antibody	  targeting	  human	  
IgG	   molecules	   resulted	   in	   angle	   shifts	   of	   around	   50	   mdeg,	   indicating	   residual	  
human	   IgG	  molecules	  on	  these	  discs.	  These	  residual	  human	   IgG	  molecules	  block	  
binding	   sites	   of	   subsequent	   sera	   resulting	   in	   lower	   signals.	   The	   incomplete	  
removal	  of	  serum	  IgG	  will	  also	  inhibit	  the	  use	  of	  a	  signal	  amplification	  step	  (e.g.	  by	  
using	   a	   (gold-­‐labeled)	   secondary	   antibody).	   As	   was	   explained	   above	   the	  
application	  of	  a	  secondary	  antibody	  to	  this	  residual	  human	  IgG	  molecules	  will	  lead	  
to	   false	   positive	   results.	   If	   removal	   of	   the	   residual	   IgG	  molecules	   appears	   to	   be	  
technically	   challenging	   the	   residual	   IgG	   molecules	   can	   also	   be	   blocked	   from	  
amplification	   by	   secondary	   antibody	   by	   incubating	   them	   with	   a	   Fab	   domain	  
specifically	  targeting	  human	  IgG	  Fc	  domains	  prior	  to	  serum	  incubation.	  This	  would	  
however	  result	  in	  an	  extra	  incubation	  step	  and	  thus	  in	  prolonged	  analysis	  time.	  At	  
the	  moment	  the	  throughput	  of	  patients	  is	  not	  very	  high,	  although	  the	  number	  of	  
tested	   peptides	   can	   be	   easily	   increased,	   every	   patient	   has	   to	   be	   tested	  
consecutively.	  With	  the	  settings	  used	  in	  the	  experiments	  described	  in	  this	  thesis,	  
the	  analysis	  cycle	  for	  one	  patient	  takes	  roughly	  1	  hour	  and	  45	  minutes,	  allowing	  
the	  measurement	  of	  13-­‐14	  patients	   in	  24	  hours.	  The	  analysis	  cycle	  can	  probably	  
be	  shortened,	  since	  the	  different	  steps	  in	  the	  cycle	  have	  not	  been	  fully	  optimized.	  
The	   serum	   incubation	   time	   might	   be	   decreased;	   it	   is	   known	   that	   the	  
association/dissociation	   of	   antibodies	   does	   not	   have	   to	   reach	   equilibrium	   to	   be	  
informative	  about	  the	  presence	  of	  autoantibodies.	  Current	  point	  of	  care	  devices	  
are	   able	   to	   indicate	   the	   presence	   of	   antibodies	   after	   an	   incubation	   of	   only	   a	  
couple	  of	  minutes.	  An	  advantage	  of	  the	  iSPR	  platform	  is	  the	  fact	  that	  the	  patients	  
can	  be	  tested	   in	  an	  automated	  fashion	  by	  using	   liquid	  handling	  procedures.	  This	  
results	   in	   a	   hands-­‐on	   time	  of	   approximately	   45	  minutes	   for	   a	   24	   hr	   experiment	  
with	  multiple	  patient	  samples.	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Microarray-­‐based	  ACPA	  profiling	  by	  scanning	  SPR	  imaging	  
Subclassifying	  patients	  based	  on	  their	  autoantibody	  profiles	  could	  result	  in	  better,	  
tailor-­‐made	   therapies.	   Instead	   of	   using	   a	   general	   therapy	   and	   waiting	   if	   it	   will	  
help,	   the	  physician	   can	  better	  predict	   the	   likeliness	  of	   therapies	   to	  be	  effective.	  
This	  will	   result	   in	   finding	  effective	  therapy	  faster,	  with	   less	  diseases	  progression,	  
so	  with	  a	  better	  prognosis	  for	  the	  patient.	  To	  assess	  if	  patterns	  could	  be	  discerned	  
in	   the	   antibody	   repertoire	   of	   rheumatoid	   arthritis	   patients	   a	   iSPR	   array	   of	  
citrullinated	   peptides	   and	   the	   corresponding	   arginine	   control	   peptides	   was	  
probed	   with	   the	   sera	   of	   97	   RA	   patients	   and	   50	   controls	   (Chapter	   4).	   Indeed	  
various	   citrullinated	   peptides	   were	   frequently	   recognized	   by	   the	   RA	   sera	  
(especially	  by	  ACPA	  positive	   sera).	  Both	   the	  number	  of	   recognized	  peptides	  and	  
the	   reactivity	   profiles	   showed	   marked	   differences	   among	   patients.	   Although	  
clustering	   of	   the	   patients	   revealed	   3	  major	   groups,	   the	   question	  whether	   these	  
profiles	   can	   be	   used	   to	   stratify	   patients	   with	   different	   clinical	   features	   awaits	  
further	  analyses	  with	  cohorts	  of	  clinically	  well-­‐defined	  RA	  patients.	  Increasing	  the	  
sensitivity	  of	  the	  iSPR	  assay	  as	  described	  above	  might	  also	  result	  in	  better	  defined	  
profiles.	  Lower	  sensitivity	  of	  the	  iSPR	  assay	  might	  result	  in	  false	  negatives.	  Most	  of	  
the	   autoantibodies	   tested	   for	   in	   Chapter	   4	   are	   not	   found	   very	   frequently	   in	   RA	  
patients	   and	   false	   negative	   patients	   for	   these	   targets	   would	   result	   in	   missed	  
correlations	   between	  peptide	   reactivities.	   Increasing	   the	  number	   of	   RA	  patients	  
might	  also	  lead	  to	  more	  optimal	  prognostic	  profiles,	  because	  some	  peptides	  were	  
only	   recognized	   by	   5%-­‐10%	   of	   the	   RA	   patients.	   Correlations	   between	   the	  
reactivities	  with	  distinct	  peptides	  are	  easily	  missed	  with	  too	  low	  patient	  numbers.	  
Last	  but	  not	   least,	   the	   subclassification	  of	  RA	  patients	  might	  be	   improved	  when	  
the	  panel	  of	  peptides	  is	  supplemented	  with	  other	  antibody	  targets	  (IgG	  to	  detect	  
rheumatoid	   factor	   (RF),	   peptides	   derived	   from	   histones,	   (pro)fillagrin	   etc.)	   and	  
other	   serological	   markers,	   such	   as	   inflammatory	   markers	   (CRP)	   and	   tissue	  
destruction	   markers.	   During	   the	   preparations	   of	   this	   thesis	   Robinson	   and	  
coworkers	  published	  a	  paper	  which	  showed	  that	  multiplex	  analysis	  of	  biomarkers	  
in	  early-­‐stage	  RA	  allowed	   the	   stratification	  of	  patients	  with	  clinically	   identifiable	  
RA	  subtypes	  (12).	  In	  this	  paper	  the	  authors	  used	  the	  IMPACT	  platform	  (Roche)	  to	  
profile	   autoantibodies,	   cytokines	   and	   bone-­‐turnover	   products,	   all	   measured	   in	  
serum.	   This	   enabled	   them	   to	  make	   a	  more	   accurate	   diagnosis	   and	  prognosis	   of	  
this	  cohort	  of	  RA	  patients	  compared	   to	  current	  clinical	   tests	   (blood	   tests	   for	  RF,	  
ACPA	  and	  inflammatory	  markers	  such	  as	  erythrocyte	  sedimentation	  rate	  and	  CRP	  
levels,	  but	  also	  imaging	  techniques	  such	  as	  X-­‐ray,	  ultrasound	  or	  MRI).	  	  
Concluding	  remarks	  Part	  1	  
The	  studies	  described	  in	  this	  thesis	  introduce	  surface	  plasmon	  resonance	  imaging	  
as	   a	   multiplex	   platform	   for	   the	   analysis	   of	   autoantibody	   profiles.	   Multiplex	  
analysis	   will	   improve	   diagnosis	   and	   prognosis	   of	   autoimmune	   diseases.	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Subclassification	  of	  a	  heterogeneous	  autoimmune	  patient	  group,	  like	  RA,	  will	  give	  
the	  physician	  tools	  to	  predict	  treatment	  effectiveness	  and	  will	   result	   in	  selecting	  
the	  most	  effective	  therapy	  faster,	  without	  having	  to	  try	  more	  generic	  treatments	  
which	   are	   only	   effective	   in	   certain	   groups	   of	   patients	   without	   knowing	   if	   the	  
patient	  belongs	  to	  that	  group	  of	  patients.	  It	  is	  conceivable	  that	  in	  the	  near	  future	  
physicians	  have	  the	  ability	  to	  test	  an	  array	  of	  biomarkers	  simultaneously.	  Imaging	  
SPR	  represents	  a	  suitable	  platform	  for	  these	  assays.	  	  
Part	  2:	  	   Autoreactivity	  to	  cell	  death-­‐associated	  epitopes	  
Mechanisms	  for	  breaking	  of	  tolerance	  to	  self-­‐antigens	  	  
Several	   models	   explaining	   the	   loss	   of	   tolerance	   to	   self-­‐antigens	   have	   been	  
developed	  and	  the	  major	  three	  will	  be	  discussed	  in	  this	  paragraph.	  The	  first	  is	  the	  
molecular	   mimicry	   model,	   which	   is	   based	   on	   the	   hypothesis	   that	   pathogens	  
express	   epitopes	   that	   are	   similar	   to	   host	   antigens.	   Cross-­‐reactive	   responses	   can	  
lead	  to	  the	  production	  of	  autoantibodies	  to	  host	  antigens.	  For	  example	  GAD65,	  an	  
autoantigen	   in	   type	   1	   diabetes	   (T1D),	   contains	   a	   sequence	   element	   that	   is	   very	  
similar	   to	   a	   sequence	   of	   the	   2C	   protein	   of	   Coxsackievirus	   B4	   (13).	   Several	  
autoantibodies	   in	   SLE	  patients,	   including	  anti-­‐Sm-­‐B/B’,	   anti-­‐Sm-­‐D,	   and	  anti-­‐Ro60	  
have	   been	   shown	   to	   cross-­‐react	   with	   the	   Epstein-­‐Barr	   virus	   nuclear	   antigen-­‐1	  
(EBNA-­‐1)	   (14).	   MacClain	   and	   coworkers	   identified	   a	   cross-­‐reactive	   epitope	   on	  
Ro60	   which	   was	   recognized	   by	   serum	   of	   pre-­‐SLE	   patients	   before	   they	   were	  
diagnosed	   (15),	   supporting	   the	   hypothesis	   that	   infection	  with	   Epstein-­‐Barr	   virus	  
might	  initiate	  the	  development	  of	  SLE.	  Similar	  associations	  have	  been	  reported	  for	  
the	   development	   of	   other	   autoimmune	   diseases	   including	   Sjögren’s	   syndrome,	  
rheumatoid	   arthritis	   and	  myositis	   (16-­‐18).	   Furthermore,	   Coxsackie	   B	   virus	   could	  
be	   isolated	   from	   pancreatic	   tissues	   of	   individuals	   with	   acute	   insulin	   dependent	  
diabetes	  mellitus	  (19,20)	  and	  inoculation	  of	  mice	  with	  the	  isolated	  virus	  resulted	  
in	   the	   development	   of	   diabetes	   in	   these	  mice	   (20).	   The	   second	  model	   involves	  
anti-­‐idiotype	   antibodies.	   Anti-­‐idiotypic	   antibodies	   recognize	   the	   antigen	   binding	  
site	  of	  another	  antibody,	  which	  means	   that	   the	  structure	  of	   the	  antigen-­‐binding	  
site	  of	  the	  anti-­‐idiotypic	  antibody	  is	  at	  least	  partially	  similar	  to	  that	  of	  the	  antigen	  
recognized	   by	   the	   other	   antibody.	   These	   anti-­‐idiotypic	   antibodies	   are	   known	   to	  
occur	   in	  autoimmune	  diseases	   (21).	   It	   is	  believed	   that	  antibodies	  with	  a	   specific	  
idiotype	   can	   trigger	   the	   production	   of	   anti-­‐anti-­‐idiotypic	   antibodies.	   This	   might	  
give	  rise	  to	  a	  whole	  network	  of	   interacting	  antibodies	  believed	  to	  be	   involved	   in	  
both	   physiological	   and	   pathological	   processes	   (22,23).	   Due	   to	   the	  
complementarity	   of	   the	   initial	   triggering	   antigen,	   the	   idiotypic	   antibody	  mimics	  
the	   complementary	   autoantigen,	   and	   as	   a	   consequence	   the	   anti-­‐idiotypic	  
antibody	  is	  directed	  to	  the	  autoantigen.	  The	  third	  model	  is	  based	  on	  the	  principle	  
that	   certain	   events,	   such	   as	   cell	   death,	   might	   lead	   to	   posttranslational	  
modifications	   (PTMs)	   of	   self	   antigens,	   creating	   novel	   epitopes,	   which	   when	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presented	  to	  the	   immune	  system	  might	  break	   immunologic	  tolerance	  and	  result	  
in	   the	   production	   of	   autoantibodies.	   This	   model	   is	   extensively	   discussed	   in	  
Chapters	  5	  &	  6	  and	  will	  be	  further	  addressed	  below.	  
Posttranslational	  modifications	  and	  autoimmunity	  
Proteins	   are	   built	   of	   only	   20	   different	   amino	   acids	   during	   translation.	  
Posttranslational	   modifications	   (PTMs)	   of	   amino	   acids	   extend	   the	   structural	  
heterogeneity	   of	   proteins,	   by	   attaching	   other	   functional	   groups	   (such	   as	   a	  
phosphate,	  hydroxyl,	  methyl,	   various	   lipids	  and	  carbohydrates),	  by	   changing	   the	  
chemical	  nature	  of	  an	  amino	  acid	  (e.g.	  citrullination),	  by	  cleavage	  of	  the	  protein,	  
or	   by	   making	   structural	   changes	   (e.g.	   formation	   of	   disulfide	   bonds).	   PTMs	  
associated	  with	  cell	  death	  processes	  are	  often	  hypothesized	  to	  be	  involved	  in	  the	  
generation	  of	   autoimmunity.	   They	   are	  believed	   to	   activate	   the	   immune	   system,	  
because	   the	   resultant	   neo-­‐epitope	   might	   not	   be	   recognized	   by	   the	   immune	  
system	  as	  “self”	  (24).	  This	  hypothesis	  is	  supported	  by	  the	  following	  observations:	  
1) A	  lot	  of	  autoantigens	  are	  modified	  during	  cell	  death	  processes.	  One	  example	  
is	  the	  La	  (or	  SS-­‐B)	  autoantigen,	  which	  is	  targeted	  by	  the	  immune	  system	  in	  SLE	  
and	   Sjögren’s	   syndrome,	   and	   is	   dephosphorylated	   and	   cleaved	   during	  
apoptosis	  (25).	  
2) Ineffective	  clearance	  of	  dying	  cells	  and	  the	  resultant	  inappropriate	  processing	  
and	   presentation	   of	   self	   antigens	   is	   associated	   with	   certain	   autoimmune	  
diseases	   (26-­‐28).	   The	   relation	  between	  defective	   clearance	  of	   cell	   remnants	  
and	  autoimmunity	   is	   substantiated	  by	  observations	   in	   knock-­‐out	  mice.	  Mice	  
deficient	   of	   receptor	   tyrosine	   kinases,	   such	   as	   Tyro	   3,	   Axl	   and	   Mer,	   have	  
defective	   clearance	   of	   apoptotic	   cells,	   lymphadenopathy	   and	   features	   of	  
autoimmunity	  (29,30).	  	  
3) Autoantibodies	   which	   specifically	   target	   modified	   biomolecules	   have	   been	  
found	   in	   patients.	   In	   sera	   of	   SLE-­‐overlap	   patients,	   for	   example,	   antibodies	  
were	   found	   that	   specifically	   bind	   to	   the	   apoptotically	  modified	  U1-­‐70K	   as	   a	  
result	  of	  the	  formation	  of	  a	  neo-­‐epitope	  that	  is	  not	  present/accessible	  in	  the	  
native	  protein	  (31,32).	  This	  neo-­‐epitope	  was	  recognized	  more	  efficiently	  than	  
the	   epitopes	   on	   the	   native	   protein	   by	   several	   early	   disease	   serum	   samples,	  
whereas	   serum	   samples	   from	   more	   established	   disease	   patients	   show	  
comparable	   reactivities	   with	   both	   the	   modified	   and	   non-­‐modified	   protein	  
(33).	   This	   is	   consistent	   with	   a	   primary	   immune	   response	   directed	   to	   the	  
apoptotically	  modified	  U1-­‐70K	  and	  with	   the	  appearance	  of	   autoreactivity	   to	  
the	  non-­‐modified	  protein	  through	  epitope-­‐spreading	  (34).	  
4) The	  autoantibodies	  towards	  modified	  biomolecules	  can	  be	  found	  very	  early	  in	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Are	  oxygen	  radicals	  involved	  in	  the	  generation	  of	  autoantigenic	  PTMs?	  
Reactive	   oxygen	   species	   (ROS)	   are	   oxygen-­‐based	   molecules	   which	   are	   highly	  
reactive.	   They	   include	   superoxide	   radicals	   (O2•-­‐),	   hydroxyl	   radicals	   (OH•)	   and	  
hydrogen	   peroxide	   (H2O2).	   ROS	   are	   formed	   in	   the	   mitochondria	   as	   a	   natural	  
byproduct	  of	  normal	  oxygen	  metabolism	  (40).	  However	  during	  stress,	   like	  under	  
inflammatory	   conditions,	  ROS	   levels	   can	   increase	  dramatically	  and	  damage	  DNA	  
(41),	  proteins	   (42)	   and	   lipids	   (43).	  During	   inflammation	   the	   immune	   system	  kills	  
foreign	  pathogens	  by	  releasing	  ROS	  rapidly,	  a	  process	  which	  is	  called	  the	  oxygen	  
or	  respiratory	  burst	  (44).	  NADPH	  oxidase	  uses	  electrons	  derived	  from	  intracellular	  
NADPH	   to	   generate	   superoxide	   anions,	   which	   is	   further	   processed	   to	   form	  
hydrogen	   peroxide	   and	   other	   ROS.	   Cells	   dying	   by	   necrosis	   also	   release	   ROS;	  
necrotic	   pathways	   involve	   mitochondrial	   damage	   (45)	   which	   is	   associated	   with	  
the	   release	   of	   superoxide	   radicals	   (46).	   ROS	   are	   thought	   to	   induce	   abnormal	  
posttranslational	   modifications	   of	   self-­‐antigens	   and	   the	   resultant	   neo-­‐antigens	  
might	   bypass	   immunological	   tolerance	   and	   contribute	   to	   the	   development	   of	  
autoimmune	   responses	   (47).	   These	   posttranslational	   modifications	   can	   be	   the	  
oxidation	   of	   a	   protein	   alone,	   but	   the	   oxidation	   reaction	   could	   also	   lead	   to	  
modifications	   in	   charge	   (48)	   of	   residues,	   resulting	   in	   changes	   in	   3-­‐dimensional	  
folding	  (49).	  Antigens	  in	  a	  variety	  of	  autoimmune	  diseases,	  including	  scleroderma	  
(50),	   SLE	   (51)	   and	   T1D	   (52),	   have	   been	   shown	   to	   be	   oxidatively	   modified.	  
Topoisomerase	  I,	  a	  scleroderma-­‐specific	  autoantigen	  is	  fragmented	  as	  a	  result	  of	  
oxidative	   modification	   (53).	   When	   immunodeficient	   BALB/c	   SCID	   mice	   were	  
injected	   with	   pro-­‐oxidative	   agents,	   the	   mice	   experienced	   scleroderma-­‐like	  
symptoms	   and	   produced	   antibodies	   to	   topoisomerase	   I	   (54).	   Ro60	   can	   be	  
modified	   by	   lipid	   oxidation	   products.	   These	   products,	   mainly	   the	   4-­‐hydroxy-­‐2-­‐
alkenals,	  can	  form	  adducts	  with	  free	  amino	  groups	  of	  lysine	  and	  with	  other	  amino	  
acids.	   These	   aldehyde-­‐modified	   proteins	   are	   highly	   immunogenic	   (51).	   The	  
oxidative	  modification	   of	   GAD65,	   a	  major	   autoantigen	   in	   T1D,	  was	   reported	   by	  
several	   groups	   (52).	   Trigwell	   and	   colleagues	   found	   an	   oxidative	   modification	  
which	  leads	  to	  the	  oligomerization	  of	  GAD65.	  T1D	  patient	  sera	  contain	  antibodies	  
which	  bind	  to	  these	  complexes	  more	  efficiently	  than	  to	  the	  smaller	  oligomers	  or	  
the	  native	  protein.	  Khan	  and	  colleagues	  found	  an	  oxidative	  modification	  of	  GAD65	  
which	  not	  only	  appeared	  to	  be	  more	   immunogenic	   than	  the	  native	  protein	   (55),	  
the	  antibodies	  towards	  this	  GAD65	  modification	  were	  also	  found	  to	  be	  predictive	  
for	   complications	   such	   as	   retinopathy	   and	   nephropathy	   (56).	   The	   effects	   of	  
hydrogen	   peroxide	   induced	   necrosis	   on	   autoantigenic	   proteins	   associated	   with	  
various	   autoimmune	   diseases	   are	   described	   in	   Chapter	   5.	   Upon	   exposure	   to	  
hydrogen	   peroxide	   the	   proteins	   showed	   a	   retarded	   electrophoretic	   mobility.	  
Although	   almost	   every	   investigated	   autoantigen	   showed	   this	   retarded	  
electrophoretic	   mobility,	   differences	   in	   number	   of	   modified	   amino	   acids	   and	  
modification	  rates	  were	  observed.	  This	  might	  be	  explained	  by	  the	  number	  and	  the	  
Chapter	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microenvironment	  of	  amino	  acids	  that	  can	  be	  oxidized.	  It	  would	  be	  interesting	  to	  
know	  the	  chemical	  identity	  of	  this	  modification.	  Follow-­‐up	  studies	  using	  isolation	  
and	  mass-­‐spectrometry-­‐based	  identification	  techniques	  might	  elucidate	  this.	  The	  
radical	  which	  is	  most	  likely	  involved	  in	  the	  oxidative	  modification	  of	  autoantigenic	  
proteins	  is	  the	  hydroxyl	  radical.	  Amongst	  the	  ROS,	  the	  short-­‐lived	  hydroxyl	  radical	  
is	   known	   to	   be	   the	   most	   reactive	   radical;	   it	   immediately	   attacks	   biomolecules	  
after	   its	   generation	   (57-­‐59).	   Recombinant	   proteins	   exposed	   in	   vitro	   to	   hydroxyl	  
radicals,	  generated	  by	  the	  Fenton	  reaction	  (60,61),	  showed	  migration	  patterns	  in	  
SDS-­‐PAGE	   reminiscent	   of	   those	   observed	   for	   proteins	   from	   hydrogen	   peroxide-­‐
treated	   cells.	   Moreover,	   none	   of	   the	   alternative	   necrosis	   induction	   methods	  
(exposure	  to	  ethanol,	  HgCl2	  or	  heat	  (62-­‐65),	  which	  are	  associated	  with	  release	  of	  
superoxide	   radicals,	   nor	   in	   vitro	   generators	   of	   intracellular	   superoxide	   radicals	  
(66,67)	   led	   to	   these	  modifications	   (data	   not	   shown).	   Although	   hydroxyl	   radicals	  
can	   be	   generated	   out	   of	   hydrogen	   peroxide	   or	   superoxide	   during	   necrosis,	  
concentrations	   are	   probably	   not	   high	   enough	   to	   cause	   this	   specific	   oxidative	  
modification.	   Taken	   together,	   it	   is	   very	   likely	   that	   the	   oxidative	   modification	  
causing	   the	   retarded	   migration	   pattern	   in	   SDS-­‐PAGE	   is	   caused	   by	   hydroxyl	  
radicals.	   The	   observation	   that	   none	   of	   the	   alternative	   necrosis-­‐inducing	  
compounds	   led	   to	   similar	   oxidative	   modifications,	   while	   recombinant	  
autoantigenic	   proteins	   exposed	   to	   hydroxyl	   radicals	   generated	   by	   the	   Fenton	  
reaction	  resulted	  in	  a	  similar	  altered	  migration	  pattern	  of	  autoantigenic	  proteins,	  
might	  indicate	  that	  these	  modifications	  are	  not	  due	  to	  necrotic	  processes,	  but	  are	  
rather	  caused	  by	  this	  type	  of	  oxidative	  stress.	  To	  investigate	  whether	  T1D	  patients	  
contain	   autoantibodies	   towards	  ROS	  modified	  proteins,	   the	   reactivity	  of	   patient	  
sera	  with	  proteins	  from	  hydrogen	  peroxide-­‐treated	  murine	  pancreatic	  cells	  (Min6)	  
was	  determined	  by	  western	  blotting	  (Chapter	  6).	  This	  did	  not	  reveal	  autoantibody	  
reactivities	   that	   frequently	  occur	   in	   T1D	   sera.	   Thus,	   our	  data	  do	  not	   support	   an	  
important	   role	   for	   oxidative	   modification	   in	   the	   generation	   of	   T1D-­‐specific	  
autoepitopes,	  although	  it	  should	  be	  noted	  that	  the	  T1D	  patient	  sera	  used	  in	  these	  
experiments	  were	   from	   established,	   adult	   patients,	   in	  which	   the	   reactivity	  with	  
the	   triggering	   epitope(s)	   might	   have	   been	   lost.	   Moreover,	   the	   immortalized	  
murine	   cell-­‐line	  may	   not	   be	   the	   best	   source	   of	   (modified)	   target	  molecules	   for	  
human	  autoantibodies.	  Differences	   in	  proteome	  between	  immortalized	  cells	  and	  
tissue	  can	  be	  expected,	  especially	  if	  the	  cell-­‐line	  is	  not	  of	  human	  origin.	  It	  will	  be	  
interesting	   to	   study	   the	  autoantibody	  profiles	  of	  T1D	  patients	  using	  human	   islet	  
cells.	  The	  observations	  that	  the	  oxidative	  modification	  (i)	  does	  not	  seem	  to	  play	  a	  
role	  in	  the	  generation	  of	  T1D	  specific	  autoepitopes,	  (ii)	  seems	  to	  be	  the	  result	  of	  a	  
specific	  oxidative	  stress	  not	  associated	  with	  necrotic	  cell	  death	  and,	  (iii)	  is	  present	  
on	   almost	   every	   investigated	   autoantigen	   might	   indicate	   that	   this	   type	   of	  
modification	   is	   not	   relevant	   for	   the	   pathogenesis	   of	   autoimmune	   diseases.	  
However,	   it	   is	  very	  conceivable	  that	  these	  high	  ROS	  concentrations	  also	  occur	   in	  
vivo	   and	   that	   proteins	   are	   oxidatively	  modified	   similarly	   at	   sites	   with	   high	   ROS	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concentrations.	   Indeed	   evidence	  was	   obtained	   that	   excessive	   oxidative	   stress	   is	  
involved	   in	   the	   pathology	   of	   scleroderma,	   either	   through	   a	   reduction	   of	  
antioxidants	  (69,70)	  or	  by	  an	  abnormal	  generation	  of	  ROS	  (71)	  or	  both.	  Moreover,	  
several	   studies	   show	   that	   total	   serum	  antioxidant	   status	  of	  prediabetic	  and	  T1D	  
patients	  is	  lower	  in	  comparison	  with	  age-­‐matched	  controls	  (72-­‐74).	  Beta	  cells	  are	  
also	  known	  to	  be	  more	  prone	  to	  oxidative	  damage	  than	  most	  other	  tissues,	  since	  
the	  beta	  cell	  mitochondria	  have	  exceptionally	   low	   levels	  of	  antioxidants	   (75-­‐78).	  
Individuals	   more	   susceptible	   to	   oxidative	   stress	   could	   have	   differences	   in	  
oxidative	   modifications	   compared	   to	   individuals	   with	   normal	   oxidative	   status;	  
more	  proteins	  can	  be	  modified	  and	  increased	  presentation	  to	  the	  immune	  system	  
might	  result	  in	  breaking	  of	  immunological	  tolerance.	  It	  remains	  to	  be	  established	  
if	  excessive	  oxidative	  stress	  actually	  leads	  to	  the	  oxidative	  modification	  observed	  
in	   vivo.	   And	   of	   course	   it	   would	   be	   interesting	   to	   know	   if	   these	   differences	   in	  
oxidative	   modification	   status	   are	   also	   found	   between	   proteins	   from	   tissues	   of	  
autoimmune	  patients	  and	  proteins	  from	  the	  same	  tissues	  in	  healthy	  controls.	  	  
Does	  enterovirus	  infection	  play	  a	  role	  in	  the	  development	  of	  type	  1	  
diabetes?	  
Viral	  infections	  are	  believed	  to	  contribute	  to	  the	  pathogenesis	  of	  T1D	  as	  they	  can	  
induce	  strong	  cellular	   immune	  responses	  and	  can	  damage	  the	  beta	  cells	  (79-­‐82).	  
Although	   rubella	   virus,	   mumps	   virus,	   cytomegalovirus,	   retroviruses	   and	  
rotaviruses	   have	   all	   been	   linked	   to	   the	   development	   of	   T1D,	   enteroviruses,	  
especially	   Coxsackievirus	   B	   (CVB),	   are	   most	   frequently	   associated	   with	   T1D	  
(83,84).	  Anti-­‐enterovirus	  antibodies,	  as	  well	  as	  enterovirus	  RNA,	  have	  been	  found	  
in	   the	   blood	   of	   many	   patients	   newly	   diagnosed	   with	   T1D	   (85-­‐94).	   This	   is	  
supported	  by	  the	  results	  presented	  in	  Chapter	  6.	  Both	  T1D	  sera	  and	  control	  sera	  
showed	   reactivity	   towards	   a	   Mr	   33,000	   protein.	   This	   protein	   most	   likely	  
represents	   the	   structural	   protein	   VP-­‐1	   based	   on	   its	   comigration	   pattern	   in	   SDS-­‐
PAGE	  and	  the	  time	  course	  of	  the	  appearance	  of	  this	  protein	  after	  infection	  of	  the	  
cells.	   Differences	   were	   found	   in	   the	   prevalence	   of	   antibodies	   recognizing	   a	  
Mr	  100,000	   protein	   between	   T1D	   patients’	   sera	   and	   control	   sera.	   Although	   the	  
identity	   of	   this	   Mr	   100,000	   protein	   was	   not	   established	   in	   the	   experiments	  
described	   in	   this	   thesis,	   it	   is	   conceivable	   that	   this	   protein	   is	   a	   Min6	   protein.	  
Differences	   in	   duration,	   frequency	   and	   localization	   of	   enteroviral	   infection	  
between	  T1D	  patients	  and	  control	  subjects	  might	  result	  in	  increased	  levels	  of	  the	  
modified	  form	  of	  this	  Mr	  100,000	  protein.	  When	  this	  modified	  Mr	  100,000	  protein	  
is	  presented	  to	  the	  immune	  system,	  e.g.	  in	  individuals	  with	  a	  genetic	  susceptibility	  
for	   the	   development	   of	   T1D,	   an	   autoimmune	   response	  might	   follow	   (Fig.	   1).	   In	  
addition	   to	   the	   identity	   of	   the	   Mr	   100,000	   protein,	   the	   potential	   role	   of	   the	  






Figure	   1:	   Model	   for	   the	   role	   of	   viral	   infections	   in	   the	   etiology	   of	   T1D.	   Infections	   of	   beta	   cells	  
activate	  the	  innate	  immune	  system,	  which	  will	  result	  in	  the	  production	  of	  cytokines	  and	  chemokines	  
which	   attract	   cells	   of	   the	   adaptive	   immune	   system	   to	   the	   site	  of	   infection.	   The	  Tc	   cells	   recognize	  
(virally	  modified)	  self-­‐antigens	  attached	  to	  MHC	  complex	  I	  on	  the	  beta	  cell	  and	  will	  induce	  apoptosis	  
of	   the	   beta	   cell.	   In	   genetically	   susceptible	   individuals	   processes	   as	   (i)	   bystander	   activation,	   (ii)	  
molecular	  mimicry,	  and	  (iii)	  disturbed	  tolerance	  can	  further	  enhance	  the	  immune	  reaction	  and	  can	  
result	   in	  more	  beta	   cell	   distruction.	  APC=	  Antigen	  presenting	   cell,	   Th	  =	  helper	  T	   lymphocyte,	   Tc	  =	  
cytotoxic	  T	  lymphocyte,	  Ab	  =	  antibody.	  
	  
	  
Concluding	  remarks	  Part	  2	  
Part	   2	   of	   this	   thesis	   focuses	   on	   the	   role	   of	   posttranslational	   modifications	   in	  
breaking	   tolerance	   to	   self-­‐antigens	   in	   susceptible	   individuals.	   Oxidative	  
modifications	   of	   known	   autoantigens	   were	   identified	   in	   lysates	   from	   hydrogen	  
peroxide-­‐induced	   necrotic	   cells.	   It	   is	   unclear	   if	   oxidative	   modifications	   are	  
involved	  in	  the	  pathogenesis	  of	  autoimmune	  diseases.	  Several	  questions	  still	  need	  
to	  be	  answered.	  Are	  the	  observed	  in	  vitro	  modifications	  also	  present	  in	  vivo	  and,	  
more	  importantly,	  are	  proteins	  that	  are	  modified	  upon	  oxidative	  stress	  present	  in	  
affected	   tissues	  of	   autoimmune	  patients?	  Do	  healthy	   individuals	   also	  have	   such	  
proteins	  and	  do	  these	  differ	  between	  healthy	  and	  diseased	  individuals?	  Can	  these	  
modified	  proteins	   induce	  autoimmunity	   in	   animal	  models?	  CVB-­‐3	   infected	  Min6	  
cell	   lysates	  contain	  a	  Mr	  100,000	  protein	  which	  was	  recognized	  more	   frequently	  
by	  T1D	  sera	  than	  by	  control	  sera.	  This	  Mr	  100,000	  protein	  most	  likely	  is	  a	  cellular	  
Min6	   protein.	   The	   data	   described	   in	   this	   thesis	   may	   facilitate	   follow-­‐up	  	  
studies	   to	   obtain	   more	   insight	   in	   the	   role	   of	   posttranslational	   modifications	   in	  
autoimmunity.	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Summary	  
Autoimmune	   diseases	   arise	   from	   an	   inappropriate	   immune	   response	   towards	  
substances	   and	   tissues	   normally	   present	   in	   the	   body.	   One	   of	   the	   characteristic	  
features	   of	   autoimmune	   diseases	   is	   the	   occurrence	   of	   high	   titers	   of	  
autoantibodies	   in	   the	   sera	   of	   these	   patients.	   In	   sera	   of	   patients	   suffering	   from	  
rheumatoid	   arthritis	   (RA)	   autoantibodies	   are	   found	   targeting	   citrullinated	  
proteins,	   and	   these	   autoantibodies	   sometimes	   can	   be	   detected	   years	   before	  
disease	   onset.	   These	   anti-­‐citrullinated	   protein	   antibodies	   (ACPA)	   are	   exclusively	  
found	   in	  RA	  patients	   and	   recently	   it	  was	   shown	   that	   the	  RA	  patients	  who	  don’t	  
produce	   ACPA	   represent	   a	   specific	   subpopulation	   of	   patients	   with	   a	   different	  
prognosis	   than	   ACPA-­‐positive	   RA	   patients,	  making	   ACPA	   a	   very	   good	   diagnostic	  
and	  prognostic	  tool.	  	  
	  
Although	  the	  clinical	  utility	  of	  these	  autoantibodies	  is	  appreciated,	  little	  is	  known	  
about	   the	   mechanisms	   related	   to	   their	   production	   and	   the	   regulation	   of	   the	  
autoimmune	   response.	   One	   model	   hypothesizes	   that	   posttranslational	  
modifications	   occurring	   during	   cell	   death	   can	   result	   in	   the	   generation	   of	   neo-­‐
epitopes	  and	  the	  loss	  of	  immunological	  tolerance	  to	  self-­‐antigens.	  
	  
The	   increasing	   number	   of	   distinct	   autoantibodies	   and	   the	   diversity	   of	  
autoantibodies	  with	  similar	  or	  related	  specificities	  motivate	  the	  need	  for	  assays	  in	  
which	   multiple	   autoantibodies	   in	   the	   same	   sample	   can	   be	   detected	  
simultaneously.	   The	   goal	   of	   the	   first	   studies	   described	   in	   this	   thesis	   was	   to	  
develop	   a	  multiplex	   assay	   based	   on	   imaging	   surface	   plasmon	   resonance	   (iSPR),	  
which	  can	  be	  used	  to	  subdivide	  RA	  patients	  based	  on	   their	  autoantibody	  profile	  
(described	  in	  Part	  1:	  Chapters	  2	  to	  4).	  Another	  goal	  was	  to	  gain	  more	  insight	  in	  the	  
development	   of	   autoimmune	  diseases	   and	   to	   investigate	   the	   role	   of	   cell	   death-­‐
associated	   protein	   modifications	   in	   the	   initiation	   of	   the	   autoimmune	   response	  
(described	  in	  Part	  2:	  Chapters	  5	  and	  6).	  
	  
This	   thesis	   starts	   with	   an	   introductory	   chapter,	   Chapter	   1,	   which	   gives	   an	  
overview	  of	  our	   current	  knowledge	  on	   the	  generation	  of	  autoantibodies,	  with	  a	  
special	  focus	  on	  the	  proposed	  role	  of	  cell	  death-­‐associated	  protein	  modifications	  
in	   breaking	   immunological	   tolerance.	   In	   addition,	   the	   iSPR	   technology	   for	  
measuring	  autoantibody	  profiles	  in	  a	  multiplex	  format	  is	  introduced.	  
	  
The	   presence	   of	   (auto)antibodies	   in	   biofluids	   can	   be	   measured	   by	   various	  
experimental	   approaches,	   such	   as	   enzyme	   linked	   immunosorbent	   assay	   (ELISA),	  
immunodiffusion,	  immunoprecipitation,	  immunoblotting,	  etc.	  Multiplex	  platforms	  
have	   the	   advantage	   to	   test	   for	   the	   presence	   of	   multiple	   autoantibodies	  
simultaneously,	   under	   the	   same	   assay	   conditions.	   In	   Chapter	   2	   the	   newly	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developed	   microarray-­‐iSPR	   system	   is	   described.	   Using	   microarray-­‐iSPR	   multiple	  
ligands	   are	   immobilized	   at	   defined	  positions	   on	   a	   gold-­‐coated	   surface	   and	   their	  
interactions	  with	   biomolecules	   in	   the	   analyte	   solution	   are	  measured	   in	   parallel.	  
We	  demonstrate	  that	  this	  system	  displays	  a	  wide	  dynamic	  range,	  which	  is	  due	  to	  
the	   continuous	   scanning	   of	   resonance	   angles.	   The	   binding	   of	   analytes	   to	  
microarrays	  containing	  low	  and	  high	  molecular	  weight	  ligands	  could	  be	  measured	  
with	  a	  high	  sensitivity	  and	  accuracy.	  Other	  important	  features	  of	  this	  system	  are	  
that	   the	   interactions	   are	   monitored	   in	   real-­‐time	   and	   do	   not	   require	   labeled	  
compounds.	  	  
	  
The	   application	   of	   the	   microarray-­‐iSPR	   system	   for	   autoantibody	   profiling	   in	   RA	  
patients	  is	  demonstrated	  in	  Chapter	  3.	  Chips	  spotted	  with	  arrays	  of	  two	  different	  
peptide	   sets	   could	   be	   used	   for	   up	   to	   50	   interaction/regeneration	   cycles.	   In	  
Chapter	   4	   a	   multiplex	   assay	   was	   generated	   using	   several	   citrullinated	   ACPA	  
targets,	   which	   allows	   the	   detection	   of	   ACPA	   profiles.	   The	   spotted	   peptides	  
correspond	  to	  citrullinated	  epitopes	  of	  human	  filaggrin,	  vimentin,	  fibrinogen	  and	  
α-­‐enolase,	  as	  well	  as	  to	  citrullinated	  epitopes	  of	  peptides	  isolated	  from	  synthetic	  
random	   peptide	   libraries	   recognized	   by	   patient	   ACPA.	   Indeed,	   distinct	   ACPA	  
profiles	  were	   discerned	   in	   the	   sera	   of	   RA	   patients.	   The	   question	  whether	   these	  
profiles	   can	   be	   used	   to	   stratify	   patients	   with	   different	   clinical	   features	   awaits	  
further	  analyses	  with	  larger	  cohorts	  of	  clinically	  well-­‐defined	  RA	  patients.	  
	  
Citrullination	   is	  a	   type	  of	  protein	  modification	   that	   is	  particularly	   seen	  upon	   the	  
induction	  of	  cell	  death.	  Many	  other	  modifications	  may	  be	  triggered	  in	  dying	  cells,	  
e.g.	   as	   a	   result	   of	   loss	   of	   compartmentalization	   or	   of	   the	   activation	   of	   enzymes	  
playing	  a	  role	  in	  the	  cell	  death	  process.	  In	  addition,	  cell	  death	  is	  often	  associated	  
with	   the	   production	   of	   reactive	   oxygen	   species	   (ROS).	   In	   the	   experiments	  
described	   in	   Chapter	   5	   it	   was	   investigated	   whether	   ROS	   can	   induce	   protein	  
modifications	  that	  may	  be	  involved	  in	  the	  generation	  of	  neo-­‐epitopes	  targeted	  by	  
autoantibodies.	   ROS-­‐induced	   modification	   of	   a	   number	   of	   autoantigens	   was	  
observed,	   as	   demonstrated	   by	   a	   retarded	   migration	   in	   SDS-­‐polyacrylamide	   gel	  
electrophoresis	   with	   extracts	   of	   H2O2-­‐treated	   Jurkat	   cells.	   These	   modifications	  
were	   substantiated	   by	   the	   results	   obtained	   with	   cell	   lysates	   incubated	   with	  
oxidating	   agents	   and	   with	   the	   corresponding	   recombinant	   proteins	   that	   were	  
expressed	   in	   bacteria	   and	   oxidized	   in	   vitro.	   These	   modifications	   were	   only	  
detected	  when	  Jurkat	  cells	  were	  treated	  with	  H2O2	  concentrations	  high	  enough	  to	  
induce	   necrosis,	   implying	   the	   involvement	   of	   necrosis-­‐associated	   processes.	  
Although	  the	  observed	  modifications	  are	  not	  restricted	  to	  autoantigenic	  proteins	  
there	   might	   be	   differences	   in	   rate	   of	   modification	   or	   the	   number	   of	   modified	  
residues	   per	   protein.	   It	   remains	   to	   be	   established	   if	   these	   oxidatively	  modified	  
autoantigenic	   proteins	   are	   exposed	   to	   the	   immune	   system	   and	   lead	   to	   a	  
modification-­‐dependent	  immune	  response.	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Susceptibility	  to	  type	  1	  diabetes	  (T1D)	  is	  dictated	  by	  a	  complex	  interplay	  between	  
genetic	   determinants	   and	   environmental	   influences.	   Accumulating	   evidence	  
supports	   the	   involvement	   of	   viral	   infection,	   particularly	   Coxsackievirus	   (an	  
enterovirus)	   infection,	   in	   the	   etiology	   of	   T1D.	   Also	   necrosis	   and	   the	   associated	  
ROS	   production	   are	   often	   proposed	   to	   be	   involved	   in	   the	   destruction	   of	   the	  
insulin-­‐producing	   pancreatic	   beta	   cells	   and	   the	   generation	   of	   T1D-­‐associated	  
autoimmunity.	   The	   experiments	   described	   in	   Chapter	   6	   were	   aimed	   at	   the	  
question	   whether	   T1D	   patient	   sera	   contain	   autoantibodies	   that	   specifically	  
recognize	  host	  cell	  antigens	  modified	  as	  a	  result	  of	  a	  Coxsackie	  B3	  virus	  infection	  
or	   as	   a	   result	   of	   the	   induction	   of	   necrosis.	   The	   results	   of	   western	   blotting	  
experiments	  with	  material	  from	  a	  necrotic	  pancreatic	  beta	  cell	  line	  (Min6)	  did	  not	  
reveal	  antibody	  reactivities	  that	   frequently	  occur	   in	  T1D	  and	  not	   in	  control	  sera.	  
However,	   a	   Mr	   100,000	   protein	   from	   Coxsackievirus-­‐	   infected	   Min6	   cells	   was	  
recognized	   by	   63%	   of	   the	   T1D	   sera	   and	   by	   only	   10%	   of	   the	   sera	   from	   healthy	  
controls.	  Although	  the	  identity	  of	  this	  Mr	  100,000	  protein	  was	  not	  established	  in	  
these	  experiments,	   it	   is	   tempting	   to	  speculate	   that	   this	  protein	   is	  a	  host	  protein	  
that	   is	   modified	   upon	   infection	   with	   Coxsackie	   B3	   virus	   and	   represents	   an	  
important	   target	   for	   the	   immune	   system	   in	   T1D	   patients.	   During	   these	  
experiments	   we	   also	   observed	   that	   T1D	   patients	   present	   with	   increased	   virus-­‐
specific	  antibody	  (VP-­‐1)	  levels	  compared	  to	  control	  individuals.	  This	  may	  indicate	  
a	   difference	   in	   enteroviral	   infection	   between	   the	   T1D	   group	   and	   the	   control	  
group.	   It	   remains	   to	   be	   investigated	   whether	   this	   difference	   is	   related	   to	   the	  
development	  of	  T1D.	  	  
	  
In	   Chapter	   7	   the	   findings	   described	   in	   this	   thesis	   are	   discussed	   in	   a	   broader	  
context.	  The	  questions	  whether	  ACPA	  profiling	  can	  contribute	  to	  the	  prediction	  of	  
disease	  development	   and	  whether	   this	   can	   contribute	   to	   improved,	   tailor-­‐made	  
treatment	   protocols	   are	   addressed.	   In	   addition,	   the	   possibilities	   that	  
environmental	  factors,	  such	  as	  viruses,	  and/or	  the	  induction	  of	  cell	  death,	  which	  
all	   may	   lead	   to	   unusual	   posttranslational	   modifications,	   play	   a	   role	   in	   breaking	  





Auto-­‐immuunziektes	   worden	   gekenmerkt	   door	   atypische	   reacties	   van	   het	  
immuunsysteem	   tegen	   lichaamseigen	   stoffen	   en	   weefsels.	   Een	   van	   de	  
karakteristieke	   eigenschappen	   van	   auto-­‐immuunziektes	   is	   de	   aanwezigheid	   van	  
hoge	   titers	   autoantilichamen	   in	   de	   sera	   van	   deze	   patiënten.	   Zo	   worden	   er	   in	  
patiënten	   met	   reumatoide	   artritis	   (RA)	   autoantilichamen	   gevonden	   die	   gericht	  
zijn	   tegen	   gecitrullineerde	   eiwitten	   en	   deze	   autoantilichamen	   kunnen	   soms	   al	  
jaren	   voor	   de	   eerste	   symptomen	  worden	   gedetecteerd.	  De	   anti-­‐gecitrullineerde	  
eiwit	  antilichamen	  (ACPA)	  worden	  uitsluitend	  gevonden	  in	  RA-­‐patiënten	  en	  recent	  
is	   aangetoond	   dat	   RA-­‐patiënten	   die	   geen	   ACPA	   produceren	   een	   specifieke	  
subpopulatie	   patiënten	   zijn,	   met	   een	   andere	   prognose	   dan	   ACPA-­‐positieve	   RA-­‐
patiënten.	   Dit	   maakt	   ACPA	   een	   heel	   goed	   diagnostisch	   en	   prognostisch	  
hulpmiddel.	  
	  
Ondanks	  dat	  de	  toepasbaarheid	  van	  autoantilichaam	  detectie	  is	  aangetoond,	  is	  er	  
weinig	  bekend	  over	  de	  productie	  van	  autoantilichamen	  en	  de	  regulering	  van	  auto-­‐
immuunreacties.	  Eén	  model	  stelt	  dat	  posttranslationele	  modificaties	  die	  ontstaan	  
tijdens	  celdood	  kunnen	  resulteren	  in	  de	  ontwikkeling	  van	  nieuwe	  epitopen	  en	  het	  
verlies	  van	  de	  immunologische	  tolerantie	  tegen	  eigen	  antigenen.	  
	  
Het	   toenemende	   aantal	   specifieke	   autoantilichamen	   en	   de	   diversiteit	   van	   de	  
autoantilichamen	   onderstrepen	   de	   noodzaak	   voor	   tests	   waarin	   meerdere	  
autoantilichamen	   in	  hetzelfde	  monster	   tegelijk	  kunnen	  worden	  aangetoond.	  Het	  
doel	  van	  de	  eerste	  experimenten	  die	  in	  dit	  proefschrift	  beschreven	  staan	  (Deel	  1:	  
Hoofdstukken	  2	   t/m	  4)	   is	   het	  ontwikkelen	   van	  een	  multiplex-­‐test,	   gebaseerd	  op	  
imaging	  surface	  plasmon	  resonance	  (iSPR).	  Deze	  test	  zou	  in	  staat	  moeten	  zijn	  om	  
RA-­‐patiënten	   op	   basis	   van	   hun	   autoantilichaamprofiel	   onder	   te	   verdelen	   in	  
subgroepen.	   Een	   ander	   doel	   was	   het	   verkrijgen	   van	   meer	   inzicht	   in	   de	  
ontwikkeling	   van	   auto-­‐immuunziektes	   en	   de	   rol	   van	   celdood-­‐geassocieerde	  
eiwitveranderingen	   in	   het	   ontstaan	   van	  de	   auto-­‐immuunreacties	   (beschreven	   in	  
Deel	  2:	  Hoofdstukken	  5	  en	  6).	  
	  
Dit	  proefschrift	  begint	  met	  een	   inleidend	  hoofdstuk,	  waarin	  een	  overzicht	  wordt	  
gegeven	  van	  onze	  huidige	  inzichten	  in	  het	  ontstaan	  van	  autoantilichamen.	  Daarbij	  
wordt	   met	   name	   aandacht	   besteed	   aan	   de	   veronderstelde	   rol	   van	   celdood-­‐
geassocieerde	   eiwitveranderingen	   in	   het	   doorbreken	   van	   immunologische	  
tolerantie.	  Daarnaast	  wordt	  de	   iSPR-­‐technologie	  om	  autoantilichaamprofielen	   te	  
meten	  geïntroduceerd.	  	  
	  
De	   aanwezigheid	   van	   (auto)antilichamen	   in	   lichaamsvloeistoffen	   kan	   worden	  
gemeten	   op	   verschillende	   manieren,	   zoals	   met	   enzyme-­‐linked	   immunosorbent	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assay	   (ELISA),	   immunodiffusie,	   immunoprecipitatie,	   immunoblotting,	   etc.	  
Multiplex	   platforms	   hebben	   het	   voordeel	   om	   de	   aanwezigheid	   van	   meerdere	  
autoantilichamen	  tegelijk	  te	  onderzoeken,	  allemaal	  onder	  dezelfde	  testcondities.	  
In	  Hoofdstuk	  2	  wordt	  het	  recent	  ontwikkelde	  microarray-­‐iSPR	  systeem	  besproken.	  
Met	  microarray-­‐iSPR	  kunnen	  verschillende	   liganden	  op	  gedefineerde	  posities	  op	  
een	  met	   een	   goudlaag	   bedekt	   oppervlak	   worden	   geïmmobiliseerd,	   waarna	   hun	  
interactie	   met	   biomoleculen	   uit	   een	   analiet-­‐oplossing	   simultaan	   gemeten	   kan	  
worden.	  We	   tonen	   aan	   dat	   dit	   systeem	   een	   groot	   dynamisch	   bereik	   heeft,	  wat	  
komt	  doordat	  de	   resonantiehoeken	   van	  het	  optische	  detectieonderdeel	   continu	  
worden	   gescand.	   Het	   binden	   van	   analieten	   aan	   microarrays	   met	   liganden	   met	  
verschillende	   molecuulmassa’s	   kon	   tegelijk	   met	   grote	   gevoeligheid	   en	  
nauwkeurigheid	  gemeten	  worden.	  Andere	  belangrijke	  kenmerken	  van	  dit	  systeem	  
zijn	  dat	   de	   interacties	   rechtstreeks	   gevolgd	   kunnen	  worden	  en	  dat	  de	   analieten	  
niet	  gelabeld	  hoeven	  te	  worden.	  
	  
De	   toepassing	   van	   het	   microarray-­‐iSPR	   systeem	   voor	   het	   ontdekken	   van	  
autoantilichaamprofielen	   in	   RA-­‐patiënten	   is	   beschreven	   in	   Hoofdstuk	   3.	   Chips	  
waarop	  arrays	  van	  verschillende	  peptiden	  waren	  gespot	  konden	  gebruikt	  worden	  
voor	  tenminste	  50	  interactie-­‐regeneratie	  cycli.	  In	  Hoofdstuk	  4	  is	  gebruik	  gemaakt	  
van	  een	  array	  met	  verschillende	  gecitrullineerde	  peptiden	  die	  geselecteerd	  waren	  
op	  basis	   van	  hun	  herkenning	  door	  ACPA	  om	  ACPA-­‐profielen	   in	  RA-­‐	  patiënten	   te	  
detecteren.	  De	  gespotte	  peptiden	  zijn	  afgeleid	  van	  gecitrullineerde	  epitopen	  van	  
filaggrine,	  vimentine,	  fibrinogeen	  en	  α-­‐enolase,	  en	  daarnaast	  zijn	  gecitrullineerde	  
peptiden	  gebruikt	  die	  uit	  een	  synthetische	  peptidenbank	  geïsoleerd	  zijn	  vanwege	  
hun	   reactiviteit	   met	   ACPA.	   Er	   konden	   inderdaad	   ACPA-­‐profielen	   onderscheiden	  
worden	  in	  de	  sera	  van	  RA-­‐patiënten.	  De	  vraag	  of	  deze	  profielen	  gebruikt	  kunnen	  
worden	   om	   patiënten	   met	   verschillende	   klinische	   kenmerken	   te	   kunnen	  
onderscheiden	  moet	  nog	  verder	  onderzocht	  worden.	  
	  
Citrullinering	   is	   een	   type	   eiwitmodificatie	   dat	   vaak	   optreedt	   na	   de	   inductie	   van	  
celdood.	   Veel	   andere	   eiwitmodificaties	   kunnen	   ook	   geïnitieerd	   worden	   in	  
stervende	   cellen,	   bijvoorbeeld	   doordat	   de	   intracellulaire	   compartimentalisatie	  
verandert	  of	  verloren	  gaat,	  of	  door	  de	  activering	  van	  enzymen	  die	  een	  rol	  spelen	  
bij	   celdoodprocessen.	   Daarnaast	   wordt	   celdood	   vaak	   geassocieerd	   met	   de	  
productie	  van	  reactieve	  zuurstofradicalen	  (ROS).	   In	  de	  experimenten	  beschreven	  
in	   Hoofdstuk	   5	   is	   onderzocht	   of	   ROS	   eiwitmodificaties	   kunnen	   induceren	   die	  
mogelijk	   betrokken	   zijn	   bij	   het	   ontstaan	   van	   neo-­‐epitopen	   die	   door	  
autoantilichamen	   worden	   herkend.	   Wanneer	   extracten	   van	   H2O2-­‐behandelde	  
Jurkat	   cellen	   geanalyseerd	   werden	   met	   behulp	   van	   SDS-­‐polyacrylamide	  
gelelectroforese,	   resulteerde	   dit	   in	   een	   langzamere	   migratie	   van	   een	   aantal	  
bekende	   autoantigenen.	   Dat	   deze	   modificaties	   door	   ROS	   werden	   veroorzaakt	  
werd	   onderstreept	   door	   de	   resultaten	   verkregen	   met	   lysaten	   van	   cellen	   die	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geïncubeerd	   waren	   met	   oxiderende	   stoffen	   en	   met	   de	   corresponderende	  
recombinante	  eiwitten	  die	   in	  bacteriën	   tot	  expressie	  waren	  gebracht	  en	   in	  vitro	  
geoxideerd	  waren.	  Deze	  modificaties	  konden	  alleen	  aangetoond	  worden	  wanneer	  
Jurkat	  cellen	  behandeld	  werden	  met	  H2O2-­‐concentraties	  die	  hoog	  genoeg	  zijn	  om	  
necrose	   te	   induceren,	   wat	   een	   rol	   van	   necrose-­‐geassocieerde	   processen	  
impliceert.	   Ondanks	   dat	   de	   waargenomen	   modificaties	   zich	   niet	   beperken	   tot	  
autoantigene	   eiwitten,	   kunnen	   er	   verschillen	   zijn	   in	   de	   snelheid	   of	   het	   aantal	  
gemodificeerde	   residuen	   van	   autoantigene	   eiwitten	  worden	   gemodificeerd.	   Het	  
moet	  nog	  verder	  onderzocht	  worden	  of	  het	   immuunsysteem	  wordt	  blootgesteld	  
aan	   deze	   oxidatief	   gemodificeerde	   autoantigene	   eiwitten	   en	   of	   deze	  
gemodificeerde	  eiwitten	  leiden	  tot	  een	  modificatie-­‐afhankelijke	  immuunreactie.	  
	  
Gevoeligheid	   voor	   type	   1	   diabetes	   (T1D)	   wordt	   bepaald	   door	   een	   complex	  
samenspel	   tussen	   genetische	   kenmerken	   en	   omgevingsinvloeden.	   Steeds	   meer	  
bewijs	  wordt	  gevonden	  voor	  de	  betrokkenheid	  van	  virale	   infecties,	  voornamelijk	  
Coxsackievirus	  (een	  enterovirus)	  infectie,	  in	  het	  ontstaan	  van	  T1D.	  Ook	  necrose	  en	  
de	  daarbij	   geassocieerde	  ROS	  productie	  worden	  verondersteld	  betrokken	   te	   zijn	  
bij	  de	  destructie	  van	  de	  insuline	  producerende	  beta-­‐cellen	  in	  de	  alvleesklier	  en	  bij	  
de	  ontwikkeling	  van	  T1D	  geassocieerde	  auto-­‐immuniteit.	  De	  experimenten	  die	  in	  
Hoofdstuk	  6	  beschreven	  zijn	  hadden	  als	  doel	  om	  antwoord	  te	  geven	  op	  de	  vraag	  
of	  sera	  van	  T1D	  patiënten	  autoantilichamen	  bevatten	  die	  specifiek	  reageren	  met	  
lichaamseigen	  antigenen	  die	  gemodificeerd	  zijn	  als	  gevolg	  van	  het	  doorlopen	  van	  
een	   CoxsackieB3	   virus	   infectie,	   of	   als	   gevolg	   van	   de	   inductie	   van	   necrose.	   De	  
resultaten	   van	   immunoblotting	   experimenten	   met	   materiaal	   van	   necrotische	  
beta-­‐cellen	  (de	  Min6	  insulinoma	  cellijn)	  lieten	  geen	  antilichaam	  reactiviteiten	  zien	  
die	  vaak	  voorkomen	  in	  T1D-­‐sera	  en	  niet	  in	  controle	  sera.	  Een	  Mr	  100,000	  eiwit	  uit	  
het	   lysaat	   van	   Coxsackievirus-­‐geinfecteerde	   Min6-­‐cellen	   werd	   echter	   herkend	  
door	   antilichamen	   in	   63%	   van	   de	   T1D-­‐sera	   en	   slechts	   10%	   van	   de	   sera	   van	  
gezonde	   controles.	   Ondanks	   dat	   de	   identiteit	   van	   dit	   Mr	   100,000	   eiwit	   niet	   is	  
vastgesteld	   tijdens	   deze	   experimenten,	   is	   het	   aannemelijk	   dat	   dit	   een	   cellulair	  
eiwit	  is	  dat	  gemodificeerd	  is	  als	  gevolg	  van	  de	  infectie	  met	  Coxsackie	  B3	  virus	  en	  
dat	   het	   een	   belangrijk	   doelwit	   vormt	   voor	   het	   immuunsysteem	   van	   T1D-­‐
patiënten.	  Tijdens	  deze	  experimenten	  werd	  ook	  waargenomen	  dat	  T1D-­‐patiënten	  
hogere	  concentraties	  virus-­‐specifieke	  antilichamen	  (gericht	  tegen	  het	  virale	  VP-­‐1	  
eiwit)	   hebben	   vergeleken	   met	   controle	   individuen.	   Dit	   kan	   een	   verschil	   in	  
enterovirus-­‐infectie	  tussen	  de	  T1D	  groep	  en	  de	  controle	  groep	  betekenen.	  Het	  is	  
nog	  niet	  duidelijk	  of	  dit	  iets	  betekent	  voor	  het	  ontstaan	  van	  T1D.	  
	  
In	   Hoofdstuk	   7	  worden	   de	   bevindingen	   die	   beschreven	   staan	   in	   dit	   proefschrift	  
bediscussieerd	   in	   een	   bredere	   context.	   De	   vragen	   of	   ACPA-­‐profielen	   kunnen	  
bijdragen	  aan	  het	  voorspellen	  van	  het	  ziekteverloop	  van	  RA	  en	  of	  deze	  profielen	  
kunnen	   bijdragen	   aan	   verbeterde	   op-­‐maat-­‐gemaakte	   behandelingsprotocollen	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worden	  behandeld.	  Daarnaast	  wordt	   bediscussieerd	   of	   omgevingsfactoren	   zoals	  
virussen	  en/of	  de	  inductie	  van	  celdood	  en	  de	  daarbij	  betrokken	  posttranslationele	  
modificaties	  een	  rol	  spelen	  bij	  het	  doorbreken	  van	  de	  immunologische	  tolerantie	  
tegen	  eigen	  eiwitten.	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  8	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   (inmiddels	   Radboud	   Universiteit	   genaamd).	   Tijdens	   haar	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   van	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  van	  Utah	  te	  Salt	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de	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  Kojo	  Elenitoba-­‐Johnson.	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  het	  doctoraalexamen	  en	  ze	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  in	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  als	  Junior	  Onderzoeker	  op	  de	  
afdeling	  Autoimmuun	  Biochemie	  NWI	  (inmiddels	  Biomoleculaire	  Chemie)	  van	  de	  
Radboud	   Universiteit	   Nijmegen,	   dit	   onder	   leiding	   van	   Prof.	   dr.	   Ger	   Pruijn.	  
Gedurende	   deze	   periode	   werd	   het	   onderzoek	   verricht	   dat	   is	   beschreven	   in	   dit	  
proefschrift.	   Sinds	   oktober	   2008	   werkt	   zij	   bij	   Mallinckrodt	   Baker	   (inmiddels	  
Avantor	  Performance	  Materials)	  als	  R&D	  Scientist	  en	  is	  verantwoordelijk	  voor	  de	  





Promoveren	   is	   een	   raar	   iets.	   Het	   is	   een	   logische	   stap	   als	   je	   wilt	   werken	   in	   de	  
wetenschap.	  Het	   is	   vier	   jaar	   lang	  werken	  naar	   één	  doel	   en	  het	   beheerst	  min	  of	  
meer	   je	   leven.	   Het	   is	   veel	   meer	   dan	   werk	   of	   het	   leren	   van	   onderzoeks-­‐
vaardigheden.	   Belangrijker	   dan	   het	   ontwikkelen	   van	   een	   passie	   voor	   het	  
onderzoek	   is	   het	   ontwikkelen	   van	   relaties	  met	   de	  mensen	   om	   je	   heen.	   Dit	   om	  
advies	  te	  vragen	  als	  je	  vast	  bent	  gelopen,	  maar	  ook	  voor	  een	  goed	  gesprek	  als	  je	  
gefrustreerd	   bent	   of	   er	   even	   doorheen	   zit.	   En	   daarnaast	   natuurlijk	   voor	   de	  
broodnodige	  ontspanning	  op	  zijn	  tijd.	  Ik	  ben	  daarom	  blij	  dat	  ik	  na	  al	  die	  jaren	  nu	  
eindelijk	  iedereen	  kan	  bedanken	  die	  met	  mij	  mee	  hebben	  geleefd	  en	  mij	  met	  raad	  
en	  daad	  hebben	  bijgestaan	  tijdens	  dit	  hele	  proces.	  
	  
Om	  te	  beginnen	  een	  woord	  van	  dank	  voor	  Ger.	  Ik	  wil	  je	  graag	  bedanken	  dat	  je	  het	  
zag	  zitten	  om	  met	  mij	  in	  zee	  te	  gaan	  voor	  dit	  project.	  Ik	  heb	  veel	  van	  je	  geleerd,	  je	  
liet	  me	   vrij	   om	  me	   te	   ontwikkelen	   tot	   zelfstandig	   onderzoeker	   en	   coachte	   daar	  
waar	   nodig	   was.	   Je	   deur	   stond	   altijd	   open	   en	   ook	   tijdens	   de	   periodes	   dat	   ik	  
veelvuldig	  in	  Enschede	  was,	  hield	  je	  een	  vinger	  aan	  de	  pols.	  Bedankt	  voor	  je	  steun	  
en	  het	  vertrouwen	  dat	  je	  in	  me	  had!	  
	  
Beste	   Walther,	   ondanks	   dat	   ik	   de	   eerste	   AiO	   was	   die	   niet	   meer	   door	   u	   werd	  
begeleid	  wil	   ik	   u	   toch	   bedanken	   voor	   uw	   interesse	   in	  mijn	   onderzoek	   en	   in	   het	  
bijzonder	  de	  discussies	   rond	  de	  oxidatieve	  modificatie	  die	   in	  hoofdstuk	  5	  wordt	  
besproken.	   Ik	   voelde	   me	   meteen	   thuis	   bij	   de	   “VRT”	   en	   heb	   genoten	   van	   de	  
barbecues,	  de	  labdagjes	  en	  de	  gezelligheid	  in	  de	  groep.	  	  
	  
Richard,	  bedankt	  voor	  je	  enthousiaste	  begeleiding	  van	  de	  SPR-­‐experimenten.	  Wie	  
wil	  er	  nu	  geen	  begeleider	  die	  wijn	  trakteert	  bij	  de	  eerste	  goede	  resultaten?	  Je	  was	  
een	  beetje	  zoekende	  naar	  jouw	  ideale	  rol	  in	  het	  wetenschappelijk	  onderzoek/het	  
bedrijfsleven.	  Dit	  had	  heel	  wat	  verhuizingen	  tot	  gevolg.	  Ik	  hoop	  dat	  je	  je	  plek	  hebt	  
gevonden	  en	  ik	  wens	  je	  veel	  succes	  met	  het	  grootmaken	  van	  de	  IBIS	  iSPR.	  	  
	  
Alle	   andere	   collega’s	   van	   de	   biochip-­‐group	   natuurlijk	   ook	   bedankt	   voor	   de	   fijne	  
tijd.	   In	  het	  bijzonder	  wil	   ik	  hier	  Bianca	  bedanken.	   Lieve	  Bianca,	  we	  hebben	  heel	  
wat	  uurtjes	  samen	  doorgebracht	  achter	  het	  iSPR-­‐apparaat.	  Bedankt	  voor	  je	  hulp,	  
steun	  en	  de	  gezelligheid!	  Je	  nam	  me	  overal	  mee	  naar	  toe,	  zodat	  ik	  me	  snel	  thuis	  
voelde	   op	   het	   lab	   in	   Enschede.	  We	   zijn	   elkaar	   een	   beetje	   uit	   het	   oog	   verloren,	  
maar	   ik	  hoop	  dat	   je	  op	  een	   fijne	  plek	  bent	   terechtgekomen	  en	  dat	   je	  natuurlijk	  
een	  leuke	  vent	  bent	  tegengekomen	  ;-­‐).	  
	  
Barbara,	   heel	   erg	   bedankt	   voor	   jouw	   hulp	   bij	   de	   virusexperimenten,	   het	   is	   een	  
mooi	  hoofdstuk	  geworden.	  Frank	  bedankt	  voor	  jouw	  kritische	  blik	  op	  de	  tekst.	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Natuurlijk	   wil	   ik	   ook	   alle	   (oud-­‐)collega’s	   van	   de	   VRT/BMC,	   de	   eiwitgroep	   en	  
Modiquest	  bedanken	  voor	  alle	  hulp	  en	  adviezen,	  maar	  helemaal	  voor	  de	  gezellige	  
sfeer	  op	  het	   lab.	  Naast	  de	  serieuze,	  werkgerelateerde	  discussies	  hebben	  we	  ook	  
heel	  wat	  afgelachen.	  Een	  paar	  mensen	  wil	  ik	  graag	  speciaal	  noemen.	  
	  
Lieve	   Daniëlle,	   ik	   heb	   veel	   van	   je	   geleerd.	   Ik	   heb	   zoveel	   bewondering	   voor	   de	  
manier	  waarop	  jij	  werkt,	  met	  zoveel	  gedrevenheid,	  rust	  en	  precisie.	  Bedankt	  voor	  
al	  je	  hulp	  en	  adviezen	  en	  alle	  discussies.	  Het	  was	  fijn	  om	  mee	  te	  kunnen	  liften	  op	  
het	  werk	  wat	  jij	  al	  gedaan	  had	  rond	  de	  celdoodexperimenten.	  Daarnaast	  hebben	  
we	  heel	  wat	  lol	  gehad	  in	  ons	  U-­‐tje,	  die	  zeker	  rond	  kerst	  het	  gezelligst	  versierd	  was	  
van	  het	  hele	  lab.	  Bedankt	  ook	  voor	  de	  leuke	  tijd	  in	  Zürich,	  ik	  wens	  jou,	  Maarten	  en	  
natuurlijk	  Ilse	  heel	  veel	  geluk	  toe.	  
	  
Sander,	  jij	  had	  de	  moeilijk	  taak	  om	  het	  gat	  dat	  Daniëlle	  achterliet	  te	  vullen	  en	  daar	  
ben	   je	   goed	   in	   geslaagd!	  We	   hebben	   heel	   wat	   leuke	   discussies	   gehad	   rond	   de	  
oxidatieve	   modificatie.	   Bedankt	   daarvoor	   en	   natuurlijk	   heel	   veel	   succes	   in	  
Duitsland.	  
	  
Ik	  heb	  de	  luxe	  gehad	  dat	  ik	  tijdens	  mijn	  verblijf	  bijgestaan	  werd	  door	  3	  studenten.	  
Sabine,	  Loes	  en	  Thijs,	  bedankt	  voor	   jullie	   inzet	  en	  enthousiasme.	   Ik	  heb	  veel	  van	  
jullie	  geleerd.	  Thijs,	  we	  zaten	  niet	  altijd	  op	  1	  lijn,	  maar	  ik	  heb	  veel	  respect	  voor	  de	  
weg	   die	   je	   hebt	   afgelegd.	   Ik	   begreep	   dat	   je	   ondertussen	   zelf	   ook	   aan	   het	  
promoveren	   bent,	   dat	   bewijst	   maar	   dat	   ik	   ongelijk	   had.	   Heel	   veel	   succes	   in	   je	  
verdere	  loopbaan!	  
	  
Joyce,	  samen	  zijn	  we	  op	  stap	  geweest	  in	  Dresden	  en	  Londen	  en	  kwamen	  er	  toen	  
achter	   dat	  wij	   vrij	   veel	   gemeenschappelijk	   hadden.	  We	   houden	   o.a.	   allebei	   van	  
praten,	   zelfs	   in	   onze	   slaap	   ;-­‐).	   Bedankt	   voor	   je	   hulp	   bij	   het	   afronden	   van	   mijn	  
promotie.	   Judith	  en	  Annemarie,	  bedankt	   voor	   jullie	   luisterend	  oor,	  ook	  nadat	   ik	  
ben	   weggegaan.	   Reinout,	   jij	   ook	   bedankt	   voor	   het	   meedenken	   en	   alle	   leuke	  
discussies.	  
	  
Lieve	  Carla	  (S.),	  jij	  maakte	  het	  reizen	  op	  het	  traject	  Deventer	  -­‐	  Nijmegen	  een	  stuk	  
aangenamer.	  Ik	  heb	  helaas	  in	  Nijmegen	  niet	  veel	  met	  je	  samengewerkt,	  want	  zelfs	  
op	  afstand	  kon	  ik	  zien	  dat	  je	  een	  top-­‐analist	  bent.	  Gelukkig	  werken	  we	  nu	  al	  weer	  
een	   tijdje	   samen	   bij	   Avantor	   waar	   we	   iets	   vaker	   van	   elkaars	   expertise	   gebruik	  
maken.	   Bedankt	   dat	   je	   me	   bij	   wilt	   staan	   als	   paranimf.	   Veel	   geluk	   met	   je	   twee	  
mannen!	  
	  
En	  dan	  Els.	   Lieve	  Els,	   ik	  ben	  bang	  dat	  dit	   kleine	   stukje	  geen	   recht	   kan	  doen	  aan	  
hoe	  dankbaar	  ik	  je	  ben.	  Jouw	  deur	  stond	  altijd	  open	  en	  daar	  heb	  ik	  heel	  wat	  uren	  
gebruik	  van	  gemaakt.	  Bedankt	  voor	  je	  steun,	  je	  eerlijkheid	  en	  je	  interesse.	  Je	  weet	  




Lieve	   Elke,	   Jenne,	   Mieke	   en	   Mabel.	   Nu	   zijn	   we	   echt	   allemaal	   doctor	   of	   dokter	  
(sorry	  Elke	  voor	  het	  stelen	  van	  je	  quote).	  We	  gaan	  samen	  al	  heel	  wat	  jaartjes	  mee.	  
Het	  was	  fijn	  om	  bij	  jullie	  terecht	  te	  kunnen,	  eerst	  met	  frustraties	  rond	  tentamens,	  
verslagen	   en	   (afstudeer)stages	   en	   later	   met	   alle	   tegenslagen	   rond	   het	  
promoveren.	  Bedankt	  voor	  jullie	  steun,	  maar	  vooral	  voor	  alle	  gezelligheid!	  
	  
Wilma,	  Hanke,	   Simone	   en	   Inge,	   ik	   ben	   blij	  met	   onze	   vriendschap.	   Bedankt	   voor	  
alle	   leuke	   etentjes	   en	   stapavondjes,	   heerlijk	   om	   alles	   even	   lekker	   los	   te	   laten.	  
Simone	  ook	  jij	  bedankt	  dat	  je	  me	  bij	  wilt	  staan	  als	  paranimf.	  Lieve	  Wilma,	  bedankt	  
voor	  je	  luisterend	  oor.	  
	  
Soms	  kleven	  er	  nare	  associaties	  aan	  schoonfamilie,	  maar	  die	  heb	  ik	  absoluut	  niet.	  
Lieve	  Gerard	  en	  Riet,	  Claudy,	  Danny,	  Fleur	  en	  Thijmen,	  ik	  voelde	  me	  meteen	  thuis	  
bij	  jullie	  en	  geniet	  van	  alle	  leuke	  dingen	  die	  we	  samen	  ondernemen.	  Bedankt	  voor	  
alle	  onvoorwaardelijke	  steun	  en	  liefde.	  	  
	  
Lieve	   Gerco	   en	   Rob,	   het	   was	   niet	   altijd	   makkelijk	   om	   op	   te	   groeien	   met	   twee	  
broers	  die	   alles	   lijken	   te	   kunnen.	  Gerco,	   ik	   heb	   veel	   respect	   voor	  wat	   jij	   bereikt	  
hebt,	   grotendeels	   door	   heel	   hard	   te	   werken.	   Je	   betrokkenheid	   bij	   je	   patiënten	  
siert	  je.	  Lieve	  Rob,	  jouw	  loopbaan	  leek	  net	  als	  de	  mijne	  een	  never-­‐ending	  story	  te	  
worden,	  maar	  het	  is	  je	  toch	  gelukt	  om	  het	  voor	  mij	  af	  te	  ronden!	  Ik	  ben	  supertrots	  
dat	   jullie	  mijn	  broers	   zijn!	   Ik	  wil	   jullie,	   samen	  met	  Charlotte,	  Tim	  en	   Jasper	  heel	  
erg	  bedanken	  voor	  jullie	  interesse	  en	  steun	  wanneer	  dat	  nodig	  was.	  
	  
Lieve	  papa	  en	  mama,	  bedankt	   voor	   jullie	   vertrouwen	   in	  mij	   en	  de	   keuzes	  die	   ik	  
maakte.	   Jullie	   hebben	   me	   altijd	   de	   vrijheid	   gegeven	   om	   mijn	   eigen	   keuzes	   te	  
maken.	   Jullie	   hebben	   me	   gestimuleerd	   en	   gemotiveerd	   om	   alles	   waar	   ik	   aan	  
begon	   ook	   af	   te	  maken.	   Lieve	  mama,	   hoe	   “echt”	   werd	  mijn	   onderzoek	   toen	   je	  
tijdens	  mijn	  promotietijd	  zelf	  de	  diagnose	  “syndroom	  van	  Sjögren”	  kreeg.	   Ik	  ben	  
blij	   dat	   we	   dit	   achter	   ons	   hebben	   kunnen	   laten	   en	   ben	   trots	   op	   je	  
doorzettingsvermogen!	  
	  
Lieve	   Loïs	   en	   Noud,	   bedankt	   voor	   al	   jullie	   knuffels,	   kusjes	   en	   glimlachen.	   Jullie	  
maken	  mij	  zo	  gelukkig.	  Ik	  hou	  van	  jullie!	  
	  
Lieve	  Rick,	  het	  laatste	  woord	  is	  voor	  jou.	  Je	  bent	  een	  ware	  rots	  in	  de	  branding.	  Je	  
hebt	   als	   geen	   ander	  met	  me	  meegeleefd,	  me	  opgevrolijkt	   als	   het	   nodig	  was,	   of	  
successen	  met	  me	  gevierd.	  Dit	  boekje	   is	  een	  gezamenlijke	  prestatie,	   zeker	  nu	   jij	  
zo’n	   grote	   rol	   hebt	  met	   de	   lay-­‐out.	   Ik	   hoop	  dat	  we	   samen	  nog	  heel	   veel	  mooie	  
dingen	  mogen	  meemaken.	  Ik	  hou	  van	  je!	  
	  
	  	  
	  
